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Summary 
During pregnancy, the maternal cardiovascular system undergoes major 
adaptation. One of these changes is a 40-50 % increase in circulating blood volume 
which requires a systemic remodelling of the vasculature in order to regulate 
maternal blood pressure and maximise blood supply to the developing placenta 
and fetus. These changes are broadly conserved between humans and rats making 
them an appropriate pre-clinical model in which to study the underlying 
mechanisms of pregnancy-dependent cardiovascular remodelling. Whilst women 
are normally protected against cardiovascular disease; pregnancy marks a period 
of time where women are susceptible to cardiovascular complications. 
Cardiovascular disease is the leading cause of maternal mortality in the United 
Kingdom; in particular hypertensive conditions are among the most common 
complications of pregnancy. One of the main underlying pathologies of these 
pregnancy complications is thought to be a failure of the maternal cardiovascular 
system to adapt. 
 The remodelling of the uterine arteries, which directly supply the maternal-
fetal interface, is paramount to a healthy pregnancy. Failure of the uterine 
arteries to remodel sufficiently can result in a number of obstetric complications 
such as preeclampsia, fetal growth restriction and spontaneous pregnancy loss. At 
present, it is poorly understood whether this deficient vascular response is due to 
a predisposition from existing maternal cardiovascular risk factors, the 
physiological changes that occur during pregnancy or a combination of both. 
Previous work in our group employed the stroke prone spontaneously hypertensive 
rat (SHRSP) as a model to investigate pregnancy-dependent remodelling of the 
uterine arteries. The SHRSP develops hypertension from 6 weeks of age and can 
be contrasted with the control strain, the Wistar Kyoto (WKY) rat. The phenotype 
of the SHRSP is therefore reflective of the clinical situation of maternal chronic 
hypertension during pregnancy. We showed that the SHRSP exhibited a deficient 
uterine artery remodelling response with respect to both structure and function 
accompanied by a reduction in litter size relative to the WKY at gestational day 
(GD) 18. A previous intervention study using nifedipine in the SHRSP achieved 
successful blood pressure reduction from 6 weeks of age and throughout 
pregnancy; however uterine artery remodelling and litter size at GD18 was not 
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improved. We concluded that the abnormal uterine artery remodelling present in 
the SHRSP was independent of chronic hypertension. From these findings, we 
hypothesised that the SHRSP could be a novel model of spontaneously deficient 
uterine artery remodelling in response to pregnancy which was underpinned by 
other as yet unidentified cardiovascular risk factors. 
 In Chapter 1 of this thesis, I have characterised the maternal, placental and 
fetal phenotype in pregnant (GD18) SHRSP and WKY. The pregnant SHRSP exhibit 
features of left ventricular hypertrophy in response to pregnancy and altered 
expression of maternal plasma biomarkers which have been previously associated 
with hypertension in human pregnancy. I developed a protocol for accurate 
dissection of the rat uteroplacental unit using qPCR probes specific for each layer. 
This allowed me to make an accurate and specific statement about gene 
expression in the SHRSP GD18 placenta; where oxidative stress related gene 
markers were increased in the vascular compartments. The majority of SHRSP 
placenta presented at GD18 with a blackened ring which encircled the tissue. 
Further investigation of the placenta using western blot for caspase 3 cleavage 
determined that this was likely due to increased cell death in the SHRSP placenta. 
The SHRSP also presented with a loss of one particular placental cell type at GD18: 
the glycogen cells. These cells could have been the target of cell death in the 
SHRSP placenta or were utilised early in pregnancy as a source of energy due to 
the deficient uterine artery blood supply. Blastocyst implantation was not altered 
but resorption rate was increased between SHRSP and WKY; indicating that the 
reduction in litter size in the SHRSP was primarily due to late (>GD14) pregnancy 
loss. Fetal growth was not restricted in SHRSP which led to the conclusion that 
SHRSP sacrifice part of their litter to deliver a smaller number of healthier pups. 
 Activation of the immune system is a common pathway that has been 
implicated in the development of both hypertension and adverse pregnancy 
outcome. In Chapter 2, I proposed that this may be a mechanism of interest in 
SHRSP pregnancy and measured the pro-inflammatory cytokine, TNFα, as a marker 
of inflammation in pregnant SHRSP and WKY and in the placentas from these 
animals. TNFα was up-regulated in maternal plasma and urine from the GD18 
SHRSP. In addition, TNFα release was increased from the GD18 SHRSP placenta as 
was the expression of the pro-inflammatory TNFα receptor 1 (Tnfr1). In order to 
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investigate whether this excess TNFα was detrimental to SHRSP pregnancy, a 
vehicle-controlled intervention study using etanercept (a monoclonal antibody 
which works as a TNFα antagonist) was carried out. Etanercept treatment at GD0, 
6, 12 and 18 resulted in an improvement in pregnancy outcome in the SHRSP with 
an increased litter size and reduced resorption rate. Furthermore, there was an 
improved uterine artery function in GD18 SHRSP treated with etanercept which 
was associated with an improved uterine artery blood flow over the course of 
gestation. In Chapter 3, I sought to identify the source of this detrimental excess 
of TNFα by designing a panel for maternal leukocytes in the blood and placenta at 
GD18. A population of CD3- CD161+ cells, which are defined as rat natural killer 
(NK) cells, were increased in number in the SHRSP. Intracellular flow cytometry 
also identified this cell type as a source of excess TNFα in blood and placenta from 
pregnant SHRSP. I then went on to evaluate the effects of etanercept treatment 
on these CD3- CD161+ cells and showed that etanercept reduced the expression 
of CD161 and the cytotoxic molecule, granzyme B, in the NK cells. Thus, 
etanercept limits the cytotoxicity and potential damaging effect of these NK cells 
in the SHRSP placenta.  
 Analysing the urinary peptidome has clinical potential to identify novel 
pathways involved with disease and/or to develop biomarker panels to aid and 
stratify diagnosis. In Chapter 4, I utilised the SHRSP as a pre-clinical model to 
identify novel urinary peptides associated with hypertensive pregnancy. Firstly, a 
characterisation study was carried out in the kidney of the WKY and SHRSP. Urine 
samples from WKY and SHRSP taken at pre-pregnancy, mid-pregnancy (GD12) and 
late pregnancy (GD18) were used in the peptidomic screen. In order to capture 
peptides which were markers of hypertensive pregnancy from the urinary 
peptidomic data, I focussed on those that were only changed in a strain dependent 
manner at GD12 and 18 and not pre-pregnancy. Peptide fragments from the 
uromodulin protein were identified from this analysis to be increased in pregnant 
SHRSP relative to pregnant WKY. This increase in uromodulin was validated at the 
SHRSP kidney level using qPCR. Uromodulin has previously been identified to be a 
candidate molecule involved in systemic arterial hypertension but not in 
hypertensive pregnancy thus is a promising target for further study. 
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 In summary, we have characterised the SHRSP as the first model of 
maternal chronic hypertension during pregnancy and identified that inflammation 
mediated by TNFα and NK cells plays a key role in the pathology. The evidence 
presented in this thesis establishes the SHRSP as a pre-clinical model for pregnancy 
research and can be continued into clinical studies in pregnant women with 
chronic hypertension which remains an area of unmet research need. 
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Chapter 1 Introduction 
1.1  The Cardiovascular System 
The cardiovascular (CV) system is composed of the heart and vessels that 
form a rapid transport system delivering blood to the tissues of the body. Its vital 
role is highlighted by the fact that it is the first system to form and function in 
the developing embryo (1). Fundamentally, the CV system functions: as a 
convective transport system providing nutrients and washing away waste 
products; as a messenger system by delivery of hormones and bioactive molecules; 
and to regulate body temperature (1). The driving force which powers transport 
around the CV system is the heart. The heart is principally composed of four 
chambers: two muscular pumps, ventricles, and two reservoirs, atria. The right 
chambers of the heart perfuse the pulmonary circulation whilst the left chambers 
of the heart perfuse the systemic circulation. The heart is a muscle whereby 
contraction, thus ejection of blood, is known as systole followed by the relaxation 
of the ventricle allowing it to be filled with blood in diastole. Both right and left 
ventricles pump the same amount of blood synchronously but the left ventricle 
must eject blood at a much higher pressure to serve the distant systemic 
circulation. Thus, it is larger and more powerful than the right. Oxygenated blood 
enters from the pulmonary circulation where it is pumped into the systemic 
circulation via the aorta. Deoxygenated blood returns from the systemic 
circulation via the vena cava where it is then returned to the lungs by the 
pulmonary artery to be oxygenated once more (Fig 1-1).  
 
 
27 
 
 
Figure 1-1: The Cardiovascular System. 
The systemic and pulmonary systems are arranged in series i.e. they are reliant on the function of 
the other. The circulatory system delivers blood to the organs arranged in parallel i.e. their blood 
flow is not dependent on the blood flow of an upstream organ. This allows the cardiovascular 
system to adapt the blood supply dependent on the demand from a specific tissue. The exception 
to this role is the “portal” blood supply in the liver and kidney where the tissue additionally 
receives partially deoxygenated blood from other tissues in the body. Image from Levick (2010). 
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 Cardiac output (CO) is defined as the volume of blood ejected by one 
ventricle in one minute. Cardiac output is therefore equal to stroke volume (SV) 
(the volume of blood ejected per heartbeat) multiplied by the heart rate (HR) 
(number of heart beats per minute): CO = SV x HR. Cardiac output is dynamic 
dependent upon the oxygen demand of the body (2). The blood from the heart is 
then distributed to tissues dependent upon this demand. A pressure gradient 
drives the movement of blood through the CV system. Blood pressure is measured 
in “millimetres of mercury” (mmHg) above atmospheric pressure after the original 
method of measuring blood pressure using a mercury column (3). Blood flow is 
pulsatile due to the contraction and relaxation of the ventricles in the heart. In 
the systemic arterial circulation, the initial ejection of blood by the left ventricle 
during systole is approximately 120 mmHg above atmospheric pressure. During 
diastole this falls to approximately 80 mmHg. Therefore “normal” blood pressure 
is defined as 120/80 mmHg (4). 
 The vasculature forms the “plumbing” of the CV system. Every vessel wall 
is composed of three layers: the tunica intima, the tunica media and the 
adventitia (Fig 1-2). Only capillaries do not have three layers and are principally 
composed of endothelial cells. 
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Figure 1-2: The Structure of a Vessel. 
A vessel is normally composed of three layers. The innermost intima (1) is characterised by 
endothelial cells arranged on a thin layer of basement membrane (basal lamina & intimal connective 
tissue). This forms the main barrier to the blood and produces a number of vasoactive factors. The 
middle layer, media (2), is composed of smooth muscle cells in an elastin and collagen matrix 
contained within the internal and external lamina. Myoendothelial junctions through fenestrations in 
the internal elastic lamina facilitate contact between the intima and media. The outermost adventitia 
(3) is principally composed of collagenous connective tissue which attaches the vessel to its 
surroundings. Also within this outer layer, there are sympathetic fibre terminals which regulate 
vascular function and small vasa vasorum (vessels of vessels) which act to nourish the medial layer.  
Image from Levick (2010). 
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The arteries of the CV system are classified by their additional functions 
other than to carry blood (Table 1-1). Vessels are branched which functions to 
slow down the flow of blood for safe delivery to the tissues. To control the 
conductance of blood through the vessels there must also be resistance to restrict 
blood flow. Resistance is defined by Darcy’s law of flow (5) where a vessel with 
high resistance needs a large difference in pressure to drive blood flow. Large, 
wide arteries require only a low drop in pressure to drive flow whereas smaller 
arterioles need a larger difference in pressure. The measurement of the amount 
of pressure difference needed to drive blood flow is known as the resistance index. 
Therefore, large arteries contribute only approximately 2% to total systemic 
resistance and the smallest arteries and arterioles contribute approximately 60% 
(1).  
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Table 1-1 Classification of Arteries. 
Table adapted from Levick (2010). 
 
  Blood Pressure Regulation 
Blood pressure is the force of blood against the walls of the vessels. “Blood 
pressure” can refer to intraventricular blood pressure, systemic arterial blood 
pressure, capillary hydrostatic pressure or systemic venous return. For the 
purposes of this thesis, the generic term “blood pressure” will refer to systemic 
arterial blood pressure. Blood pressure is dynamic and varies with age, race, 
gender, circadian rhythm and transiently such as during periods of stress or 
standing. Therefore, a number of mechanisms are in place to regulate changes in 
blood pressure. These can be categorised into short term and long term changes. 
Vessel Example Function Wall/Lumen Composition (%) 
Elastic Artery Aorta 
Iliac Artery 
Pulmonary 
Trunk 
Elastin content allows 
the vessel to store 
mechanical energy 
ensuring continuous 
blood flow to the 
smaller vessels. 
Collagen prevents over-
expansion. 
2 mm/25 mm Endothelium: 5 
Smooth Muscle: 25 
Elastin: 40 
Collagen: 27 
Conduit Artery Brachial 
Radial 
Femoral 
Cerebral 
Coronary 
Uterine 
Conduct flow from the 
large elastic arteries to 
the small arterioles. 
Thick wall prevents 
collapse at sharp bends. 
Rich sympathetic 
nervous innervation to 
alter the blood flow to 
different vascular beds. 
1 mm/4 mm  
Arteriole  Site of high resistance 
vessels causing a major 
drop in blood pressure. 
These act to constrict 
or dilate to alter local 
blood flow. 
30 μm/30 μm Endothelium: 10 
Smooth Muscle: 60 
Elastin: 10 
Collagen: 20 
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Blood pressure equals cardiac output multiplied by total peripheral resistance (BP 
= CO x TPR) thus changing either cardiac output (CO = SV x HR, section 1.1) or 
total peripheral resistance directly affects blood pressure. Short term mechanisms 
of blood pressure regulation focus on altering total peripheral resistance as this is 
quicker and more effective than changing CO. Longer term mechanisms of blood 
pressure regulation adjust blood volume which predominantly affects CO (6).  
 The three main short term mechanisms of blood pressure control operate 
within seconds or minutes: baroreceptors, chemoreceptors or the central nervous 
system (CNS) ischemic response. All of these short term mechanisms act through 
the nervous system which is controlled by three main cardiac centres in the 
medulla: cardio-acceleratory centre (sympathetic), cardio-inhibitory centre 
(parasympathetic) and the vasomotor centre (sympathetic). Physiologically, short 
term fluctuations in blood pressure are predominantly regulated by the 
baroreceptors found in the carotid sinuses which adjoin to the glossopharyngeal 
nerve and the aortic arch which joins to the vagus nerve (1). The direct effects 
altering TPR by activation of the baroreceptors account for three quarters of the 
change whereas their neuroendocrine effect account for the remainder (Fig 1-3) 
(6). The other two mechanisms of short term blood pressure control, 
chemoreceptors (7) and the CNS ischemic response, are more relevant to acute 
changes such as clinical shock or asphyxia. The chemoreceptors are located in the 
small, highly vascularised carotid and aortic bodies, adjacent to the carotid sinus 
and aorta. Chemoreceptors are responsive to changes in levels of O2, CO2, pH and 
hyperkalaemia. Activation of the chemoreceptors increases blood pressure 
through tachycardia and vasoconstriction restoring SV and increasing total 
peripheral resistance. CNS ischemic response is activated by cerebral hypoxia 
leading to a powerful stimulation of the sympathetic system and noradrenaline 
release to increase blood pressure (8). 
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Figure 1-3: Baroreceptor Reflex Regulating Blood Pressure. 
Increased sympathetic output leads to increased contractility of the heart through noradrenaline and 
adrenaline actions on β1-adrenoreceptors and constriction of both the arteries and veins through α-
adrenoreceptors. Venous constriction contributes to both increasing peripheral resistance and 
cardiac output by restoring venous return to the heart and increasing stroke volume. The 
parasympathetic system releases acetylcholine which acts through muscarinic receptors on the heart 
and vessels to reduce contractility and release nitric oxide causing vasorelaxation. CO: cardiac 
output, TPR: total peripheral resistance, RAAS: renin angiotensin aldosterone system. 
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 Intermediate and long term control of blood pressure is mainly affected 
through peptides and hormones which act to alter blood volume through modifying 
sodium and fluid reabsorption at the kidney. An increase in arterial pressure 
results in a decrease in sodium and fluid resorption and an increase in sodium 
excretion; this is known as pressure natriuresis. The main peptides are: 
catecholamines, the renin angiotensin aldosterone system (RAAS), vasopressin and 
the natriuretic peptides. The intermediate neuroendocrine term effects of 
catecholamines are shown in Figure 1-3. The RAAS (Fig 1-4) is a major regulator 
of blood pressure; drugs which inhibit the RAAS pathway are currently the first 
line drug to be prescribed to hypertensive patients under 55 (9) and many 
monogenic forms of hypertension are due to mutations in this pathway (section 
1.2.1.1) (10). Angiotensin II, the main active peptide of this pathway acts to 
increase blood pressure in three ways: by stimulating aldosterone production 
which promotes sodium and fluid retention thus increasing plasma volume, 
boosting sympathetic nervous system activity to induce systemic vasoconstriction 
and by stimulation of the thirst centres in the hypothalamus. Angiotensin II has its 
main effect on blood volume through stimulation of the mineralocorticoid 
hormone, aldosterone, from the adrenal cortex. Aldosterone acts through the 
mineralocorticoid receptors in the kidney to retain sodium and water at the 
expense of potassium and hydrogen ions (11). Vasopressin (also known as anti-
diuretic hormone) is released by stimulation from angiotensin II as well as 
activation of arterial baroreceptors and osmoreceptors in the brain. 
Physiologically, vasopressin works at the kidney to balance water excretion to 
balance plasma volume and osmolality. When blood pressure is decreased, 
vasopressin concentration is stimulated above baseline levels to induce systemic 
vasoconstriction sparing the cerebral and coronary vessels and reducing urine 
output from the kidney.  
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Figure 1-4: The Renin Angiotensin Aldosterone System (RAAS). 
Renin is produced from specialised juxtaglomerular cells in the kidney. It catalyses the proteolytic 
cleavage of angiotensinogen to produce angiotensin I. Angiotensin I has limited activity until it is 
cleaved by angiotensin converting enzyme (ACE) expressed on the surface of endothelial cells into 
the active peptide angiotensin II. This process principally happens in the lung as it is the first expanse 
of endothelial cells reached by angiotensin I. Angiotensin II then goes on to stimulate the release of 
aldosterone from the adrenal cortex, directly stimulate vasoconstriction and increase sympathetic 
outflow. These combined mechanisms have the effect of increasing blood pressure. JGA: 
juxtaglomerular apparatus, RA: renal artery, RV: renal vein. Image from Levick (2010). 
  
 
 
36 
 
 The natriuretic peptides, namely atrial natriuretic peptide (ANP) (12) and 
brain natriuretic peptide (BNP) (13), act to reduce blood pressure, thus are 
counter-regulatory to the RAAS system. ANP is the predominant physiological 
peptide with levels of BNP being greatly increased in heart failure. Pro-forms of 
ANP and BNP are released from specialised cardiomyocytes in either the atria or 
ventricles in response to increased cardiac filling pressure (14). These peptides 
reduce plasma volume by modest vasodilation binding to the vessels directly (15) 
and promoting salt and fluid loss at the kidney and transferring fluid from the 
plasma to the interstitial compartment (16). The inactive and active forms of ANP 
and BNP have promise as potential biomarkers for CV morbidity and mortality 
associated with hypertension (17). 
 Signalling pathways involving reactive oxygen species (ROS) are involved in 
both short and long term mechanisms of blood pressure regulation. ROS can be 
short-lived radicals such as superoxide (•O2) or more sTable non-radical 
derivatives such as H2O2. ROS are produced by all vascular cell types from a 
number of sources including: mitochondria, xanthine oxidase, uncoupled nitric 
oxide synthase and NADPH oxidase (18).  Mice lacking ROS-generating enzymes 
have lower blood pressure than wild type animals and are resistant to the 
development of angiotensin II dependent hypertension (19). In the kidney, ROS 
promotes sodium retention resulting in an increase in blood pressure (20). 
However, the role of vascular derived ROS can have seemingly opposing effects. 
For example, an increase in •O2 results in increased vasoconstriction through 
scavenging of the vasodilator nitric oxide (21) but increased H2O2 has been shown 
to act as a vasodilator in some circumstances (22). Despite their paradoxical 
effects, it is well established that an imbalance derived from increased vascular 
ROS production and decreased clearance, known as oxidative stress, is associated 
with vascular pathology and an increase in blood pressure (23). 
 Mechanisms of Vascular Contraction and Relaxation 
Vascular reactivity plays a central role in CV physiology. The sum of the 
resistance to blood flow across all of the systemic vasculature is known as the 
systemic vascular resistance or total peripheral resistance (TPR). The level of 
physiological TPR is determined by a balance between vasodilation, which reduces 
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TPR, and vasoconstriction which increases TPR. Dysregulation of the molecular 
mechanisms of vasoconstriction and dilation are central to CV disease. 
1.1.2.1 Vasoconstriction 
The physiology of the vascular smooth muscle cells (VSMC) is unique with 
regards to its molecular machinery which allows the vessels to fulfil a specific type 
of slow, sustained constriction. The contraction is initiated by a rise in 
intracellular calcium which can occur through depolarisation-dependent or 
independent mechanisms. This is determined by the size of the arteries and the 
balance of receptors expressed on the VSMC surface (24, 25). Most vasoconstrictor 
molecules act through receptors coupled to the Gq protein and subsequent 
activation of the phospholipase C signalling pathway (Fig. 1-5). Intracellular 
calcium release culminates in the activation of myosin light chain kinase (MLCK) 
which goes on to phosphorylate myosin. This allows myosin-actin interaction and 
induces contraction. In contrast to the sarcomeric structure of the skeletal 
muscle, myosin-actin bundles are organised into dense bodies disseminated across 
the VSMC. These are connected by intermediate filaments forming a contractile 
mesh which propagates contraction over the whole cell. The first phase of 
vasocontraction (30-60 seconds) is calcium dependent, however, a further tonic 
phase exists in VSMCs where the contraction is sustained through activation of 
RhoA kinase (26). Sympathetic stimulation is the major determinant of 
physiological vasoconstriction. Noradrenaline is released from sympathetic nerves 
where it diffuses across the neuromuscular junction and binds α1-adreoreceptors 
on the VSMC surface. The α1-adreoreceptor is a Gq protein coupled receptor and 
acts to induce contraction as shown in Fig. 1-5 Other molecules such as angiotensin 
II, endothelin-1 and adrenaline can also elicit vasocontraction through binding to 
their respective VSMC surface receptors.
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Figure 1-5: Gq Coupled Receptor Phospholipase C Mechanism of Vascular Smooth Muscle Cell Contraction. 
Gq protein coupled receptors stimulate phospholipase C  to split membrane phospholipid (PIP2) into the second messengers diacylglycerol (DAG) and inositol triphosphate 
(IP3). IP3    triggers the release of calcium (Ca2+) from the sarcoplasmic reticulum (SR). If the cell has a large SR, Ca2+ release is global and contributes directly to the 
activation of myosin light chain kinase (MLCK).  If the cell has a small SR, Ca2+ release localised a the inner cell membrane triggers the opening of Ca2+  activated 
chloride (Cl-) channels which results in depolarisation .  DAG  stimulates the opening of TRP non-selective cation channels leading to depolarisation and activates protein 
kinase C (PKC) which phosphorylates MLCK.  Depolarisation leads to an action potential causing an influx of Ca2+ through L-type Ca2+ channels. These pathways 
converge on the phosphorylation and activation of MLCK which phosphorylates myosin leading to contraction of the smooth muscle cell.  
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1.1.2.2 Vasodilatation & the Role of the Endothelium 
The contribution of the endothelium to vasodilatation is dependent upon 
vascular bed, species, age, gender and developmental stage (27). There are three 
major groups of vasoactive substances released by the vascular endothelium which 
act upon the vascular smooth muscle cells to elicit a relaxation response (Table 
1-2). The molecular pathways responsible for endothelium dependent 
vasorelaxation exhibit a degree of redundancy. For example, in eNOS knockout 
mice (28) and in vessels from human subjects with CV disease where eNOS is 
impaired (29) another form of NOS enzyme, neuronal NOS (nNOS), is upregulated 
in the endothelium as a compensatory mechanism. Endothelial dysfunction, when 
these mechanisms of vasorelaxation are impaired, is a hallmark of many CV 
diseases and is positively correlated with adverse clinical outcomes (30). Excessive 
levels of inflammation (31) and/or oxidative stress (21) are considered to be two 
key drivers of endothelial dysfunction during disease by either direct damage of 
the endothelial layer itself or disruption of the molecular pathways detailed in 
Table 1-2. 
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Table 1-2 Molecular Mechanisms of Endothelium-Dependent Vasorelaxation. 
 
  
Molecule Enzyme Mechanism of Relaxation in VSMCs 
Nitric Oxide (NO) Endothelial 
nitric oxide 
synthase 
(eNOS) 
Stimulates guanylyl cyclase to produce cyclic 
GMP leading to activation of protein kinase G 
(PKG). PKG induces hyperpolarisation through 
activation of K+ channels, promotes 
dephosphorylation of myosin, inhibits IP3 
mediated Ca2+ release and increases Ca2+ 
sequestration. 
Prostaglandins 
(e.g. PGl2) 
Cyclooxygenase 
(COX) 
Stimulates adenylate cyclase to produce 
cyclic AMP leading to activation of protein 
kinase A (PKA). PKA activation leads to 
hyperpolarisation through activation of K+ 
channels. 
Endothelial 
Derived 
Hyperpolarised 
Factor (EDHFs 
e.g. H2O2, CO, 
H2S)  
H2O2: catalase  
CO: heme 
oxygenase-1 
(HO-1) 
H2S: 
cystathionine-
γ-lyase (CSE) 
Lead to hyperpolarisation by activation of K+ 
channels or Na+/K+ ATPase. 
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1.2  Cardiovascular Disease 
CVD includes, but is not limited to, myocardial infarction, stroke, left 
ventricular hypertrophy, peripheral vascular disease and renal failure. CVD 
accounts for 27% of deaths in the United Kingdom (British Heart Foundation, 2015). 
Furthermore, approximately 10% of the population are living with CVD (British 
Heart Foundation, 2015). This is at great cost to the National Health Service (NHS) 
as, based on the British National Formulary; drugs for CVD make up 4 out of the 5 
top prescribed drugs in the United Kingdom (NHS, 2011). Globally, CVD  has been 
identified as a major disease burden worldwide as the leading cause of non-
communicable disease death globally and projected to overtake infectious 
diseases as a cause of mortality and morbidity by 2030 (32). One underlying 
problem driving the increase in CVD is that known risk factors such as obesity, 
metabolic syndrome, atherosclerosis and hypertension are prevalent in the 
developed world. This thesis will focus on hypertension as a risk factor for CVD. 
  Hypertension 
Hypertension is a chronic raised systemic arterial blood pressure that is 
defined as pathological at the level which causes an increased risk for adverse CV 
outcomes such as myocardial infarction or stroke.  Hypertension is diagnosed by a 
SBP of 140 mm Hg or above and/or a DBP of 90 mmHg or above (Table 1-3). 
Hypertension is a “silent killer” as it is thought that as many as one third of people 
with hypertension do not know that they are affected as it occurs with few obvious 
symptoms (33). The only definitive way to know whether someone has 
hypertension is for the individual’s blood pressure to be measured. However, 
blood pressure measurement by a physician is not straightforward due to 
phenomena such as “white coat hypertension” (34). Recent NICE guidelines have 
supported the use of ambulatory blood pressure measuring to prevent misdiagnosis 
and the subsequent cost of unnecessary treatment (9). Untreated, hypertension 
can elicit major damage on the vital organs (35) which establishes it as a key risk 
factor for CVD. Hypertension is quantitatively the most important risk factor for 
CVD accounting for 13.5% premature deaths globally and approximately half of all 
cases of stroke (54%) and ischemic heart disease (47%) (36). In particular, its 
incidence has begun rapidly increasing in the developing world (37). A recent study 
carried out in the United Kingdom in 2014 assessed hypertension as a risk factor 
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for 12 different adverse CV outcomes in 1.25 million individuals (38). This study 
established blood pressure as an independent risk factor for CVD and showed that 
individuals with hypertension developed CVD 5 years earlier (95% CI 4.8 – 5.2) and 
their lifetime overall risk of CVD at 30 years of age was approximately 22% higher 
Table 1-3 JNC-8 Guidelines for Blood Pressure Classification in Adults ≥18. 
Classification SBP (mmHg)  DBP (mmHg) 
Normal <120 AND <80 
Pre-Hypertension 120 – 139 OR 80 – 89 
Stage 1 Hypertension 140 - 159 OR 90 - 99 
Stage 2 Hypertension ≥160  OR ≥100 
Table compiled by author. 
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 In 5 – 10% of individuals with hypertension the increase in blood pressure is 
secondary to an underlying pathology such as a genetic mutation or primary 
aldosteronism. However, in most (90 – 95%), the cause of hypertension is unknown 
(essential or primary hypertension). Both primary and secondary hypertension 
present with great clinical heterogeneity. Blood pressure has a smooth bell-shaped 
distribution in the population which indicates that it is a net effect of multiple 
factors each with a small cumulative contribution (39). It is known that the 
dysregulation of blood pressure is a complex multifactorial disease with a number 
of known genetic and environmental factors. 
1.2.1.1 Genetic Factors 
Compelling evidence for a genetic component in blood pressure regulation 
comes from twin studies, adoptive studies and family studies.  Hypertension has 
a heritability between 30 – 50 % (40) and this decreases with the individual’s age 
at onset (41). Early twin studies showed increased concordance in blood pressure 
between monozygotic than dizygotic twins (42). These findings were supported by 
the Montreal adoption study which showed increased correlation of blood pressure 
in biological siblings relative to adopted siblings (43). Large family studies, for 
example from the long-running Framingham Heart Study, also reported heritability 
of long term systolic (57%) and diastolic blood pressure (55%) (44). 
The advent of studying the contribution of specific genes in hypertension 
began with linkage analysis in large families with a monogenic cause of 
hypertension (secondary). These diseases are predominantly characterised by 
genes involved in the renal salt and fluid handling (45). For example, Liddle’s 
Syndrome is caused by a gain of function mutation in the sodium channel, ENaC, 
which results in it not being degraded correctly by the ubiquitin proteasome and 
subsequent increase in salt and fluid resorption at the kidney (46). Whilst 
individuals with Mendelian forms of hypertension are in the small minority, 
knowledge of the genes involved has given rise to most of the candidate genes and 
drug approaches for current hypertension research and treatment. A number of 
studies have utilised knowledge generated from Mendelian forms of hypertension 
to inform candidate gene studies in humans with hypertension (47, 48).  
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The polygenic nature of hypertension was proposed in Paige’s “Mosaic 
Theory” (49). This theory was recently updated by Padmanabhan, Caulfield and 
Dominiczak to incorporate the complexity of genetic interactions that have been 
uncovered in hypertension (Fig 1-6) (50). Modern research has focussed on large 
genome wide association studies (GWAS) to detect novel genetic variants (single 
nucleotide polymorphisms or SNPs) involved in hypertension. However, the 
contribution of such studies is presently small. Most hits from GWAS are in non-
coding regions or in coding regions where the gene in question has a small effect 
on blood pressure making functional annotation difficult. However, there has been 
success in this area (51, 52) and with the advent of better bioinformatic resources 
and bigger datasets GWAS will have the ability to identify more target genes. 
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Figure 1-6: The 2014 Update on the Paige Mosaic Model of Hypertension. 
The Paige model of hypertension was proposed in 1960 to explain the multifactorial nature of 
hypertension, inclusive of: genetic, environment, adaptive, neural, mechanical and hormonal 
mechanisms. The updated 2014 model builds on this theory by the addition of specific genes 
(coloured) and pathways (grayscale) which are now known to play a causal role in hypertension. 
Image from Padmanabhan, Caulfield and Dominiczak (2015). 
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1.2.1.2 Environmental Factors 
Heritability studies take into account common genetic factors found in 
families but these individuals are also likely to have a shared environment. The 
environment-gene interaction in hypertension is known to be a large component 
of the disease process (53). For example, even Mendelian forms of hypertension 
with a strong genetic background are exacerbated by the environment of the 
individual. Women with a mutation in the mineralocorticoid (MCR) gene 
experience pregnancy-induced hypertension due to the significant rise in 
progesterone (54). The principal environmental factor affecting hypertension is 
dietary salt due to its effects on pressure natriuresis. Furthermore, stress, obesity, 
dyslipidaemia and insulin resistance have all been shown to have independent 
interactions with blood pressure (55). Another angle on gene-environment 
interactions is Barker’s Hypothesis (56) which proposes that there is fetal genetic 
programming which takes place in response to the intrauterine environment which 
can predispose an individual to disease later in life. In keeping with this 
hypothesis, the blood pressure of offspring has been associated with maternal 
blood pressure during pregnancy (57, 58). 
1.2.1.3 Sex Differences in Hypertension 
Blood pressure differences between males and females add a further layer 
of complexity to the understanding of the development of hypertension. 
Premenopausal women tend to have lower blood pressure (59) and have a 
significantly reduced CV risk (60) than age-matched men. Estrogen is the main 
female sex hormone produced in three forms: estradiol (premenopausal), estrone 
(postmenopausal) and estriol (pregnancy). Estrogen, particularly estradiol, has 
predominantly vasoprotective effects (Fig 1-7). Testosterone is the main androgen 
or male sex hormone. In the vasculature, androgens have been found to have 
predominantly deleterious effects (Fig 1-7) however can also cause acute 
vasodilation (61). Increased maternal testosterone levels during pregnancy are 
associated with endothelial dysfunction in male but not female offspring (62). This 
is thought to be due to direct effects of testosterone on impaired placental 
development and vascular remodelling in vivo (63).  Despite this, the cardio-
protective phenotype in females is not as simple as the presence or absence of 
specific hormones. Postmenopausal women are not protected against CVD and 
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even have a slightly higher blood pressure than men (64) but supplementation with 
hormone replacement therapy (HRT) has not been shown to have any conclusively 
beneficial effects on the CVS in two large clinical trials (65, 66). Furthermore, 
testosterone is paradoxically reduced in chronic disease (67). This disconnection 
between physiology and epidemiological data requires further research to dissect 
these seemingly counter-intuitive results. 
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Figure 1-7: The Effects of Sex Hormones on Blood Pressure Regulation. 
Estrogens tend to have cardioprotective effects and androgens tend to have deleterious effects; however the mechanisms are not well defined. Estradiol has been shown 
to attenuate sympathetic outflow induced by aldosterone however testosterone levels have been shown to correlate with noradrenaline release. Estrogens down-regulate 
components of the RAAS and the angiotensin II receptor 1 whereas androgens directly stimulate sodium reabsorption and increase angiotensinogen synthesis in the 
kidney. Estradiol has been shown to induce eNOS and acts as an antioxidant in the vasculature. Antioxidant therapy lowers blood pressure in male rats but not female 
rats suggesting that testosterone has pro-oxidant properties.  
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1.3  Inflammation & Hypertension 
The immune system is composed of two specialised arms: the innate and 
adaptive. The innate immune system is the body’s first line of defence and acts 
immediately to recognise “non-self” molecules or viral and bacterial markers such 
as double stranded RNA or coat molecules which it then destroys directly (e.g. 
phagocytosis) or indirectly through antigen presentation to cells of the adaptive 
immune system. Cells of the innate immune system include macrophages, 
dendritic cells and natural killer (NK) cells. Killing of target cells is principally 
carried out by the macrophages and NK cells whilst the dendritic cell 
predominantly acts as an antigen presenting cell. However, there is some overlap 
in these functions. The adaptive immune system, unlike the innate immune system 
is highly specific and begins to act several days after the advent of an infection. 
Effectors of the adaptive immune system are T and B cells.  
Activation of the immune system, or inflammation, has been reported to be 
involved in the development and end-organ damage associated with hypertension 
since the 1960s (68). Early studies showed that immunosuppression by cortisone 
reduced blood pressure in a rat model of hypertension (69). More sophisticated 
work which followed in the next 20 years showed that the active Na+ retaining 
mineralocorticoid deoxycorticosterone acetate (DOCA) and salt administration 
induced an increase in blood pressure in both wild type and athymic nude mice 
but this increase was only sustained in wild type mice (70). Furthermore, 
splenocytes from mice with DOCA induced hypertension transplanted into wild 
type mice caused an increase in blood pressure (71). In addition, leukocyte 
infiltration was seen in the heart, kidneys, adventitia and perivascular fat 
surrounding vessels from people with hypertension and in hypertensive animal 
models (68, 72, 73). This is associated with the increased expression of 
chemokines and adhesion molecules which recruit immune cells to these sites (68, 
72, 73). An increase in ROS which can be produced from immune cells themselves 
as well as the sources discussed in section 1.1.1 results in the activation of 
oxidation sensitive pro-inflammatory transcription factors which stimulate the 
production of cytokines and adhesion molecules leading to further leukocyte 
recruitment (68). 
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Research focussing on the role of the adaptive immune system in the 
development of hypertension has benefited greatly in recent years with the 
development of RAG and SCID mouse models which lack T and B cells (74, 75). 
However, this thesis will focus on the role of the innate immune system where the 
mechanisms underlying blood pressure control are less well defined.  
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Figure 1-8: The Main Cell Types Involved from the Innate and Adaptive Immune System in Hypertension. 
The key cell types from the innate immune system involved in hypertension are macrophages (principally a professional phagocyte but can also present antigens), 
dendritic cells (principally an antigen presenting cell but also a professional phagocyte) and natural killer (NK) and natural killer T cells (non-professional phagocytes). 
Cells of the innate immune system are linked to the adaptive immune system by antigen presentation or chemokine production with promotes leukocyte recruitment. T 
cells are mediators of cell based immunity. They can develop into either CD4+ helper T (Th) cells which assist the actions of other immune cells by releasing T cell 
cytokines or CD8+ cytotoxic T (Tc) cells which can recognise and kill target cells expressing specific antigens on their cell surface. Regulatory T cells (CD4+ or CD8+ 
and CD25+) act to suppress T cell activity at the end of an immune reaction and to prevent autoimmune T cell activity. B cells are mediators of humoral immunity. Plasma 
cells work in concert with Th cells to proliferate and produce antibodies to a specific threat. Memory B cells retain the information regarding a previous threat to allow it 
to produce a more rapid response with a greater production of antibodies upon secondary infection. Image adapted from Schiffrin (2014). 
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 Activation of the Innate Immune System in Hypertension 
Cells of the innate immune system (macrophages, dendritic cells and NK 
cells) are signalled by chemokine release and adhesion molecule expression from 
vessels or tissues under stress and/or injury (76). Mouse models where 
macrophages are functionally deficient or depleted are resistant to elevations in 
blood pressure induced by angiotensin II infusion and DOCA. They are also 
protected from end organ damage and vascular remodelling (77-79). However, the 
relative contribution of the reduction in blood pressure and a direct effect of 
knocking down the macrophage cells are not clear. Macrophages produce reactive 
oxygen species in response to angiotensin II stimulation therefore they could play 
a role directly in vascular remodelling and tissue damage induced by oxidative 
stress (80). With respect to dendritic cells, blockade of a specific type of antigen 
presentation which activates naïve T cells has also been shown to blunt the 
response to angiotensin II induced blood pressure increase in mice (81). The 
evidence for a role of the innate immune system in the development and end 
organ damage of hypertension is convincing. However, what is lacking is a 
mechanistic basis for such findings. Furthermore, this work has predominantly 
been carried out in preclinical models and lacks clinical translation. This thesis 
will focus on NK cells and their role in the development of hypertension. 
Pro-inflammatory cytokines which are predominantly released from 
immune cells play a key role in hypertension associated damage by affecting 
tissues directly or indirectly by recruiting other immune cells (82). Some key 
examples are IL-6 which plays a role in the development of angiotensin II induced 
hypertension in a mouse model (83) and is positively associated with blood 
pressure in apparently healthy humans (84). Interferon-γ knockout mice are also 
protected from cardiac damage induced by angiotensin II induced hypertension 
(85). This thesis will focus on another pro-inflammatory cytokine, TNFα, and its 
role in the development of hypertension. 
 Natural Killer Cells 
NK cells are large granular lymphocytes shown to demonstrate traits of both 
the innate and adaptive immune system (86). Among other functions, this group 
of cells possess spontaneous cytotoxic ability, acting as an effective defence 
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against infected and cancerous cells. They produce a number of cytokines which 
recruit and regulate cells of the adaptive immune system (87). NK cells are 
described as immune sentinels thus have a widespread distribution throughout the 
body. They are unique in that they are able to identify stressed or infected cells 
without binding major histocompatibility complex (MHC) or antibodies and 
therefore provide a rapid immune reaction. In most tissues, NK cells represent 
only a small percentage of the lymphocyte population, for example, 5-10% of the 
lymphocyte population in the spleen and 2-18% in human peripheral blood (88).  
The potent cytotoxic ability of NK cells is regulated on three levels. Firstly, 
NK cells undergo an education process whereby only those that recognise “self” 
are promoted to having cytotoxic ability (89). Secondly, these cytotoxic cells are 
tightly regulated by a sophisticated system involving a complex of interactions 
between the target cell and either activating or inhibitory receptors on the NK 
cell surface (Fig 1-9). NK cell surface receptors classically recognise MHC class I 
ligands as “self” or when these are up-regulated due to stress, “dangerous self”, 
or missing, “missing self”, such as during infection or in cancerous cells. NK cells 
can also recognise cell adhesion or virally-derived molecules. Receptors on NK 
cells can be predicted to be either activating or inhibitory based upon a 
characteristic immune-receptor tyrosine-based activation or inhibitory motif; 
ITAM or ITIM respectively. These specialised domains are phosphorylated by Src 
kinases resulting in the recruitment of scaffolding proteins for further signal 
transduction in the case of ITAMs; or recruitment of protein phosphatases to turn 
off signalling in ITIMs (90).  Finally, resting NK cells have a relatively low cytotoxic 
ability compared to “primed” NK cells. Priming involves a translational switch of 
the mRNA of cytotoxic molecules abundant in resting NK cells thus resulting in 
activation of the cytotoxicity (91). This is regulated by the cytokine 
microenvironment in which the NK cell is present; such as type-1 interferons, IL-
12, IL-18 and IL-15 to varying degrees in humans and rodents (92). It can also be 
regulated by the close proximity of other immune cell types such as T cells, 
monocytes and dendritic cells (93-95).  
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Figure 1-9 The Natural Killer (NK) Cell-Target Cell “Zipper” in Humans. 
The evolution of potent cytotoxic ability is accompanied by an equally powerful control mechanism 
in NK cells. Activating receptors (green) predominantly recognise self “stress” ligands or infectious 
ligands. Inhibitory receptors (blue) predominantly recognise “self” ligands such as the human version 
of the major histocompatibility complex genes (the human leukocyte antigen (HLA) family) which 
prevent NK cells from damaging host tissue. Image adapted from Vivier et al. (2008). 
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1.3.2.1 NK Cell Receptors 
Whilst the general regulatory mechanisms of NK cell surface receptors are 
conserved between humans and rodents; the identity of these receptors are not 
directly comparable. For example, CD56 the main extracellular marker of NK cell 
populations in humans is not expressed in rodents. Therefore, direct comparison 
of NK cell populations between rodents and humans requires care. Interspecies 
variation in cell surface receptors also exists between rats and mice. Additionally, 
further complexity exists as intraspecies variation is observed in different strains 
of laboratory mice (96). The NK cell receptors are mainly transcribed from the 
natural killer gene complex (NKC); this is located on chromosome 4 in rats, 6 in 
mice and 12 in humans (97-99).  
1.3.2.2 Natural Killer Receptor Protein (Nkrp) Receptors 
The first group of receptors to be identified which were selective for 
natural killer cells were the natural killer receptor protein 1 (Nkrp1) group, 
encoded by the killer-cell lectin-like receptor group b 1 (Klrb) genes found within 
the NKC. Nkrp1 receptors are a marker of commitment to the NK cell lineage and 
are expressed throughout development from immature to mature NK cells in 
rodents and humans (100). Nkrp1 receptors recognise “self” or “missing self” in 
an MHC-dependent manner by interacting with target cell C-type lectin-related 
molecules (Clr) (101, 102). There are 4 Nkrp1 members in the rat: Nrkp1-a, b, f 
and g. Nkrp1a and b are clustered on the proximal part of the rat NKC whereas 
Nkrp1f and g are found on the distal part. Nkrp1a (CD161) is currently the most 
widely used marker to identify natural killer cell populations in rats however 
CD161 is also known to be expressed on specific subsets of T cells and dendritic 
cells (103-105). Therefore, the accepted definition of rat NK cells is CD3- CD161+ 
to exclude T cells (CD3+). This classification has been used in the experiments 
presented in this thesis (Chapter 5). In mice, there are 7 family members: Nkrp1-
a, b, c, d, e, f and g (106). The mouse Nkrp1-c, d, f and g are considered to be 
orthologues of the rat Nrkp1-a, b, f and g respectively (107). In contrast to the 
multiple Nkrp1 family members in rodents, there is only a single human NKRP1A 
(CD161) receptor. This shares 46% homology with rat Nkrp1 and 46-47% with mouse 
Nkrp1 receptors. CD161 expression is only limited to a subset of human NK cells 
whereas all rodent NK cells express CD161 (108). In humans, CD161 is up-regulated 
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by interleukin-12 (IL-12) (109) and binds lectin-like-transcript 1 which has an 
inhibitory function and supresses cytotoxic activity against the target cell (109-
111). In parallel, humans also express KLRF1 genes which are thought to be 
evolutionarily related to the NKRP1 family and have an activating function (102).  
Nkrp1a was first shown to be an activating receptor in rats in the 1980s, where 
antibodies to Nkrp1a induced the release of cytotoxic granules from NK cells (112). 
This mechanism was further developed in a rat natural killer cell line (RNK-16) 
where all Nrkp1 receptors were knocked out and the presence of Nkrp1a alone 
was sufficient to induce a significant rise in NK intracellular calcium (113). These 
knockout cells also had cytotoxic ability against a cancer cell line dependent upon 
the generation of phosphoinositide signalling (114). Nkrp1a activation also 
stimulates the release of pro-inflammatory interferon-γ (113). In contrast, Nkrp1b 
incubation inhibits the cytotoxic activity of the RNK-16 cell line (115). In the event 
of infection or genotoxic stress, the inhibitory Nkrp1b receptor is down-regulated 
(116). Due to its similar inhibitory function, human NKR-P1A is thought to be 
orthologous to Nkrp1b in rat.  Furthermore, Nkrp1a and b have a high degree of 
intraspecies allelic variation in rats and this has led to the misclassification of 
“novel” Nrkp1 family members. The other Nkrp1 receptors in the rat, f and g, 
have only recently been characterised (105). Unlike Nkrp1a and b which have a 
high degree of sequence variability between strains of rat and between rats and 
mice, the sequences of Nkrp1f and g are highly conserved (117). Nrkp1f activation 
was shown to induce an increase in intracellular calcium and induce target cell 
lysis but not to the same degree as Nkrp1a. This suggests that Nrkp1f is not as 
potent an activating factor as Nrkp1a. Inhibitory Nkrp1g effectively reduced target 
cell lysis induced by both Nkrp1a and Nkrp1f and showed up-regulation of the ITIM 
downstream signalling cascade (105). 
1.3.2.3 Pattern-Recognition Receptors 
An evolutionary conserved mechanism exists in the innate immune system 
that allows broad recognition of molecular motifs derived from a potentially 
harmful external source such as glycoproteins or double stranded RNA from 
pathogens (pathogen associated molecular patterns or PAMPs) or an internal 
source such as modifications resulting from oxidative damage or necrosis (damage 
associated molecular patterns or DAMPs) (118). These motifs are recognised by an 
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evolutionary conserved group of receptors known as the toll-like receptors (TLRs) 
(119). Activation of TLRs in NK cells results in a signalling cascade which activates 
pro-inflammatory gene expression through the transcription factors NFκB and 
interferon regulatory factors (IRF) (120). 
1.3.2.4  NK Cells in Hypertension & Vascular Dysfunction 
The most prominent cytokines produced by the NK cell are interferon γ (IFNγ) 
and TNFα which function as an innate form of defence and to recruit cells of the 
adaptive immune system (121). In humans, TNFα and IFNγ work in concert to 
promote the cytotoxic ability of NK cells through up-regulation of the expression 
of intracellular adhesion molecule 1 (ICAM-1) on target cells (122). Uncontrolled 
release of these pro-inflammatory cytokines is a central cause of morbidity and 
mortality in autoimmune disorders (123, 124). In particular, NK cells have been 
shown to have a causative role in vascular pathology, hypertension and 
hypertensive end-organ damage through both secretion of pro-inflammatory 
cytokines and cytotoxic ability. NK cells possess the receptors to adhere to 
endothelial cells (87) and are a causative factor for endothelial damage as a result 
of viral infection (125) and transplantation (126). IFNγ receptor knockout mice are 
protected from end-organ damage from angiotensin II induced hypertension 
suggesting a role for IFNγ in angiotensin II induced vascular damage (85). Recently, 
Kossman et al. identified the source of this damaging IFNγ to be NK cells which 
become activated by IL-12 secreting monocytes in a positive feedback loop to 
potentiate endothelial dysfunction and increased oxidative stress in mouse aorta 
(127). TNFα blockade has also been shown to reduce angiotensin II induced cardiac 
damage (128, 129); yet the relative contribution of TNFα in the model proposed 
by Kossman et al. was not explored. The study by Kossman et al. also focussed on 
the aorta and did not assess effects on the resistance vessels which are 
predominantly involved in the regulation of blood pressure. The NKC has been 
identified as a susceptibility locus for L-NAME induced hypertension in C57BL/6 
mice (130). Taherzadeh et al. exploited the genetic differences in the NKC 
between the C57BL/6 and BALB/C mouse strain showing that C57BL/6 mice had 
an increased propensity for hypertension and vascular remodelling. The authors 
then developed a congenic strain, BALB.B6-Cmvlr, where the C57BL/6 NKC is 
inserted on to a BALB/C background. The congenic strain developed significantly 
higher blood pressure than the BALB/C accompanied by an infiltration of NK cells 
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surrounding the mesenteric arteries. The BALB.B6-Cmvlr congenic also shows a 
significant increase in vascular remodelling and NK cell invasion in a balloon-model 
of vascular injury (131). These finding indicate that the NKC locus is involved in 
hypertension and vascular injury but the identification of which gene in the NKC 
is responsible or whether these findings are relevant clinically is yet to be shown. 
With respect to the model central to this thesis, the SHRSP, the role of NK cells 
has not been previously studied. However, non-specific activation of circulating 
NK cells has been shown in the related SHR strain and is thought to contribute to 
the significant age-related reduction in T cell mediated immunity in the SHR 
relative to the WKY (132). 
 Tumor Necrosis Factor α (TNFα) 
Tumor necrosis factor α (TNFα) is a pleiotropic pro-inflammatory cytokine 
not normally detecTable in healthy individuals but is up-regulated in the event of 
an infection, inflammation or an autoimmune disorder (133). In the majority of 
published work on TNFα, it has been measured as a biomarker of inflammation. 
However, delineating the signalling mechanisms of TNFα remains an active area 
of research. TNFα is produced in a 26 kDa transmembrane form which can then be 
cleaved by metallopeptidase ADAM17 (also known as TNFα converting enzyme; 
TACE) into the 17 kDa soluble TNFα. Both the transmembrane and soluble forms 
of TNFα have distinct roles in the activation of target cells either by direct cell to 
cell contact or acting on remote sites respectively (134). In cells outside of the 
immune system, TNFα receptor 1 (TNFR1) is the major mediator of intracellular 
TNFα signalling (135) (Fig. 1-10). 
TNFα signalling through TNFR1 induces apoptosis and a pro-inflammatory 
response in the target cell. This is primarily through the intracellular TNFR1 death 
domain (TNF-receptor associated death domain; TRADD) which can associate with 
other death domain containing proteins and initiate a signalling cascade for 
apoptosis (136). The TRADD also acts as a scaffold for the activation of the pro-
inflammatory gene transcription factor, NF-κB. TRAF2 is associated with the 
TRADD (TNF receptor-associated factor 2) which recruits the enzyme I-κB kinase 
(IKK). IKK is then activated by RIP (receptor-interacting protein) serine/threonine 
kinase. Once IKK is activated it targets the regulatory subunit of NF-κB, I-κB, for 
destruction by the proteasome. NF-κB is then available to be phosphorylated and 
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translocates to the nucleus (137). TNFα also transiently stimulates JNK and the 
p38 signalling pathways which contribute to inflammation and apoptosis; 
activation of these pathways is only prolonged under apoptotic conditions (135).  
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Figure 1-10: Summary of TNFα Signalling through TNFR1. 
TNFR1 signalling converges on phosphorylation of the I-κB protein which binds and inhibits the 
nuclear localisation sequence of the pro-inflammatory NF-κB (p50-p65) transcription factor. Once I-
κB is phosphorylated it is targeted for degradation by the proteasome. Secondly NF-κB (p50-p65) 
must also be phosphorylated itself by MAP kinases such as p38 to be fully activated for nuclear 
translocation. The stress-activated (SAPK)/C-Jun N-terminal kinase group (JNK) is activated by 
TNFR1 signalling. JNK translocates to the nucleus to enhance the activity of the activating protein-1 
(AP-1) transcription factor. In response to TNFR1 activated JNK signalling, AP-1 transcribes genes 
involved in inflammation such as MCP-1 and E-selectin. The activation of p38 also stabilises mRNA 
of inflammatory cytokines IL-1 and IL-6. ADAM17: ADAM metallopeptidase 17, TRADD: TNF 
receptor associated death domain, FADD: Fas-Associated protein with Death Domain, RIP: receptor 
interacting protein, TRAF2: TNF receptor associated factor 2, MEKK1: MAP/Erk kinase kinase 1, 
MKK: MAP kinase kinase.  
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1.3.3.1  TNFα in Hypertension & Vascular Dysfunction 
TNFα has been shown to play a role in blood pressure regulation. Modest 
increases in circulating levels of TNFα are associated with hypertension (138, 139) 
however large increases in TNFα such as in septic shock are associated with a sharp 
decrease in blood pressure and increased survival (140) (Fig 1-11). The effect of 
TNFα on blood pressure may also be determined by the source, location and type 
(acute or chronic) of inflammation which could explain the often variable and 
sometimes conflicting results for the effect of TNFα inhibitors on blood pressure 
in humans and pre-clinical models.  
TNFα can control blood pressure through direct effects on the kidney (Fig. 
1-11). TNFα is predominantly expressed by immune cells resident in the kidney 
but can also be produced by renal cells (141). Renal TNFα production is increased 
in response to increases in blood pressure, reactive oxygen species and angiotensin 
II (141). Increased TNFα production promotes leukocyte recruitment and 
activation which then results in more TNFα production and thus a self-
perpetuating loop of inflammation. The principal cause of kidney damage elicited 
by TNFα is primarily through this mechanism of inflammation and through TNFα-
dependent cell death pathways (Fig. 1-11). In addition, TNFα in the kidney is able 
to directly regulate salt and fluid balance through modifying the expression of 
components of the RAAS cascade (142, 143) and Na+ transporters (144).  
 
 
62 
 
 
 
 
Figure 1-11: TNFα Levels and Blood Pressure Regulation. 
Chronic increases in TNFα such as that seen in hypertension (red box) perpetuates increases in 
blood pressure and associated end-organ damage. However, an acute, large increase in TNFα such 
as in sepsis (green box) induces mechanism that acts to reduce blood pressure. In both situations, 
TNFα causes activation of the immune system. Figure adapted from Ramseyer & Garvin (2013). 
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TNFα signalling has also been shown to have direct deleterious effects on the 
vasculature in hypertension (Fig 1-12) (145). TNFα infusion induces a significant 
reduction in endothelial dependent relaxation in large and small arteries of both 
humans and rodents (146-148). In endothelial cells, TNFα diminishes the 
bioavailability of vasodilator NO through down-regulation of the expression of the 
eNOS pathway (149, 150) and through increased superoxide production which 
scavenges NO (151). TNFα pre-incubation also significantly reduces the 
vasodilatory effects of endothelium dependent hyperpolarising factor in omental 
arteries from pregnant women (152) and directly affects hyperpolarisation in 
endothelial cells from intact arteries from animal models (153). With respect to 
vasoconstriction, TNFα promotes endothelin 1 (ET-1) mRNA expression (154) and 
can alter VSMC calcium handling (155). TNFα induces endothelial cell activation 
through the expression of other pro-inflammatory cytokines leading to immune 
cell infiltration and a self-perpetuating vascular inflammation (156). 
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Figure 1-12: Tumor Necrosis Factor-α in Vascular Dysfunction. 
TNFα induces endothelial cell dysfunction by reducing vasodilators NO and EDHF and enhancing vasoconstriction through ROS and ET-1 production. Endothelial cell 
activation is triggered through the expression of pro-inflammatory cytokines and adhesion molecules leading to immune cell recruitment and endothelial damage. TNFα 
plays a role in vascular remodelling through activation of MAP kinases that promote vascular smooth muscle cell proliferation and migration and matrix metalloproteinases 
(MMPs) which act to degrade the extracellular matrix (ECM). NO: nitric oxide, EDHF: endothelium derived hyperpolarizing factor, eNOS: endothelial nitric oxide synthase, 
ET-1: endothelin-1. 
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1.4   Animal Models of Hypertension 
1.4.1.1 Animal Models 
The use of animal models in research has steadily increased over the last 
decade; this has principally been due to an increase in the use of animals bred for 
specific genetic modifications (157). The attraction of animal models of human 
disease is that they allow the study of specific disease pathology and treatment 
in situ. Broadly, the ideal animal model of human disease would exhibit 
phenotypic similarities to the human condition, respond similarly to humans when 
treated with clinically relevant drugs and be easily reproducible. Animal models, 
specifically rodents, provide the researcher with an invaluable tool for studying 
complex diseases such as hypertension. Rodent models offer a number of 
advantages for study: they breed easily producing large litters, have a short 
lifespan allowing for relatively long-term and intergenerational studies and the 
ability to have environmental control. Animal models are excellent for studying 
human disease without additional complexity, however, this can also a 
disadvantage. For example, animal models are often inbred with a similar genetic 
background in a tightly regulated environment to produce consistent results. This 
is not the case for humans where the genetic background is diverse with many 
different environments. Furthermore, many animal studies do not take into 
account effects that may be gender specific or affect a certain group of people, 
for example, BMI or race. However, the use of both genders in animal experiments 
has now been addressed in recent guidelines from the National Institute of Health 
(158). 
1.4.1.2 Rat Models of Hypertension 
Rats are the leading animal model for hypertension research (159). There 
are a number of hypertensive rat models, which exhibit similarities to the human 
condition and provide a range of tools to complement the diversity of hypertensive 
disease seen. Examples of rat models currently in use employ surgically-induced 
hypertension (160), dietary hypertension (161), endocrine hypertension (162), 
neurogenic hypertension (163), psychogenic hypertension (164), chemically 
induced hypertension (165) or angiotensin II infusion induced hypertension. 
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A genetic rat model of hypertension incorporates two different 
methodologies: genotype driven or phenotype driven. The mouse is currently the 
model of choice for geneticists owing to extensive knowledge of the mouse 
genome and existing infrastructure for producing genetically modified animals. 
Despite this, genetically modified rat models for studying hypertension do exist 
such as the (mREN-2)27 transgenic rat (166). With the recent advent of new gene 
editing technologies such as CRISPR-Cas (167); inexpensive  and straightforward 
genome editing will be more widely available in rats. Genotype-driven models are 
excellent for dissecting out a single gene in a mechanism of interest. One 
disadvantage is that, by definition, these models are more reflective of rare 
monogenic forms of hypertension. As discussed in section 1.2.1.1, essential 
hypertension of unknown cause accounts for the majority of cases of human 
hypertension. Essential hypertension is known to be polygenic with varying 
degrees of penetrance. This led researchers to develop phenotype-driven rat 
models. Using this approach, rats from an outbred strain are selected for the 
highest blood pressure and selectively bred through sequential brother x sister 
mating to produce a hypertensive inbred strain. Hypertensive animal models can 
also be selected to respond to a specific stimulus such as high salt or high fat. 
These inbred strains resemble the human phenotype of essential hypertension 
where one single gene does not account for the observed phenotype. There are a 
number of inbred hypertensive rat strains currently in use which are summarised 
in Table 1-4. The variety of strains available is helpful to validate findings from 
one strain to the other, for example, the hypertensive susceptibility locus found 
on rat chromosome 1 has been identified in four different rat models (168-171). 
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Table 1-4 Existing Inbred Rat Models of Hypertension 
Name Origin SBP Adult Males 
(mmHg) 
SBP Adult Females 
(mmHg) 
Reference for 
SBP Values 
Control Strain Background 
Strain 
Spontaneously 
Hypertensive Rat 
(SHR) 
Kyoto, Japan 
(172) 
185 163 (173) Wistar-Kyoto (WKY) Wistar-Kyoto 
(WKY) 
Stroke Prone 
Spontaneously 
Hypertensive Rat 
(SHRSP) 
Kyoto, Japan 
(174) 
245 197 (175) WKY WKY 
Milan Hypertensive 
Rat (MHS) 
Milan, Italy 
(176) 
163 SBP was not 
significantly 
different in 
females1. 
(177) Milan Normotensive 
Rat 
Wistar 
                                         
1 SBP of 163.7 ± 1.9 mmHg is given as an average of a group containing both male and female animals. The authors state there is no significant difference between 
male and female animals. 
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Dahl Salt Sensitive 
Rat (Dahl S) 
Brookhaven, 
USA (178) 
152 141 (179)2 Dahl Salt Resistant 
Rat 
Sprague-
Dawley 
Lyon Hypertensive 
Rat (LH) 
Lyon, France 
(180) 
173 - (181) Lyon Normotensive 
Rat and/or Lyon 
Low Blood Pressure 
Rat 
Sprague-
Dawley 
Sabra Salt Sensitive 
Rat (SBH) 
Jerusalem, 
Italy (182) 
186 157 (183) 3 Sabra Salt Resistant 
Rat  
Wistar 
New Zealand 
Genetically 
Hypertensive Rat 
(NZGH) 
Dunedin, New 
Zealand (184) 
158 148 (185) New Zealand 
Normotensive Rat 
Wistar 
 
SBP in the Table is given for adult animals 4-6 months of age. Table compiled by author. 
                                         
2 Dahl S rats were salt loaded (0.8 % NaCl in drinking water) for 2 weeks. 
3 Sabra Salt Sensitive Rats were salt loaded (0.1% NaCl in drinking water) for 4 weeks. 
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1.4.1.3 The Stroke Prone Spontaneously Hypertensive Rat 
The spontaneously hypertensive rat (SHR) and stroke prone spontaneously 
hypertensive rat (SHRSP) were obtained by selective inbreeding of Wistar-Kyoto 
(WKY) rats in the laboratory of Okamoto and colleagues at the Kyoto University 
Faculty of Medicine, Japan (172, 174). Firstly, the SHR was developed by selective 
inbreeding of WKY with high systolic blood pressure in 1963 (172). The SHR blood 
pressure begins to spontaneously increase from 4 weeks of age reaching an SBP in 
males of 180-200 mmHg relative to 130 mmHg in the contrasting WKY strain (186). 
In 1971, the SHR was divided into three sub-strains (A - C); where sub-strain A 
consistently exhibited higher SBP and an increased propensity for cerebrovascular 
disease. Inbreeding of offspring from sub-strain A produced the SHRSP (Fig 1-13). 
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Figure 1-13: Genealogy of the Stroke Prone Spontaneously Hypertensive Rat. 
Image provided by Dr. Delyth Graham. 
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The SHRSP has an increased incidence of CV complications, specifically a 
higher tendency for stroke, as well as a more rapid onset of hypertension from 5 
weeks of age rising to a SBP in male animals of approximately 230 – 250 mmHg 
(174) relative to the normotensive WKY in the original Kyoto strain. The SBP varies 
between sub-strain and in Glasgow the eventual SBP is approximately 190-200 
mmHg (personal communication, Dr. Delyth Graham). Furthermore, SHRSP blood 
pressure is salt-sensitive, whereby replacing drinking water with a 1% NaCl 
solution produces a rise in blood pressure of approximately 30 mmHg and 
accelerates the occurrence of stroke (187). In contrast, the SHR and WKY are less 
salt sensitive (187). Male SHRSP have a shorter lifespan (52 – 64 weeks (188) or 14 
– 20 weeks with salt loading (189)) relative to the SHR (approximately 2 years) and 
the WKY (approximately 3 years) (190). The pronounced CV phenotype and salt-
sensitivity of the SHRSP makes it an ideal model to study human hypertension. The 
SHRSP displays a number of pathologies associated with human hypertension which 
make it a clinically relevant model (Fig 1-14). 
 
 
Figure 1-14: Characteristics of the Stroke Prone Spontaneously Hypertensive Rat. 
  
• Increased blood pressure with age.
• Sex difference in blood pressure.
• Endothelial dysfunction.
• Cardiac hypertrophy.
• Renal dysfunction.
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1.4.1.4 Sex Differences in the Spontaneously Hypertensive Rat and the Stroke 
Prone Spontaneously Hypertensive Rat 
 Higher blood pressure in males is reflected in inbred models of hypertension 
such as the SHR, SHRSP, Dahl and (mREN-2)27 rats (191). Furthermore, there have 
been no studies to date which have shown a robust difference in blood pressure 
between male and female normotensive animals; suggesting that the observed 
gender dimorphism is specifically related to pathologies underlying the 
development and establishment of hypertension. The SHRSP and related SHR have 
been used to explore mechanistic differences in blood pressure regulation 
between male and female animals. As shown in Table 1-4, systolic blood pressure 
is greater in male SHR and SHRSP. 
 The Y chromosome in the SHRSP has been shown to carry a hypertension 
susceptibility locus (175). Furthermore, castration of male SHRSP before 
adulthood results in a reduction in blood pressure increase in these animals 
however anti-androgen treatment was not effective against established 
hypertension (192). This suggested an involvement for male sex hormones in the 
development but not maintenance of high blood pressure. Ovarectomized females 
show no difference in blood pressure in the SHR (193) but there is a significant 
increase in blood pressure when SHRSP are subject to the same procedure (194). 
The utilisation of animal models for studying the contribution of sex hormones to 
blood pressure regulation should be interpreted with caution as timing of surgery 
and dosage of hormone replacement therapy are often found to vary (191). 
Vascular biology also differs between male and female SHRSP. Aortic rings from 
SHRSP females have a greater endothelium-dependent nitric oxide mediated 
vasodilation (195) than males and have altered calcium handling machinery 
involved in vasoconstriction (196). In the SHR, vascular smooth muscle cells 
(VSMCs) from male animals have higher proliferative and migratory capacity (197). 
Female SHRSP are also relatively protected from hypertension related kidney 
damage (198) and have significantly reduced proteinuria when aged (199). Female 
SHRSP have been shown to have a significantly increased anti-inflammatory T 
regulatory cell (TReg) response induced by hypertension (200). Furthermore, 
female SHRSP were found to have a significantly lower mortality attributed to a 
more effective anti-inflammatory response (201). 
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1.5  Pregnancy & the Cardiovascular System 
Pregnancy presents a major challenge to the maternal CV system; it requires 
rapid and extensive remodelling in order to provide for the developing fetus. The 
main driving forces for these changes are an increase in metabolic demand from 
the mother and fetus and maximising the uteroplacental blood flow. Changes in 
measurable CV  parameters can be detected as early as 5 weeks of gestation in 
humans (202) and mostly return to normal two weeks post-partum in humans 
(203). CV changes are measured at gestational day 3.5 in rodents (204) and resolve 
slightly later with significantly elevated SV and CO detecTable up to three weeks 
after pregnancy (205). The occurrences of these changes in the CV system which 
occur very early in pregnancy, even before placentation, highlight the vital role 
that they play. Indeed, deficiency in the adaptation of the maternal CV system 
underlies a number of obstetric syndromes.  
  Cardiovascular System Adaptation to Pregnancy in Humans 
and Rodents 
The dynamic process of systemic CV remodelling associated with pregnancy 
is most well-characterised in humans and in mice. Data from mice were used to 
expand upon changes seen in rats (Table 1-5) as adaptation in the two species is 
thought to be broadly similar. In humans and rodents, the blood flow to non-
reproductive organs is unaltered by pregnancy whilst the uterine blood flow 
increases by around 20-fold (206). The key change during pregnancy affecting the 
CV system is a marked increase in blood volume due to activation of the RAAS 
early in pregnancy. This leads to an approximately 50% increase in CO which is 
seen in both humans and rodents (207, 208). In humans, the increase in CO early 
in pregnancy is primarily mediated by SV then later in pregnancy mediated by an 
increase in heart rate (209), whereas, it is thought to be predominantly due to an 
increase in SV in rodents (205). The vasculature accommodates this increase in CO 
by marked systemic vasodilatation. As a counter-balance, increased sympathetic 
drive to the heart, adrenal glands, kidney and skeletal muscle are vital to 
counteract hypotension. This combination of increased preload due to higher 
circulating blood volume and decreased afterload due to the global reduction in 
systemic vascular resistance results in eccentric remodelling of the heart and an 
increase in left ventricular mass, similar to that which is seen in elite athletes 
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(210, 211). Maladaptation of the maternal CV system is an underlying cause of CVD 
in pregnancy. For example, in pre-eclampsia there is a significantly reduced 
volume expansion and systemic vasodilatation but the sympathetic nervous system 
remains excessively activated relative to normotensive women (212).  
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Table 1-5 Physiological Adaptation of the Maternal Cardiovascular System in Humans and Rodents. 
 Humans Rodents 
Cardiac Output Increases up to  45% by the second trimester  with an 
additional 15% for twin pregnancies (208) . 
Increases up to 28% by gestational day 9.5 (205) and 40 - 60% 
by gestational day 17.5 (204, 207). 
Heart Rate Gradual increase throughout pregnancy to a maximum of 20-
25% by the third trimester. 
Gradual increase of 10-15% up to gestational day 17.5 (204, 
205). 
Stroke Volume Increase early in pregnancy up to the second trimester. Increases up to 30 - 40% by gestational day 17.5 (205, 207) 
Blood Volume Increases 20-100% with 45% being the most common (209). 
Plasma volume increases by 50% (213). Haematocrit 
decreases from normal value of 12-16 g/dl to minimum 
healthy levels of 11 g/dl in first trimester and 10.5 g/dl in 
second and third trimester (214). 
Increase of 26% in plasma volume and haematocrit is 
decreased by 18% by gestational day 17.5 (204, 205). 
Cardiac Remodelling Left ventricular wall thickness increases by 28% and wall 
mass by 40-52% (203, 215, 216). 
Left ventricular mass increases by 20-40% by gestational day 
17.5 (205, 207). 
Systemic Vascular Resistance Decreases up to 35-40% in the first trimester followed by a 
plateau or slight increase in the third trimester (217). 
Decreases up to 29% by gestational day 9.5 and up to 36% by 
gestational day 17.5 (205). 
Renal Plasma Flow Vasodilation of the kidneys causes a 50% increase in renal 
plasma flow and glomerular filtration rate (218).  
Vasodilation of the kidneys reaches a maximum at mid-term 
which is accompanied by a 20% increase in glomerular 
filtration rate (219). 
Renin-Angiotensin System Renin-angiotensin system (RAS) is activated from gestational 
week 6-8 and rises until gestational week 28 – 30 (209). Every 
component of the RAS system is increased apart from 
angiotensin converting enzyme (ACE) (220). 
RAS is activated in pregnancy. In humans where most of the 
increase in renin comes from the placenta; in rodents it may 
be a combination of both the placenta and kidneys (221). 
Sympathetic Activity Sympathetic nerve activity is increased from the first 
trimester (222). Increased maternal baroreceptor sensitivity 
and decreased responsiveness to α-adrenergic stimulation 
(223, 224). The pressor effect of infused angiotensin II is 
reduced (225). Vasoconstrictor response to sympathetic 
stimulation in the uterine arteries is reduced (226) 
Sympathetic nerve activity is increased primarily through 
the activation of the hypothalamic paraventricular and 
arcuate nuclei (227). Pressor response to angiotensin II, 
noradrenaline and vasopressin is reduced in pregnant rats 
(228). Vasoconstrictor response to sympathetic stimulation is 
reduced (229). 
All percentages quoted are representative as a change from pre-partum baseline. 
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 In summary, the CV system of pregnant humans and rodents are broadly 
similar; characterised by a high volume, low pressure system with eccentric 
cardiac remodelling. 
 Mechanisms of Pregnancy-Dependent Cardiovascular 
Remodelling in Humans and Rodents 
The pregnancy-related hormones – estrogen, progesterone and relaxin – 
play a central role in mediating CV adaptation to pregnancy. Estrogen and 
progesterone are principally produced by the corpus luteum formed by the ovary 
once an ovum has been released in early pregnancy; whilst the placenta is then 
the main production site for the second and third trimesters. Levels of estrogen 
and progesterone are related to increased vasodilation in humans (230). Both mice 
and rats show also a marked increase in estrogen and progesterone production 
during pregnancy.  Progesterone and estrogen blunts the pressor response to 
angiotensin II in humans (225) and rats (231). Estrogen alone has been shown to 
have a protective effect on the CV system in SHRSP (232). Progesterone has been 
shown to have protective effects on the vasculature independent of estrogen in 
humans and rats (233). Progesterone administration lowers blood pressure in 
humans (234) and inhibits calcium mediated vasoconstriction (235) in rats. Relaxin 
is another hormone produced by the corpus luteum in humans and rodents. It 
increases to a peak by the end of the first trimester when it falls to a plateau for 
the remainder of pregnancy (236).  Human recombinant relaxin administration in 
female, virgin rats and in mid-gestation rats results in approximately a 20% 
increase in CO (237, 238). Relaxin has also been shown to elicit a reduction in 
systemic vascular resistance (239) and an increase in renal blood flow (240) in 
pregnant rats. Placental growth factor (PlGF), another pregnancy-related factor 
produced in vast quantities by the placenta, has been shown to be involved in 
maternal CV adaptation to pregnancy.  PlGF knockout mice had an altered blood 
pressure profile during pregnancy as well as reduced CO, increased left ventricular 
hypertrophy and renal pathology (207). The pattern of PlGF levels over pregnancy 
is similar in mice and in humans. PlGF levels are reduced in women who develop 
pre-eclampsia (241) therefore these findings may have some relevance in clinical 
situation. Treatment of an animal model of pre-eclampsia with human 
recombinant PlGF resulted in a decrease in blood pressure concurrent with a 
reduction in the circulating molecule soluble FLT-1 which acts as an endogenous 
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antagonist to VEGF signalling but had no beneficial effect on fetal weight or fetal 
loss. This suggests that PlGF plays a role specifically in the adaptation of the CV 
system perhaps through modulation of VEGF signalling (242).  
 Blood Pressure during Pregnancy in Humans and Rodents 
The increase in CO during pregnancy must be accompanied by a reduction 
in systemic vascular resistance to stabilise maternal blood pressure. Typically 
during a healthy human pregnancy, systolic and diastolic blood pressure follows a 
similar U-shaped pattern (243, 244). Blood pressure decreases towards the middle 
of pregnancy (gestational week 20) followed by a steady increase toward delivery 
(Fig. 1-15A). In women who develop hypertensive disorders of pregnancy, this 
initial dip in blood pressure is absent followed by a rapid increase from mid-
gestation (Fig. 1-15B). Women who are hypertensive before they become pregnant 
can fall into either of these categories. Some women experience the normal fall 
in blood pressure and may need their anti-hypertensive medication adjusted or 
even discontinued whilst others do not (39). 
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Figure 1-15: Blood Pressure Profile of Normotensive Pregnancy and Pregnancy Associated with 
Hypertensive Complications. 
Women with normotensive pregnancy (A) experience a characteristic dip in blood pressure during 
the first half of pregnancy; this is absent in women who experience pregnancy-induced hypertension 
(B). Image adapted from Ayala et al. (1997) 
Normotensive Pregnancy Hypertensive Pregnancy
A B
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 The blood pressure profile of pregnant rats has both similarities and 
difference to humans (Fig. 1-16A-D). Normotensive WKY rats exhibit a decrease in 
systolic blood pressure until gestational day (GD) 7 when there is a plateau until 
GD 14 when systolic blood pressure decreases again towards parturition (Fig. 1-
16C).  The WKY rat is similar to the human in that it experiences an early decrease 
in systolic blood pressure but there is a contrast in that blood pressure decreases 
rather than increases towards parturition. it is hypothesised that there is a 
“hypotensive factor” which increases in the circulation to induce this fall in blood 
pressure (245). The early blood pressure profile of the SHRSP during pregnancy is 
similar to that of women who go on to develop hypertensive complications of 
pregnancy where there is limited blood pressure reduction during early gestation 
(Fig. 1-16C). In particular, the SHRSP exhibits the greatest blood pressure 
difference relative to the WKY from GD 10-14. This coincides with the critical 
period of development and maturation of the rodent placenta. The change in 
diastolic blood pressure over pregnancy is not as marked as SBP in rodents; in 
contrast to humans where reductions in the two are broadly similar (Fig. 1-16D). 
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Figure 1-16: Blood Pressure Profile in the normotensive WKY rat and the Stroke prone Spontaneously Hypertensive Rat (SHRSP). 
The SHRSP is hypertensive before and during pregnancy relative to the normotensive WKY (A-B). In a similar fashion to normotensive pregnant women, the WKY 
experiences an early reduction in blood pressure during gestation; this drop is not evident in the SHRSP (C-D). The decrease in systolic blood pressure (SBP) is not as 
pronounced as diastolic blood pressure (DBP). Unlike humans, rats experience a further drop in blood pressure towards parturition (C-D).   Data are the author’s own 
from previous work. 
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1.6  Animal Models of Human Pregnancy 
For obvious ethical and practical reasons, research in pregnant women is 
particularly difficult therefore animal models of human pregnancy have been 
developed. Rodents, as discussed in section 1.4.1.1, are ideal for laboratory 
studies and various similarities exist between human and rodent pregnancy which 
are summarised in the following sections. 
 Placentation in Humans and Rats 
The placenta of humans and rats are both chorioallantoic, derived from the 
chorion and allantois, and share a similar haemochorial structural organisation 
where the maternal blood is in direct contact with the chorion which encapsulates 
the fetal vasculature. The haemochorial placenta is an invasive structure 
characterised by extensive remodelling of the maternal spiral arteries discussed 
in section 1.6.3. Whilst the defined trimesters of pregnancy are not directly 
relaTable to particular time points in the rat; the major hallmarks of placental 
development occur in broadly the same temporal pattern (246). The outer cell 
layer of the blastocyst, termed the trophectoderm, gives rise to the chorionic 
ectoderm and ectoplacental cone (only present in rodents). The inner cell mass 
of the blastocyst will give rise to the embryo and the allantois (which will finally 
form the umbilical cord). The area of transfer between the maternal and fetal 
blood arises when the chorion, from the chorionic ectoderm, and allantoic 
mesoderm come into contact, termed chorioallantoic fusion. Folds appear in the 
chorion where the fetal vessels should begin to grow outwards from the allantois. 
This is followed by extensive branching to maximise surface area contact between 
the maternal and fetal circulation. In humans, this area becomes the villous tree 
and the analogous rat structure is the labyrinth (Fig. 1-17A) (247). The 
ectoplacental cone, present only in rodent placental development, forms the 
junctional zone of the rodent placenta. This borders the maternal decidua and is 
the site of rodent trophoblast progenitor cells. 
In both humans and rat, the aforementioned development of the 
haemochorial placenta is principally actioned by the trophoblasts which also form 
the parenchyme of the tissue. Trophoblasts are organised down two pathways. 
They can fuse and develop a multi-nucleated structure known as the 
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syncytiotrophoblast which lines the floating villi and acts as the barrier to 
maternal blood. In humans, there is one syncytiotrophoblast layer which separates 
the maternal and fetal circulation whereas there are two in rats (Fig. 1-17B) (247). 
In humans, the others contribute to a cytotrophoblast shell which covers the 
decidua and forms cell columns anchoring the placenta to the uterus. Extra-villous 
trophoblasts migrate from the tips of these columns to remodel the maternal 
spiral arteries (section 1.6.3). In rodents, these invasive cells are derived from the 
junctional zone (Fig. 1-17C). 
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Figure 1-17: Comparative Placentation 
between Rodents and Humans. 
(A) Humans and rats share a 
haemochorial placental type. In the human, the 
villous tree is analogous to the labyrinth zone in 
the rat. The extravillous area in humans is 
composed of a cytotrophoblast shell punctuated 
by columns where extravillous trophoblasts 
(EVTs) leave the tips of these columns and 
invade the uterine wall. This area is different in 
rats as it contains a junctional zone which 
borders the decidua and acts as a source of 
placental hormones and invasive extravillous 
trophoblasts (EVTs). Invasive EVTs in both 
humans and rats invade the maternal spiral 
arteries and uterus to a similar depth. (B) In 
humans, the fetal and maternal circulations are 
separated by one syncytiotrophoblast layer 
whereas there are two in the rat. (C) Humans 
and rats share a common chorioallantoic 
development of the placenta, a summary of rat 
placental development is shown in (C). Images 
adapted from Rossant & Cross (2001) & Soares 
et al. (2011). 
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 Pregnancy-Dependent Uterine Artery Remodelling During 
Pregnancy in Humans and Rodents  
In addition to the adaptations that occur in the systemic vasculature; the 
uterine arteries must also adapt in order to supply the developing fetus and a new 
organ – the placenta. The anatomy of the uterine arteries between human and 
rats is broadly similar (Fig. 1-18A-B). The uterus has a dual blood supply from both 
the ovarian and uterine arteries which arise from a common anastomotic loop. 
The uterine artery is subject to a series of branching which is important for 
reducing the pressure of blood reaching the placenta to around 8 – 15 mmHg (248) 
which would otherwise damage the delicate villous structure (249). Perpendicular 
vessels derived from the uterine artery enter into the body of the uterus giving 
rise to the arcuate arteries. In the myometrium, the radial arteries branch from 
the arcuate arteries. In rats, the arcuate and radial arteries are externally located 
(247). Further branching occurs at the interface between the myometrium and 
endometrium into the spiral arteries which penetrate inwards to the endometrium 
(Fig. 1-18C). 
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Figure 1-18: The Uterine Circulation in Humans and Rodents. 
(A-B) The uterine arterial tree is similar in both humans and rodents. (C) In humans the arcuate and radial arteries are located internally; however in rats they are 
located externally. Image adapted from Osol & Moore (2013) and Robertson (1975). 
A
B
C
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1.6.2.1 Spiral Artery Remodelling During Pregnancy in Humans and Rodents 
The inner-most branches of the uterine artery, the spiral arteries, are 
subject to extensive remodelling by cells from both maternal and fetal origin. The 
unique spiral structure of these arteries themselves is thought to play a role in 
dampening both the pressure and pulse of maternal blood but also act as a reserve 
length to accommodate pregnancy associated expansion (250). Decidualisation 
transforms the endometrium of the non-pregnant uterus into the pregnant 
decidua. This is stimulated by progesterone through cyclic AMP induction (251). In 
humans, this process begins spontaneously during the luteal phase of menstrual 
cycle but in rodents only occurs in response to implantation (252).   
Decidualisation of the endometrium is characterised by changes in the 
secretory profile of endometrial stromal cells, an influx of specialised immune 
cells and maternal spiral artery remodelling (253). Upon decidualisation, 
endometrial stromal cells become characteristically round in appearance and 
express factors such as: prolactin, growth factors, pro-angiogenic factors and 
cytokines (IL-11 and IL-15) which stimulate the differentiation and proliferation 
of the specialised uterine population of natural killer (uNK) cells (254, 255). 
Decidualisation is associated with a marked increase in NK cell number; 
approximately 70% of infiltrating leukocytes within the decidua are NK cells (256). 
The other 25% are composed of macrophages, few T cells and very few B cells 
(257). The combination of decidualisation of the stromal cells and recruitment of 
NK cells primes the endometrium for the unique task of regulating the invasion of 
fetally-derived extravillous trophoblasts (EVT); these EVTs can take two pathways. 
Interstitial trophoblasts will invade the stroma and act to remodel the spiral 
arteries from the outside destroying the vascular media and replacing it with 
fibrinoid material (250, 256) (Fig 1-19A). The second pathway is for endovascular 
EVTs which will initially plug the maternal spiral arteries then travel in a 
retrograde fashion down the lumen of spiral arteries removing and replacing the 
vascular smooth muscle cells as they proceed then come to a halt somewhere 
around the inner third of the myometrium (250, 256) (Fig 1-19A). In this respect, 
rats are an excellent model of this process as they exhibit a similarly deep 
trophoblast invasion to humans; in mice this invasion is relatively shallow (258). 
The plug of the arteries is thought to prevent the untimely flow of maternal blood 
into the immature placental structure and to provide a low oxygen environment 
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which drives trophoblast proliferation (259); plugging however occurs more 
extensively in humans than in rats (252). In humans, interstitial invasion occurs 
prior to endovascular invasion (250) however in rodents it is the opposite (260). In 
addition to the role of the trophoblast, uNK cells play an important role in 
maternal spiral artery remodelling. Compelling evidence of this is seen when the 
smooth muscle layer of the uterine spiral arteries remains intact in an NK cell 
knockout mouse model (261). The uNK cells produce matrix metalloproteinases 
(MMPs) and pro-angiogenic factors that can directly promote vascular remodelling 
(262, 263). They also communicate with the invading trophoblast through the 
unique human leukocyte antigen (HLA) repertoire found on trophoblasts to 
indirectly mediate trophoblast-dependent spiral artery remodelling (256). 
Deficient remodelling of these spiral arteries is an underlying cause of pre-
eclampsia, spontaneous pregnancy loss and fetal growth restriction (264) (Fig 1-
19B). In this thesis, the focus will be on the remodelling of the uterine artery 
which is subject to a different mechanism.
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Figure 1-19: Mechanisms of Uterine Spiral Artery Remodelling. 
(A) Fetally-derived invasive extravillous trophoblasts can act interstitially to remodel the maternal spiral arteries from the outside or intravascularly and enter the lumen 
of the vessel and remodel from the inside. The process of pregnancy-dependent spiral artery remodelling begins with decidualisation which causes endothelial cell (EC) 
vacuolation and smooth muscle cell swelling (VSMC); however the major effectors of change are the EVTs. EVTs or cells which they recruit such as macrophages and 
NK cells induce apoptosis and clearing of vascular cells, breakdown the existing extracellular matrix structure between cells and in the surrounding adventitia then lay 
down new fibrinoid material. (B) When spiral artery remodelling is deficient it results in a restriction of uteroplacental blood flow which underlies conditions such as pre-
eclampsia and intra-uterine growth restriction (IUGR). Images from Whitely et al. (2010) & Moffet-King et al. (2002). 
A B
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1.6.2.2 Uterine Artery Remodelling During Pregnancy in Humans and Rodents 
Pregnancy-dependent uterine artery remodelling occurs through a 
combination of structural and functional changes. The diameter of the uterine 
artery approximately doubles in size in both humans (265, 266) and rats (266). The 
type of circumferential remodelling is designated as “outward hypertrophic” as 
there is an increase in lumen size and cross-sectional area but with no change in 
wall thickness (267). Uterine artery remodelling is slightly different in the mouse 
where medial thickening has been observed in pregnancy (268). In rodents which 
have multiple fetuses in one litter there is also significant lengthening, or axial 
remodelling, of the uterine artery where the pregnant vessel is 2-3 times the 
length of the non-pregnant vessel (248). This process is present but not as 
extensive in human pregnancy. At a cellular level, the increase in uterine artery 
size occurs through an increase in VSMC length of approximately 20% and 
proliferation of both the VSMC and endothelial cells (269). With respect to uterine 
artery function during pregnancy, the larger remodelled vessels exhibit a pattern 
of reduced contractility and increased relaxation in humans and rodents (248). 
The alterations in uterine artery structure and function are predominantly 
to allow the vessel to accommodate a greatly increased blood flow. In humans, 
uteroplacental blood flow increases from a baseline of 20 – 50 ml/min to up to 1 
l/min; a 20-fold increase (270). This is similar in rats where a 23-fold increase has 
been reported (271). Whereas the increase in uterine artery blood flow is linear 
in humans over time (272), changes in uterine artery blood flow are not detectable 
until gestational day 15 in the rat (273). Over the course of pregnancy an 
increasing proportion of uterine blood flow is directed to the placenta and by term 
90% of the uterine artery blood flow is directed there (206). Increases in uterine 
blood flow in early pregnancy are principally due to the increase in diameter of 
the uterine artery whereas in late pregnancy it is a combination of both a marked 
increase in CO and uterine artery remodelling (267) 
All vascular remodelling occurs through four key processes: growth, death, 
migration and alteration of the extracellular matrix. The mechanisms involved in 
simulating these processes in the uterine arteries during pregnancy are not well 
defined. The available evidence suggests that early remodelling relies on systemic 
mediators as uterine artery remodelling occurs before the placenta is established 
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(267) and pseudopregnant mice exhibit similar early changes in uterine artery 
structure to pregnant controls up to gestational day 5 (274). These early changes 
are small in comparison to the extensive remodelling that is seen in uterine 
arteries at late gestation. Therefore once the placenta is established, local 
signalling from the uteroplacental unit stimulates the largest changes in uterine 
artery structure. Evidence for this comes from unilateral horn ligation 
experiments in a number of animal models including rats which show that only the 
pregnant uterine horn exhibits extensive vascular remodelling (275-277). The main 
systemic factor that stimulates remodelling is thought to be estrogen (Fig. 1-20). 
Chronic estrogen treatment in ovarectomised guinea pigs stimulates a small 
increase in uterine artery diameter (278) and DNA synthesis in primary VSMC 
cultures (278). Work in estrogen receptor knockout mice have shown that the 
presence of estrogen receptor α is necessary for artery remodelling through the 
up-regulation of eNOS (279). However, no studies have yet been carried out in 
pregnant animals. The main local drivers of uterine artery remodelling are 
proposed to be shear stress and growth factors released from the placenta (267) 
(Fig. 1-20). 
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Figure 1-20: Known and Hypothetical Mechanisms of Pregnancy-Induced Uterine Artery Remodelling. 
Uterine artery remodelling in response to pregnancy is dependent upon a number of systemic, local and environmental factors. The effect of estrogen on the uterine 
arteries during pregnancy is the best studied. However pregnancy-induced changes in other vasoactive molecules such as growth factors (VEGF, PDGF and PlGF), the 
renin angiotensin aldosterone system (RAAS) and relaxin produced from the placenta or elsewhere may also play a role in uterine artery remodelling. Locally, shear 
stress due to increased blood flow is thought to induce early changes in uterine artery structure whereas placentally derived factors play more of a role later in pregnancy. 
Immune cells which have been shown to actively remodel the spiral arteries may have a role in remodelling the uterine artery however this is yet to be defined. The 
perivascular adipose tissue may also potentially secrete vasoactive factors that promote remodelling as in other vascular beds. Women who live at high altitude (low 
PO2) show altered uterine artery remodelling therefore maternal environment also plays a role. All of these pathways converge on stimulating the endothelium and 
vascular smooth muscle cells to promote structural and functional changes in the uterine artery.  
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1.7  Hypertensive Disorders of Pregnancy 
Whilst women are normally protected from CVD compared to men, 
pregnancy is a specific point in time where women appear to be susceptible to CV 
complications. CVD is the leading cause of maternal mortality in the United 
Kingdom (280) and in the United States (281). Pregnant women can suffer 
orthostatic intolerance, heart failure, peripartum cardiomyopathy and 
arrhythmias. This thesis will focus on hypertensive disorders of pregnancy which 
are broadly classified into three groups: pre-eclampsia/eclampsia (PE), 
gestational hypertension and chronic hypertension. Gestational or chronic 
hypertension can present on their own but also confer increased risk to develop 
the more serious complication of pre-eclampsia. Uncontrolled hypertension during 
pregnancy has been identified as a major prevenTable cause of maternal mortality 
(282). 
  Pregnancy as a Cardiovascular Stress Test 
How much either pre-existing CV risk, pregnancy associated changes or a 
combination of both contribute to maternal CVD during pregnancy is unknown. 
One hypothesis to describe this is that the significant adaptation of the CV system 
is a maternal “stress test” (283). The extensive CV remodelling required for a 
healthy pregnancy uncovers underlying cardiovascular risk factors. This abnormal 
vascular remodelling response pushes the woman over a clinical “threshold” 
detectable as some form of CVD during pregnancy such as pre-eclampsia or 
gestational hypertension (Fig 1-21). These women also have an increased 
incidence of CVD later in life due to these increased CV risk factors. However, 
another alternative explanation is that cardiovascular disease in pregnancy causes 
irreversible damage to the CV system manifesting as disease later in life (284). 
Realistically, it is probably a balance of both of these mechanisms. 
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Figure 1-21: Pregnancy as a Cardiovascular Stress Test. 
Image from Sattar and Greer (2002). 
 
The link between CVD in pregnancy and an increase in future cardiovascular 
risk has been noted since the early 19th century (285).  Recent studies including 
meta-analyses (286) have reported that women with severe forms of hypertension 
during pregnancy have a 3-4 fold increased risk of hypertension later in life (287-
289) , 2 fold increased risk in developing ischemic heart disease (290)  and stroke 
(291) and a 3-5 fold increase in renal disease (289, 292) but does not worsen pre-
existing renal disease (293). Furthermore, there have also been links made with 
diabetes mellitus, venous thromboembolism, hypothyroidism and depression 
(294). In a wider sense, the Cardiovascular Health after Maternal Placental 
Syndromes study (CHAMPs) also reported that women who experienced placental 
complications had 2 times the incidence of cardiovascular disease later in life 
(295). This highlights that abnormal pregnancy can be related to CVD risk later in 
life. The evidence presented suggests that common risk factors and mechanisms 
may exist that underlie CVD in both non-pregnant and pregnant women. 
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  Pregnancy-Specific Hypertensive Disorders 
Pregnancy-specific hypertensive disorders, including pre-eclampsia (PE) 
and gestational hypertension, arise after 20 weeks of pregnancy. Gestational 
hypertension can be transient or develop into chronic hypertension which is 
unmasked by pregnancy and persists postpartum. Further, gestational 
hypertension can develop into the serious complication; PE. PE is defined using 
International Society for the Study of Hypertension in Pregnancy (ISSHP) criteria 
as the development of hypertension (SBP of 140 mmHg or greater and/or DBP of 
90 mmHg or greater) and proteinuria (300 mg/24 h or greater or 2+ or greater on 
urine dipstick testing) after the 20th gestational week. PE affects between 5 and 
8% of pregnancies worldwide (296) and can present with a number of serious 
complications for mother and baby such as  preterm delivery, intrauterine growth 
restriction, hepatic or renal dysfunction, seizures, and coagulopathy. PE is 
responsible for up to 15% of maternal deaths worldwide (297). Currently, no 
effective cure for PE exists apart from delivery of the placenta highlighting a key 
role for the organ in this disease. 
The current two step model of PE states that insufficient remodelling of 
the uterine spiral arteries by extravillous trophoblasts plays a critical role in the 
underlying development of pre-eclampsia (Section 1.6.2.1). This deficient 
remodelling and restricted blood flow underlies changes to the placenta which do 
not allow it to function normally resulting in the release of soluble factors which 
propagate the systemic effects of PE (298). Hypotheses surrounding the underlying 
drivers of the pathology in PE are abundant with dysregulation proposed in 
metabolism, immunology, angiogenesis and oxidative balance. It is well deserved 
that PE is referred to as the “disease of theories” as much of the multifactorial 
cause for this disease remains poorly understood (299) (Fig. 1-22).  
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Figure 1-22 The Pathology of Pre-eclampsia. 
Pre-eclampsia is a multi-systemic disorder with respect to its underlying cause and pathology. 
Excessive activation of the angiotensin II type 1 receptor through auto-antibodies (AT1-AA), 
abnormal immune activation of maternal NK cells by invading trophoblasts, genetic predisposition 
and oxidative stress may play a role in deficient spiral artery remodelling resulting in placental 
dysfunction. The placenta in pre-eclampsia releases anti-angiogenic mediators such as soluble FLT-
1 and soluble endoglin (ENG) and other unknown mediators which have systemic effects on the 
vessels, kidney, liver and brain. The combined organ damage results in hypertension, proteinuria 
and can even develop into dangerous eclamptic seizures and HELLP syndrome.  Image from Powe 
et al. (2011). 
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  Chronic Hypertension during Pregnancy 
Chronic hypertension in pregnancy is defined by the American College of 
Obstetricians and Gynaecologists (ACOG) as a blood pressure over 140 mmHg 
systolic and 90 mmHg diastolic which has presented pre-pregnancy or before 
gestational week 20 (300). Chronic hypertension has been stated to affect around 
3% of pregnancies (301-304); additionally one longitudinal study reported an 
increase in prevalence over the study period (304). The occurrence of pregnancies 
complicated by chronic hypertension varies between populations (302) and 
ethnicities (305). The limitation of population-based studies of chronic 
hypertension in pregnancy is that the most recent cohort analysed was in 2008 
(304). Pregnancies complicated by pre-existing hypertension are regarded by the 
literature to pose a clinical problem of increasing occurrence in developed 
countries (305, 306) as a number of key risk factors for hypertension are increasing 
in women, for example, maternal age at childbirth (307), obesity (308) and 
metabolic syndrome (309). CVD prevention in young women was recently 
identified as being a neglected area in a recent editorial (310) and as 
approximately 20% of pregnancies in the United Kingdom (311) and up to 50% of 
pregnancies in the United States (312) are unplanned there is a critical need for 
pre-natal counselling for women of childbearing age with hypertension. 
 Women with chronic hypertension are at an increased risk of pregnancy 
complications. A recent meta-analysis of the existing literature on this subject 
reported that women with chronic hypertension had higher incidences of 
superimposed pre-eclampsia (25.9%, 95% confidence interval 21.0% to 31.5%), 
caesarean section (41.4%, 35.5%- 47.7%), preterm delivery <37 weeks gestation 
(28.1%, 22.6% - 34.4%), birth weight <2500g (16.9%, 13.1% -21.5%), neonatal unit 
admission (20.5%, 15.7% - 26.4%) and perinatal death (4.0%, 2.9% - 5.4%) (306). An 
analysis of the Danish National Birth Cohort (81,008 pregnancies) found that 
women with chronic hypertension had 5.5 fold (95% confidence interval 3.2-9.4) 
increased risk of preterm delivery and a 50% increase in the risk of giving birth to 
an infant that is small for gestational age after adjustment for other risk factors 
(313). Women with chronic hypertension have also been reported to have an 
increased risk of placental abruption (relative risk 2.4, 2.3 – 2.5). Additionally, 
women with both chronic hypertension and superimposed pre-eclampsia have a 
further increased risk (7.7, 6.6 – 8.9) of placental abruption (314). Women with 
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chronic hypertension also have an increased risk of giving birth to infants with 
congenital malformations, specifically cardiac (1.6, 1.4-1.9) (315). In a more 
general sense, it has been reported that mothers with pre-existing cardiovascular 
disease, including hypertension but not specifically, have an increased maternal 
and perinatal morbidity (316). Taken together, this body of evidence indicates 
that a healthy maternal cardiovascular system is important for a healthy 
pregnancy. There is little evidence that assesses how the hypertensive mother 
adapts to pregnancy, however one small recent study has shown that women with 
chronic hypertension have increased left ventricular hypertrophy (left ventricle 
mass increased by approximately 20g and posterior wall thickness increased by 
0.7mm) (317). However, scientific investigation of how the CV system of the 
hypertensive mother is affected by pregnancy is wanting. 
 Preconception counselling is highly recommended for women of 
childbearing age with chronic hypertension (318). At this point, it is useful for the 
clinician to complete a full biochemical screen in the blood and assess 24-hour 
protein in the urine. As pre-eclampsia is more prevalent in this population it makes 
later diagnosis easier. Baseline proteinuria is also an indicator of adverse 
pregnancy outcome (319). Almost all women presenting with chronic hypertension 
will have primary hypertension. Therefore, treating these women has the same 
caveats as treating any patient with essential hypertension with the added 
complication of the pregnancy. Pharmacological intervention remains a clinician-
led decision; however, a number of drugs are recommended (Table 1-6). 
Angiotensin-converting enzyme (ACE) inhibitors and angiotensin-receptor blockers 
are contra-indicated in pregnancy due to the evidence of impaired neonatal 
kidney function and congenital abnormalities when used in the second half of 
pregnancy (320, 321).   
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Table 1-6 Drugs to treat chronic hypertension in pregnancy. 
Drug Mechanism of 
Action 
Dosage Comments 
Methyldopa Centrally-
acting alpha 
agonist 
0.5 – 3 g/d 
orally in 2 -3 
doses 
First line therapy 
Well tolerated. 
Established data 
which indicates no 
negative effects on 
offspring up to 7 years 
old (322). 
Limited use as an 
emergency 
hypertensive agent. 
Labetalol Alpha- and 
beta-blocker 
200 – 2400 
mg/d orally in 
2 – 3 doses 
First line therapy. 
Well tolerated. 
Bronchoconstrictive 
effects so may 
exacerbate asthma. 
Effective as an 
emergency 
hypertensive agent. 
Metoprolol Beta-blocker 50 – 400 mg/d 
orally in 2 - 3 
doses 
Possible association 
with fetal growth 
restriction when given 
in early pregnancy 
(323) 
Nifedipine L-type calcium 
channel 
blocker 
30 – 120 mg/d 
slow release 
preparation in 
1 dose 
Less data on the use 
of nifedipine in 
pregnancy. 
No adverse effects 
when given in the 
second trimester (324) 
Hydralazine Vasodilator 100 – 600 mg/d 
orally in 2-4 
doses 
Effective as an 
emergency 
hypertensive agent. 
Largely unknown 
mechanism of action. 
Hydrochlorothiazide Diuretic 12.5 – 50 mg/d 
in 1 dose 
Not normally 
recommended but 
may be necessary in 
salt-sensitive 
hypertension. 
May restrict maternal 
plasma volume 
expansion in 
pregnancy. 
Table adapted from the American Congress of Obstetricians and Gynaecologists Task Force in 
Hypertension in Pregnancy and Seely et al. (2011). 
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Taking all of the available interventions into account, a recent meta-
analysis concluded that anti-hypertensive treatment whilst halving the risk of 
severe hypertension in the mother does not reduce the risk of pre-eclampsia, 
perinatal death, preterm delivery and babies which are small for gestational age 
(325). However, a combination of calcium channel blocker and beta blockers were 
found to significantly reduce the incidence of pre-eclampsia compared to 
methyldopa. Further research is required to determine the most effective anti-
hypertensive agent to treat chronic hypertension in pregnancy, if any. Whilst 
incidents at birth are well-documented, there is also a lack of evidence on 
whether controlling maternal blood pressure has any effect on the infant later in 
life. Another general limitation of most studies which assess the effectiveness of 
an anti-hypertensive agent on pregnancy outcome is the variance in what is used 
as a control group. For example, anti-hypertensive treatment has been compared 
against placebo-treated, untreated chronic hypertensive women, normotensive 
women or women taking another anti-hypertensive. Whilst meta-analysis is useful, 
caution must be taken in comparing different types of studies against one another 
when the control groups are not the same. The recent Control of Hypertension in 
Pregnancy Study (CHIPS) assessed the effect of tight (DBP 85 mmHg) or less tight 
(DBP 100 mmHg) control of blood pressure on pregnancy outcome. The study 
reported that there was no significant difference in adverse outcomes between 
the tight and less tight groups, however the occurrence of severe hypertension 
was reduced in the tight control group (326). Taking this study into account, there 
is still no defined target blood pressure that predicts an adverse outcome for 
mother and child. 
 This field of research would benefit greatly from a pre-clinical model that 
could be used to study the underlying mechanisms of pregnancy in the setting of 
maternal chronic hypertension. Understanding the mechanisms behind this 
increased risk for adverse outcome would help inform future work into which 
agents may be most useful for the treatment of hypertension and how the risk for 
mother and child could be reduced. 
  Rodent Models of Hypertensive Disorders of Pregnancy 
There are a number of rodent models of hypertensive pregnancy present in the 
literature which have utilised surgical, genetic, pharmacological and dietary 
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interventions to increase blood pressure (327). The variety of animal models 
available is a strength reflecting the plethora of risk factors for the development 
of hypertension. However, drawing comparisons between these animal models can 
be problematic as the methodology underlying the production of the phenotype 
varies. A summary of the most important animal models of hypertension during 
pregnancy are given here. 
Most animal models of hypertension during pregnancy are focussed on 
modelling the pathology associated with preeclampsia (section 1.7.2). A general 
limitation of these models is that they tend to mimic only the severe, early onset 
form of the disease. The rat reduced uterine perfusion pressure model (RUPP), 
developed by Granger et al. (328), involves the occlusion of the abdominal aorta 
and either one or both of the uterine arteries on gestational day (GD) 14 of 
pregnancy. The restriction of the abdominal aorta alone does not induce a 
preeclampsia like phenotype due to a compensated blood flow from the ovarian 
artery thus the clips are also needed at the ovarian end of the uterine artery. The 
RUPP rat displays pathology similar to that seen in women with PE from GD19 
onwards (329-331). The underlying cause of the phenotype in this model is induced 
by the placental-ischemia that occurs as a result of the blood flow restriction. 
Therefore, this animal model is excellent for studying factors released by the 
ischemic placenta which underlie preeclampsia but this has its limitations. The 
intervention takes place after the critical period of placental development 
whereas the placental pathology associated with preeclampsia occurs early in 
pregnancy with the failure of the spiral arteries to remodel. It is also not possible 
to study vascular remodelling in the RUPP as the vessels have been artificially 
modified. Furthermore, it does not take into account any “risk factors” for 
preeclampsia as these animals are healthy before the procedure and would not 
have developed vascular complications during pregnancy otherwise. The selective 
RUPP model, recently published by Schenone et al. (332), clips only the uterine 
artery and not the abdominal aorta. This animal model develops a lower blood 
pressure increase and does not present with proteinuria such as in the Granger 
RUPP model (332). Genetically modified or pharmacologically induced rodent 
models have also been used to study mechanisms of preeclampsia. These models 
have the advantage that the vascular and placental pathology occurs 
spontaneously without surgical intervention. Mouse knockout models for eNOS 
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(333) and catechol-O-methyltransferase (COMT-/-) (334) (an estradiol metabolite 
that is normally increased in the final trimester of human pregnancy) have been 
shown to exhibit some features of preeclampsia; but these findings have not been 
robust in follow-up studies (335) or showed conflicting results in tissue from 
women with PE (336).  A transgenic rat model which is produced from mating 
females expressing human angiotensinogen and males expressing human renin also 
exhibits a number of preeclampsia related pathologies (337). Paradoxically, the 
RAAS is not altered in the RUPP model of preeclampsia despite a similar rise in 
blood pressure in late gestation (327). This model also lacks clinical translation as 
inhibitors of the RAAS pathway are contraindicated in pregnancy (section 1.7.3). 
Furthermore, whilst the vascular remodelling is allowed to occur spontaneously in 
this model; the spiral artery remodelling is deeper and uterine artery resistance 
index is decreased relative to the normotensive animal suggesting a different 
underlying cause of the preeclampsia phenotype in contrast to human studies 
(338). Infusion of certain pharmacological agents during pregnancy, such as the 
eNOS inhibitor L-NAME, has been shown to produce a PE-like phenotype which is 
ameliorated by treatment with sildenafil (339). However, a recent clinical trial 
utilising sildenafil in women with PE did not show a therapeutic effect (340). 
Preeclampsia -like symptoms can also be induced by infusion of anti-angiogenic 
factors soluble FLT-1 (sFLT-1) (341) and soluble endoglin (sEng) (342) and pro-
inflammatory cytokine TNFα (343).  
Another group of animal models is centred on rodents who are borderline 
hypertensive pre-pregnancy then develop superimposed preeclampsia. This type 
of model has the unique benefit of taking into account predisposing maternal CV 
risk. The BPH/5 mouse model is characterised by mild blood pressure elevation 
(mean arterial pressure 128 mmHg vs. 106 mmHg) as a result of selective 
inbreeding. During pregnancy, the BPH/5 exhibits a 22mmHg increase in blood 
pressure in the second half of pregnancy relative to the wild type strain. This 
increase in blood pressure resolves postpartum. These mice also present with a 
reduced litter size, proteinuria and glomerulosclerosis at a late stage of pregnancy 
(344). Recently, the Dahl S rat (section 1.4.1.2) has also been characterised as a 
model of superimposed PE. The Dahl S exhibits a pregnancy-dependent increase 
in blood pressure, accompanied by deficient uterine remodelling and kidney 
pathology (345). Again sildenafil treatment, which has not shown promise in 
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clinical trials, reduced the severity of the maternal preeclampsia -like phenotype 
in the Dahl S (346). In spite of this variety of animal models, currently there is no 
rodent model of chronic hypertension in pregnancy that does not progress to 
manifestations of preeclampsia. 
1.8  The SHRSP as a Model of Chronic Hypertension during 
Pregnancy 
The central hypothesis of this thesis is that deficient vascular remodelling in 
response to pregnancy results from a combination of both maternal pre-disposition 
due to CV risk factors and pregnancy-specific changes. Thus, women with pre-
existing maternal hypertension would exhibit deficient pregnancy-dependent 
uterine artery remodelling and this could explain the additional risk of adverse 
pregnancy outcome in this population. Our model of choice to test this hypothesis 
was the stroke prone spontaneously hypertensive rat (SHRSP). Some aspects of 
pregnancy in the SHRSP have already been briefly characterised (347, 348) 
however the vascular adaptation to pregnancy has not been studied 
systematically.  
 Deficient Uterine Artery Remodelling in the SHRSP 
We previously examined uterine artery structure and function from virgin 
and pregnant (GD18) SHRSP and WKY rats using pressure and wire myography 
respectively. SHRSP showed a significantly impaired outward hypertrophic 
remodelling of the uterine artery relative to the WKY (Fig 1-23). In addition, where 
WKY uterine arteries showed a decrease in maximal noradrenaline response and 
increase in endothelium dependent relaxation this adaptation was all but absent 
in the SHRSP (Fig 1-23). Deficient uterine artery remodelling was associated with 
a significantly decreased pregnancy-dependent increase in uterine artery diastolic 
blood flow (349). We went on to show that significant blood pressure reduction 
using nifedipine from 6 weeks of age in the SHRSP did not have an effect on the 
abnormal uterine artery response (349). Therefore, the mechanisms behind this 
deficient vascular remodelling were not dependent on the presence of pre-
existing maternal hypertension and we hypothesised that other CV risk factors 
must underlie this pathology. 
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Figure 1-23 Abnormal Uterine Artery Remodelling in Response to Pregnancy in the Stroke Prone 
Spontaneously Hypertensive Rat (SHRSP) 
Uterine arteries isolated in calcium free media were subject to pressure myography to measure 
external (A) and internal (B) diameter, cross-sectional area (C) and wall thickness (D) in female virgin 
WKY (n=4), pregnant WKY (gestational day 18) (n=6), virgin SHRSP (n=4) and pregnant SHRSP 
(gestational day 18) (n=6). External and internal diameter as well as cross-sectional area was 
significantly decreased in the pregnant SHRSP compared to the WKY (** p<0.01). Wall stress (E) 
was significantly decreased in pregnant SHRSP compared to the pregnant WKY. The stress/strain 
curve (F) was shifted to the right upon pregnancy in both strains but was significantly decreased in 
the pregnant SHRSP. Isolated uterine artery function was also measured using wire myography in 
the same animals. Maximum response to noradrenaline (G) was significantly decreased in virgin vs. 
pregnant WKY (††† p<0.001). Virgin SHRSP had a significantly increased maximum response to 
noradrenaline relative to virgin WKY (◊◊◊ p<0.001). Pregnant SHRSP vessels did not have a 
significantly decreased response to noradrenaline vs. virgin SHRSP. Pregnant SHRSP vessels had 
a significantly increased maximum response to pregnant WKY vessels (*** p<0.001). The EC50 
values for noradrenaline were not significantly different between groups (data not shown).  
Furthermore, endothelium-dependent vasorelaxation to carbachol (H) was significantly impaired in 
both virgin and pregnant SHRSP (** p<0.01 vs. WKY). Data analysed by comparing area under the 
curve values using one-way ANOVA and Tukey’s post-hoc test. Figure from Small et al. (2016). 
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1.9 Hypothesis & Aims 
We hypothesised that deficient uterine artery remodelling seen in the SHRSP 
was dependent upon pre-existing maternal CV risk factors. Furthermore, we 
proposed that the SHRSP could act as a novel translational model of maternal 
chronic hypertension in pregnancy which would allow us to investigate novel 
therapeutic targets. 
The aims which would allow us to address this hypothesis were as follows: 
 Characterise and establish the SHRSP as a rat model of maternal chronic 
hypertension in pregnancy. 
 Identify and therapeutically target a molecule involved in the pregnancy-
associated pathology in the SHRSP. 
 Utilise this model as a basis for proteomic analysis to discover novel targets 
involved in chronic hypertension during pregnancy. 
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Chapter 2 General Materials & Methods 
This Chapter outlines laboratory practices and methods common to more than 
one Chapter. Each subsequent results Chapter has a specific materials & methods 
section. 
2.1 General Laboratory Practice 
 Laboratory equipment and reagents used in this thesis were of the highest 
possible grade commercially available. Reagents deemed hazardous were dealt 
with appropriately as described in the relevant control of substances hazardous to 
health regulations. Appendix I gives details of the preparation of all laboratory-
prepared reagents that were not obtained commercially. Reagents were weighed 
using an Ohaus Portable Advanced balance (sensitive to 0.01 g) or a Mettler HK160 
balance (sensitive to 0.00001 g). Sterile disposable plastic ware or standard 
laboratory glass wear was used to prepare reagents. Glassware was washed using 
Decon 75 detergent, rinsed with distilled H2O (dH2O) and placed in a 37 ºC drying 
cabinet. RNase free disposable plastic ware (Thermo Fisher, Paisley, UK) was used 
when appropriate. Volumes from 1 µl to 1ml were measured using BioHit® pipettes 
(Sartorius, Surrey, UK) and disposable tips or RNase free filter tips (Thermo Fisher, 
Paisley, UK) when appropriate. dH2O was used to prepare all aqueous solutions 
unless otherwise stated in appendix I. To dissolve solutions, a Jenway 1000 
hotplate/stirrer was utilised. To mix solutions, a mini vortex 2800 rpm Lab Dancer 
(Fisher Scientific, Loughborough, UK) was utilised. Small samples <2 ml were 
centrifuged using a Heraeus™ Pico™ benchtop microcentrifuge (Thermo Fisher, 
Paisley, UK); larger samples were centrifuged in a Sorvall™ Legend™ Centrifuge 
(Thermo Fisher, Paisley, UK). A Julabo TW8 water bath and thermometer was used 
for experiments requiring incubations from 37 °C to 95 °C. For experiments 
requiring temperatures 95 – 100 °C, an Eppendorf ThermoMixer® was used.  The 
pH of solutions was measured using a Metler Toledo pH meter calibrated with pH 
4.0, 7.0 and 10.0 standards (Sigma -Aldrich, Dorset, UK). 
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2.2 Animals 
  Animal Strains 
 The strains of animals used in this thesis are the stroke prone spontaneously 
hypertensive rat (SHRSP) and the control strain Wistar Kyoto (WKY) rat. These 
inbred strains have been maintained at the University of Glasgow since 1991 when 
6 males and 7 females of each strain were gifted to Prof. A.F. Dominiczak from 
Dr. D.F. Bohr from the University of Michigan, USA. These animals were previously 
sourced from the National Institutes of Health, Bethesda, USA (Genealogy shown 
in Fig. 1-13). The Glasgow strain of SHRSP have slightly lower blood pressures than 
the original strain (16 week old males: Glasgow 190-200 mmHg, original strain 230-
250 mmHg) also detailed in section 1.8. 
  Animal Housing 
 All animals were housed under controlled lighting (from 0700 to 1900 hours) 
and temperature (21 ± 3 °C) and received a normal diet (rat and mouse No.1 
maintenance diet, Special Diet Services) provided ad libitum. All animal 
procedures were approved by the Home Office according to regulations regarding 
experiments with animals in the United Kingdom (Project License Number 60/4286 
held by Dr. Delyth Graham).  
2.3 Animal Procedures 
  Time Mating 
 Females were time mated at 12 weeks of age (± 4 days). Non-pregnant 
animals were age-matched at 15 weeks (i.e. 12 weeks of age + 21 days of 
pregnancy) ± 4 days. For mating, females and stud males of the relevant strain 
were housed together in a mesh bottomed breeding cage. Day 0 of pregnancy was 
defined as the day that a coital plug was observed indicative of successful mating 
having taken place. For animals that were subject of radiotelemetry, the breeding 
cage was placed on the receiver panel to avoid any loss of data.  
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  Metabolic Cage 
 The metabolic cage allows individual housing of an animal to collect 
information on water intake and urine output over 24 hours. The metabolic cage 
has a gridded bottom which allows urine and faeces to pass through which are 
then separated by a funnel so that they can be collected separately. A fixed 
amount of water (200 ml) was given and food was available ad libitum over the 
24-hour period. Animals were acclimatised for 4 hours, 3 days prior to 
measurement. Urine samples were collected from virgin animals that were housed 
in the metabolic cage 1 day prior to mating then at GD 6, GD 12 and 18. Urine 
samples were aliquoted on ice and stored at -80 ºC until use. 
  Radiotelemetry Probe Implantation  
Radiotelemetry probes were implanted in anaesthetised animals under 2.5 
– 3.5 % isoflurane/O2 using sterile conditions. Within the abdominal cavity, the 
intestines were temporarily externalised and kept moist using sterile gauze soaked 
in sterile PBS (Thermo Fisher, Paisley, UK). Three Mersilk sloops were placed 
around the main aorta and both iliac arteries to occlude the flow of blood. The 
catheter of the probe was then implanted into a small hole made in the abdominal 
aorta using a 21 G needle and secured with a small cellulose patch and VetBond™ 
biological glue (Data Sciences International, Sheffield, UK). Following the 
implantation, the intestines were replaced and the probe was sutured into the 
muscle wall of the abdominal cavity. Each animal was placed in an individual cage 
upon a receiver which relayed the information to an attached computer collected 
by the probe every 5 minutes for 10 seconds. Animals were allowed to recover for 
10 days after surgery before they were time mated.  
2.3.3.1 Radiotelemetry Data Handling 
Data was analysed using Microsoft Excel and the daytime and night time 
average was used to calculate a daily average which is plotted in the graphs for 
clarity. 
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  Tissue Collection Protocols 
2.3.4.1  Tissue Collection at GD 14.5 – 20.5 
 Animals were sacrificed under terminal general anaesthesia. The thoracic 
cavity was opened and maternal blood was collected via cardiac puncture of the 
left ventricle using a disposable 5 ml syringe and 23 G needle. Blood was then 
transferred into heparinised VACUETTE® tubes and kept on ice before 
centrifugation at 1300 rpm for 10 minutes to obtain plasma. Plasma was aliquoted 
on ice and stored at -80 ºC until use. Maternal tissues were harvested and weighed 
then either fixed in 10% formalin or snap frozen in liquid nitrogen. The uterine 
horn was excised and animals with <4 fetuses were excluded from any further 
study at this point. Individual uteroplacental units were dissected then fetuses 
and placenta (without the attached uterine tissue) were weighed. At GD 20 only, 
fetal tissues – head, heart, liver and kidneys - were also dissected and weighed. 
Placenta were either taken intact including the uterus (mesometrial triangle and 
decidua) for fixation in 10% formalin or dissected into four layers: maternal 
uterine tissue (mesometrial triangle and decidua), junctional zone, labyrinth and 
chorionic plate then snap frozen in liquid nitrogen. Accurate dissection of the 
placenta was ensured by utilising qPCR markers for the various layers (Figure 1-
6). In order to establish continuity and good record keeping, a tissue collection 
protocol worksheet was developed (Appendix II). 
2.3.4.2  Uterine and Mesenteric Artery Collection for Myography 
 Uterine artery segments were harvested from a consistent place in the area 
of the uterine artery closer to the vagina than the ovary from the uterine horn 
with the most fetuses and the mesentery was collected in laboratory-prepared 
calcium free physiological salt solution (PSS) (0.25 M NaCl, 0.001 M KCl, 2 mM 
MgSO4, 50 mM NaHCO3, 2 mM KH2PO4, 1 mM glucose, 0.5 ml of 23 mM EDTA) 
(Appendix I) in a 50 ml disposable plastic tube and dissected using a microscope 
within 1 hour of sacrifice. The uterine artery and third order mesenteric arteries 
were dissected and used for further experiments (Fig. 2-1). The average diameter 
of the uterine artery rings was 400 µm and the mesenteric artery rings was 270 
µm. The dissected vessels were stored in calcium free PSS (Appendix I) overnight 
at 4 ºC and used for myography within 24 hours. Vessels were stored in calcium 
free PSS as they were used for both wire and pressure myography; pressure 
 
 
109 
 
myography requires that calcium is absent from the PSS to ensure vessels are 
tonic. Vessels used for myography were as clean as possible with all visible 
surrounding adipose tissue removed. 
 
Figure 2-1 Arteries used for myography studies: 
The uterine artery is highlighted in a red box (A). The third order mesenteric is indicated by an arrow 
in (B). Images are adapted from Robertson (1975) and Pourageaud et al. 1997 (350, 351). 
 
2.4  Gene expression 
  Ribonucleic Acid (RNA) Extraction 
 Tissue was homogenised using a polytron 2100 rotor homogenizer in 700 µl 
QIAzol® (Qiagen, Manchester, UK). QIAzol® contains phenol to disrupt cell 
membranes and guanidinium salt which acts to block nucleases. RNA was 
extracted using the miRNeasy® mini kit (Qiagen, Manchester, UK) according to 
manufacturer’s instructions. Briefly, 140 µl of chloroform was added to the 700 µl 
of QIAzol® then shaken vigorously by hand. This was followed by incubation at 
room temperature for 2 minutes then centrifugation for 15 minutes at 12,000 x g 
at 4 oC. Polar nucleic acid remains in the clear aqueous phase which is then 
collected into a new tube and nucleic acids are precipitated with the addition of 
1.5 volumes of ethanol. The solution is then applied to the RNeasy® mini column 
and is subject to a number of washing and concentrating steps using ethanol based 
wash buffers: RWT and RPE. RNA was eluted in 30 µl of nuclease free H2O (NFW) 
Gut Wall
Superior 
Mesenteric Artery
A B
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and the eluate was run through the column twice to maximise RNA extraction. A 
DNase step was not completed for samples as there were also needed to detect 
microRNAs (miRNAs). RNA was kept on ice and stored at -80 oC until use. 
2.4.1.1 Ribonucleic Acid Quantification and Quality Control 
Total RNA concentration (ng/µl) was determined using a Nanodrop® ND1000 
(Thermo Fisher, Paisley, UK) where a 260/280 ratio of 2.0 and a 260/230 ratio of 
2.0-2.2 was used to indicate purity. RNA is detected at 260nm; whereas 
absorbance at 280 and 230nm indicates contamination by phenols and thiocyanate 
(found in QIAzol® lysis reagent) respectively. To validate RNA quality, a sample 
amount of placental tissue from SHRSP (n=3) and WKY (n=3) was subject to Agilent 
quality control testing (Fig. 2-2) (352) where RNA integrity number (RIN) were all 
>9.0. RNA was stored at -80 °C until use. 
 
Figure 2-2 Example results from Agilent RNA quality control for WKY placenta. 
Agilent testing takes into account the full electrophoretic spectrum of RNA (A). Good quality RNA 
shows clear bands at 28s and 18s ribosomal RNA and little presence of small degradation products 
(A-B). The example shown in (C) shows a poorer quality RNA sample where 28s and 18s peaks are 
reduced and there is an increased presence of shorter fragments. Image (C) is adapted from 
Schroeder et al. (2006). 
 
  Reverse Transcription Polymerase Chain Reaction (RT-PCR) 
 RT-PCR was used to prepare complimentary DNA (cDNA). RT-PCR was 
performed using the Taqman® Reverse Transcription Kit (Applied Biosystems, 
A B
C
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Thermo Fisher, Paisley, UK) according to manufacturer’s instructions. 1 µg RNA 
input diluted in NFW was used. In summary, 20 µl reactions were set up as: 
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10 x RT buffer 2 µl 
25mM MgCl2  4.4 µl 
10 mM dNTPs 4 µl 
Oligo dTs  1 µl 
RNase Inhibitor 0.4 µl 
Multiscribe  0.5 µl 
TOTAL  12.3 µl 
RNA (1 µg) + NFW 7.7 µl 
Reactions were set up in a 96 well skirted plate (Thermo Fisher, Paisley, UK) and 
sealed with an adhesive sealing sheet to prevent evaporation (Thermo Fisher, 
Paisley, UK). The reaction was run on a Multi Block System Satellite 0.2 Thermo 
Cooler (Thermo Fisher, Paisley, UK) ) on the following settings: 25 °C 10 min, 48 
°C 30 min, 95 °C 5 min. cDNA was then stored at -20 °C until use. 
  Quantitative Polymerase Chain Reaction (qPCR) 
Fluorescence based quantitative PCR is carried out on a thermal cycler 
which incorporates a fluorescence detector. By using a fluorescent reporter in the 
PCR reaction it is possible to quantify the production of DNA. In the log linear 
phase of the PCR reaction, fluorescence from the generated DNA is higher than 
the background; when this is measurable it is known as the threshold cycle (Ct) 
(353). There are two detection chemistries with respect to qPCR which have both 
been utilised in this thesis. SYBR® green is a dye which will intercalate in double 
stranded DNA; therefore this technique is only appropriate for measuring one 
amplicon at a time and specificity must be added by the addition of primers. 
Taqman® is one example of the technology where a fluorophore is directly 
conjugated to a probe specific for the gene of interest. Using Taqman® gives the 
ability to multiplex reactions by employing different probe-fluorophore 
complexes. 
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2.4.3.1  SYBR® Green qPCR 
Sybr based qPCR was used to quantify gene expression using cDNA prepared 
in section 1.4.2. 5 µl reactions were set up using the following reagents:  
Power SYBR® PCR Mastermix 6.35 µl 
10µM Forward Primer 0.5 µl 
10µM Reverse Primer 0.5 µl 
NFW   2.65 µl 
TOTAL   10 µl 
+cDNA   2.5 µl 
Reactions were set up in a 384 well plate (Thermo Fisher, Paisley, UK) and sealed 
with an optical adhesive sealing sheet (Thermo Fisher, Paisley, UK). Relevant 
primer details are given in Chapter 1. Gene expression protocol was run on an ABI 
PRISM 7900HT PCR system at the following settings: 95 °C, 15 min; followed by 40 
cycles of 95 °C, 15 s; 60 °C, 1 min followed by a 30 minute dissociation step to 
check for primer specificity. Ct values were analysed using the 2(-delta delta Ct) 
method (354), with dCt indicating normalisation to the housekeeper, 
Glyceraldehyde-3-Phosphate Dehydrogenase (Gapdh).  
2.4.3.2  Taqman® qPCR 
Taqman® qPCR was used to quantify gene expression using cDNA prepared in 
section 1.4.2. Reactions were run in duplex where the gene of interest was run 
using a FAM labelled probe and the housekeeper using a VIC labelled probe. 10 µl 
duplex reactions were set up using the following reagents:  
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2x Taqman® mastermix           5 µl 
Probe-FAM labelled   0.5 µl 
Probe-VIC labelled   0.5 µl 
NFW     2.5 µl 
TOTAL    8.5 µl 
+cDNA    1.5 µl 
Reactions were set up in a 384 well plate (Thermo Fisher, Paisley, UK) and sealed 
with an optical adhesive sealing sheet (Thermo Fisher, Paisley, UK). Gene 
expression experiments in Chapter 3 were run on an ABI PRISM 7900HT PCR system 
at the following settings: 95 °C, 15 min; followed by 40 cycles of 95 °C, 15 s; 60 
°C, 1 min. Gene expression in Chapters 4 - 6 were run on a QuantiStudio® 12K Flex 
at the following settings: 95 °C, 15 min; followed by 40 cycles of 95 °C, 15 s; 60 
°C, 1 min. Ct values were analysed using the 2(-delta delta Ct) method (354), with 
dCt indicating normalisation to the housekeeper. The housekeeper for placental 
gene expression was β-actin (Actb) and Glyceraldehyde-3-Phosphate 
Dehydrogenase (Gapdh) in heart samples. 
2.5 Western blot 
  Protein Extraction for Western Blot 
 Protease inhibitor (Roche, West Sussex, UK) and phosphate inhibitor 
(Roche, West Sussex, UK) were added to laboratory prepared RIPA buffer pH 8.8 
(50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1mM EDTA, 1% NP-40, 0.1% SDS, 0.5% Na 
Deoxycholate) (Appendix I) on day of use. Tissue was homogenised using a polytron 
2100 rotor homogenizer in 1ml of RIPA buffer. Homogenates were centrifuged at 
8000 rpm for 10 minutes when supernatant was collected and aliquoted. 
Homogenates were aliquoted and stored at -80 °C until use. 
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  Western Blot 
Protein concentration was determined using bicinchoninic acid (BCA) assay 
(BioRad, Hemel Hempstead, UK). Protein samples were diluted to 20 μg in dH2O 
to a final volume of 15 µl then 5 µl of NuPAGE® LDS Sample Buffer was added to 
each sample. Samples were incubated at 95 °C for 5 minutes then allowed to cool 
to room temperature. Samples were loaded on to a pre-cast Novex® 4-12% 
polyacrylamide gel (Thermo Fisher, Paisley, UK) for separation by electrophoresis 
in 1x NuPAGE® MES SDS/dH2O running buffer (Thermo Fisher, Paisley, UK) at 200 v 
for 1 hour using a Mini-PROTEAN® Tetra Vertical Electrophoresis Cell (BioRad, 
Hertfordshire, UK). 10 µl of Amersham rainbow ladder RPN800E (Sigma-Aldrich, 
Dorset, UK) was loaded on the furthest left lane to determine protein size. 
Following separation, in Chapter 3 and 4 proteins were transferred using wet 
transfer at 40 v for 1 hour in a Mini Trans-Blot® cell (BioRad, Hertfordshire, UK) 
in 1x NuPAGE® transfer buffer/160ml methanol and 600 ml dH2O (Thermo Fisher, 
Paisley, UK). Western blots in Chapter 6 were transferred using the semi-dry 
Thermo Scientific™ Pierce™ Power Blotter system (Thermo Fisher, Paisley, UK) in 
Pierce™ 1-step transfer buffer for 7 minutes. Proteins were transferred to 
Amersham™ Hybond™ P 0.45 PVDF membrane which had been activated in 
methanol (GE Life Sciences, Buckinghamshire). 
  Membrane Blocking & Antibody Incubation 
Membranes were blocked with 5 % fat free milk powder in tris-buffered 
saline solution with Tween (TBS-T) for 2 hours at room temperature. Following 
blocking, membranes were incubated with the respective primary antibody 
overnight at 4 °C. Following overnight incubation in primary antibody, membranes 
were washed 4 x 5 minutes in TBS-T. Membranes were then incubated in the 
relevant horseradish peroxidase conjugated secondary antibody in 5 % fat free 
milk powder in TBS-T for one hour at room temperature. Specific details for 
membrane blocking and antibody incubation are given in the materials & methods 
section of the Chapter with the associated western blot. 
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  Western Blot Development & Analysis 
Proteins were visualised using Amersham enhanced chemiluminescence 
(ECL) western blotting detection reagents GE Life Sciences, Buckinghamshire) in 
a 1:1 ratio. ECL acts a chemiluminescent reagent which is produced by interaction 
with the horse radish peroxidase conjugated secondary antibody. Carestream 
medical X-ray film (Carestream, Hemel Hempstead, UK) was used to visualise 
protein bands. A Kodak X-Omat 1000 was used to develop the X-ray films.  
2.6 Histology 
  Tissue Preparation for Histology 
 Tissues were fixed for 24 hours in 10% formalin at room temperature. After 
24 hours, tissues were rinsed and formalin replaced with PBS. Tissues were then 
placed in histology cassettes (Thermo Fisher, Paisley, UK) and placed in a Citadel 
1000 processor (Fisher Scientific, Loughborough, UK) at the following settings: 70 
% ethanol 30 minutes, 95 % ethanol 30 minutes, 100% ethanol 30 minutes, 100% 
ethanol 30 minutes, 100% ethanol 45 minutes, 100% ethanol 45 minutes, 100% 
ethanol 60 minutes, 100% ethanol/xylene 30 minutes, xylene 30 minutes, xylene 
30 minutes, wax 30 minutes, wax 30 minutes, wax 45 minutes, wax 45 minutes. 
The total running time was 8 hours and 30 minutes. Tissues were embedded using 
Shandon Histocentre 3 embedding centre (Fisher Scientific, Loughborough, UK) 
and Histoplast paraffin (Thermo Fisher, Paisley, UK). Placenta was cut through the 
centre with the cut side face down. Kidneys were cut transversely through the 
ureter and the cut side was placed face down. Paraffin sections of 5 µm were cut 
using a Leica Finese 325 Microtome (Fisher Scientific, Loughborough, UK) and 
baked on to silanised slides at 60 °C overnight. Slides were then stored at room 
temperature until use. Paraffin blocks were stored at 4 °C. Immediately prior to 
staining, slides were deparaffinised in histoclear 2 x 7 minutes then rehydrated 
through an ethanol gradient (100%, 90% and 75%; 5 minutes each) into distilled 
H2O for 5 minutes. 
  Haematoxylin and Eosin Stain 
Haematoxylin and eosin (H&E) stain was used to assess cellular structure of 
tissues. Slides were cleared and rehydrated as described in section 2.6.1. Slides 
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were stained in VFM Harris’ haematoxylin stain (CellPath, Powys, UK) for 2 
minutes followed by 5 minute wash in running tap water. Slides were then stained 
in eosin Y solution (CellPath, Powys, UK) for one minute. Negatively charged 
haematoxylin principally stains the negative nucleic acids of the nucleus dark 
purple. Positively charged eosin stains the negatively charged proteins and 
cytoplasmic contents. Slides were dipped in tap water then dehydrated through 
an ethanol gradient (70%, 90%, 100%; 5 minutes each). Slides were cleared in 
histoclear 2 x 5 minutes and mounted using DPX (Sigma-Aldrich, Dorset, UK). Slides 
were viewed using light microscopy. 
 Threshold Quantification of Staining Using Image J 
8-10 images were taken at 4x objective and laced together using Microsoft 
Image Composite Editor 2.0. This was to ensure a high quality image when using 
the zoom tool on Image J. Positive staining for histology was determined using a 
threshold quantification method using Image J. Slides were analysed by an 
operator who was blinded to the identity of the slides; details of the operators 
are given in the author’s declaration. The area of interest was selected and 
transformed into a RGB stack. The stack which made the positive staining most 
apparent was chosen by the operator. A threshold was then chosen so that only 
true positive staining was detected. This threshold was set for all of the images 
analysed. The % positive staining was determined as the amount of pixels over the 
given threshold ratio/the total number of pixels x 100. 
2.7  Statistical Analysis 
For the animal studies reported in this thesis, every effort was made to adhere 
to the Animal Research: Reporting of in vivo Experiments (ARRIVE) guidelines 
(355). Animal groups were randomised and, where possible, blinded before data 
analysis was carried out. In this instance, no power calculations were carried out 
prior to the beginning of experiments. Data were analysed and presented using 
GraphPad version 4.0 (San Diego, California, USA) where values stated are 
indicative of the mean ± standard error of the mean (SEM). A p value of less than 
0.05 was considered to be significant for all experiments conducted. The relevant 
statistical analysis carried out for each data set is given in the associated Figure 
legend. In brief, for comparisons of a continuous variable between two 
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experimental groups (e.g. WKY vs. SHRSP) an unpaired Student’s t test was 
employed. For data sets with more than two experimental groups (e.g. WKY, 
SHRSP and etanercept treated SHRSP) one-way analysis of variance followed by a 
post-hoc Tukey’s test was used.  
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Chapter 3 Characterisation of the SHRSP as a Rat 
Model of Chronic Hypertension in Pregnancy 
3.1 Introduction 
Chronic hypertension in pregnant women confers a significant health risk for 
both the mother and fetus as discussed in section 1.7.3 (306). However, research 
on the impact of chronic hypertension during pregnancy is relatively limited. This 
led to the aim of developing the stroke prone spontaneously hypertensive rat 
(SHRSP) as a pre-clinical model of chronic hypertension during pregnancy. Previous 
work (section 1.8.1) showed that the SHRSP present at gestational day (GD) 18 
with a significant reduction in uteroplacental blood flow and litter size relative to 
the normotensive WKY (349). Concurrently, the SHRSP exhibited abnormal 
pregnancy-dependent uterine artery remodelling in response to pregnancy which 
was characterised by a decrease in the diameter of the uterine artery and a 
blunted response to endothelium dependent vasorelaxation in comparison to 
vessels from WKY at GD18 (349).  
As the SHRSP are hypertensive before and during pregnancy, we have 
previously used nifedipine in an intervention study in this model to assess the 
contribution of elevated blood pressure to the pathology associated with 
pregnancy (349). Nifedipine (25 mg/kg/day) was used from 6 weeks of age so that 
treated SHRSP never became hypertensive before or during pregnancy. Despite 
this significant blood pressure lowering, nifedipine treatment did not improve 
uterine artery structure and function or litter size in the SHRSP (Fig. 3-1) (349). 
Therefore, we concluded that the pregnancy pathology that was seen in the SHRSP 
was independent of high blood pressure. Since pregnancy has been characterised 
only briefly in the SHRSP (348) and variation exists between the inbred colonies 
(356), a thorough characterisation study was required before proceeding with 
follow-up mechanistic studies in this model. Additionally, as a model of maternal 
chronic hypertension it was unknown to what degree the SHRSP would share 
similarities with rodent models of pre-eclampsia.  
We hypothesised that the SHRSP would exhibit maternal biomarkers, placental 
damage and fetal growth restriction consistent with hypertension during 
pregnancy seen in humans and other rat models. To address this hypothesis, a 
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characterisation study was conducted in pregnant (GD18) SHRSP and WKY to 
measure a number of maternal, placental and fetal factors known to be associated 
with hypertensive pregnancy.  
 
 
Figure 3-1 Nifedipine treatment does not improve uterine artery structure or function in the SHRSP. 
Isolated uterine artery structure was assessed using pressure myography to measure external (A) 
and internal (B) diameter, cross-sectional area (C) and wall thickness (D) in pregnant (gestational 
day 18) untreated WKY (n=6), untreated SHRSP (n=6) and nifedipine treated SHRSP (n=6). External 
and internal diameter as well as cross-sectional area was significantly decreased in both untreated 
and nifedipine treated SHRSP (* p<0.05 vs. WKY; ** p<0.01 vs. WKY analysed by area under the 
curve followed by one-way ANOVA and post-hoc Tukey test).  Isolated uterine artery function was 
also measured using wire myography in the same animals. Maximum response to noradrenaline (E) 
was significantly increased in both virgin and pregnant SHRSP (* p<0.05 SHRSP vs. WKY, $ p<0.05 
Nifedipine vs. WKY analysed by area under the curve followed by one-way ANOVA and post-hoc 
Tukey test). Furthermore, endothelium-dependent vasorelaxation to carbachol (F) was significantly 
impaired in both untreated and nifedipine treated SHRSP (** p<0.01 vs. WKY analysed by area under 
the curve followed by one-way ANOVA and post-hoc Tukey test).  
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3.2 Materials & Methods 
General materials & methods can be found in Chapter 2. 
  Animals 
The work presented in this Chapter has used pregnant WKY and SHRSP that 
were untreated. This was an independent group of animals from the previous 
nifedipine study. Females were time mated at 12 weeks of age (± 4 days). Non-
pregnant animals were age-matched at 15 weeks ± 4 days (i.e. 12 weeks of age + 
21 days of pregnancy). The number of animals and particular gestational day (GD) 
is given in the associated Figure legend. 
3.2.1.1 Baseline Characteristics at Sacrifice 
Dams were weighed throughout pregnancy at GD0, 6, 12 and 18 and 
bodyweight was recorded. At the point of sacrifice (GD18), the uterine horn was 
excised and weighed separately. Pregnancy independent weight gain was 
calculated as (GD18 bodyweight – uterine horn weight). Maternal organs (heart, 
lungs, liver, spleen and kidneys) were excised, cleaned and weighed immediately 
following sacrifice. Post-mortem organ weight was normalised to tibia length as 
bodyweight changes over the course of pregnancy. In the uterine horn, the number 
of fetuses and resorptions was recorded. Resorption rate was expressed as ([the 
number of resorptions/total number in litter] x 100). 
  Identification of Implantation Sites using Evans’ Blue 
Rats were anaesthetized (2.5% isoflurane) and maintained under deep 
terminal anaesthesia throughout the procedure. 250 μl of 1% Evans’ blue dye 
(Sigma-Aldrich, Dorset, UK) in PBS was injected into the exposed femoral vein. 
After 10 minutes, the animal was sacrificed under terminal anaesthesia and the 
uterine horn was excised. Implantation sites were counted as clear bands of 
positive blue staining. 
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 Enzyme Linked Immunosorbent Assay (ELISA) 
Maternal plasma sFLT-1 (DVR100B), PlGF (DPG00) and ET-1 (QET00B) were 
measured using commercially available kits (R&D Systems, Abingdon, UK) 
according to manufacturer’s instructions. Kits were controlled using a positive 
control provided by the manufacturer and a negative control where dH2O was used 
instead of sample.  The method used a 7-point standard curve consisting of 1-in-2 
serial dilution steps from the top standard: sFLT-1 concentration of 20,000 pg/ml 
down to a bottom standard with concentration of 31.3 pg/mL, PlGF concentration 
of 1000 pg/ml down to a bottom standard with concentration of 15.6 pg/mL and 
ET-1 concentration of 2500 pg/ml down to a bottom standard with concentration 
of 0.343 pg/mL. The limits of detection for the kits were as follows: sFLT-1 13.3 
pg/ml, PlGF 7 pg/ml, ET-1 0.102 pg/ml. All samples presented were above the 
limit of sensitivity with the exception of the measurement of PlGF in 2 SHRSP 
plasma samples. All results shown in this Chapter were from one plate therefore 
there it was not necessary to calculate inter-assay variation.  
  Polymerase Chain Reaction (PCR) 
RNA extraction and gene expression studies were carried out and analysed 
as described in section 2.4. 
3.2.4.1  Uteroplacental Layer Dissection Sybr qPCR 
Primers were designed using Primer3 software (357) then synthesised by 
Eurofins, Abingdon, UK. Primer sequences for Des (F: GGGACATCCGGCTCAGTAT 
R: AGAGCATCAATCTCGCAGGT), Prl8a4 (F: GCATGTATGGTGGAAGAGGGT R: 
GCAATCTTTTCCAGTTATGAGACA), Vegfr2 (F: AAGCAAATGCTCAGCAGGAT R: 
GAGGTAGGCAGGGAGAGTCC) and Gapdh (F: GACATGCCGCCTGGAGAAAC R: 
AGCCCAGGATGCCCTTTAGT). 
3.2.4.2 Genes of Interest Taqman® qPCR 
Gene expression was carried out using the following probes from Thermo 
Fisher, Paisley, UK: Nppa (Rn00664637_g1), Nppb (Rn00580641_m1), Vegfa 
(Rn01511602_m1), Hif1a (Rn01472831_m1), Sod1 (Rn00566938_m1), Gapdh 
(4352338E) and Actb (4352340E). 
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  Western Blot for Cleaved Capsase-3  
Western blot was carried out as described in section 2.5. Membranes were 
incubated in the following primary antibody diluted in 5% Marvel skimmed milk 
powder in TBS-T overnight at 4 ºC: caspase-3 #9662  1:500 (Cell Signalling 
Technology, Leiden, Netherlands). Caspase-3 was detected using horse radish 
peroxidase (HRP) conjugated swine-α-rabbit secondary antibody (Dako, Ely, UK) 
diluted 1:1000 in 5% Marvel skimmed milk powder/TBS-T.  
  Histology 
Preparation of paraffin blocks and sections were carried out as described 
in section 2.6.1. 
3.2.6.1 Haematoxylin and Eosin (H&E) stain 
Haematoxylin and eosin (H&E) stain was used to assess cellular structure of 
the placenta. Slides were cleared and rehydrated as described in section 2.6.1. 
Slides were stained in VFM Harris’ haematoxylin (acidified) (CellPath, Newtown, 
UK) for 2 minutes followed by 5 minute wash in running tap water. Slides were 
then stained in eosin Y solution for one minute. Slides were dipped in tap water 
then dehydrated through an ethanol gradient (70%, 90%, 100%; 5 minutes each). 
Slides were cleared in histoclear 2 x 5 minutes and mounted using DPX (Sigma-
Aldrich, Dorset, UK). Slides were viewed using light microscopy. In order to 
quantify the size of the placental layers a mid-sagittal section was used; indicated 
by the presence of the maternal channel. The respective layers were drawn 
around using the polygon tool on ImageJ (National Institutes of Health, Bethesda, 
USA) and the area was expressed as a percentage of the total area. 
3.2.6.2  Perl’s Prussian Blue Stain 
Perl’s Prussian blue stain was used to assess free blood in the placenta; 
specifically, this stain detects iron (20). Slides were cleared and rehydrated as 
described in section 2.6.1. Briefly, 4% ferrocyanide solution and 4% acidified water 
(HCl) were mixed immediately before incubating slides for 45 minutes then 
counter-stained with 1% neutral red. Slides were dipped in tap water then 
dehydrated through an ethanol gradient (95%, 100%; 5 minutes each). Slides were 
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cleared in histoclear 2 x 5 minutes and mounted using DPX (Sigma-Aldrich, Dorset, 
UK). Slides were viewed using light microscopy and analysed using threshold 
quantification in ImageJ (National Institutes of Health, Bethesda, USA) as 
described in section 2.6.4. 
3.2.6.3  Periodic acid-Schiff Stain 
 Periodic acid – Schiff stain was used to quantify glycogen cell content in the 
placenta. Slides were cleared and rehydrated as described in section 2.6.1. Slides 
were incubated in 1% periodic acid (Sigma-Aldrich, Dorset, UK) in dH2O for 10 
minutes to oxidise aldehyde groups followed by 1 minute wash under running tap 
water. Slides were then stained with Schiff’s reagent (Sigma-Aldrich, Dorset, UK) 
for 10 minutes which reacts with the oxidised aldehyde groups to form a magenta 
dye. This was followed by a 1 minute wash under running tap water and 
dehydration through an ethanol gradient (70%, 90%, 100%; 5 minutes each). Slides 
were cleared in histoclear 2 x 5 minutes and mounted using DPX (Sigma-Aldrich, 
Dorset, UK). Slides were viewed using light microscopy and analysed using 
threshold quantification in ImageJ (National Institutes of Health, Bethesda, USA) 
as described in section 2.6.4. 
3.3 Results 
  Maternal Adaptation to Pregnancy in the SHRSP and WKY 
Over gestation, maternal weight gain is significantly reduced in the SHRSP 
relative to the WKY (Fig. 3-2A). Additionally, raw maternal weights are given in 
Table 3-1. Animals were also weighed at GD18 once the uterine horn was excised 
which we termed “pregnancy independent weight gain”; this was also significantly 
decreased in SHRSP relative to WKY (Fig. 3-2B). 
Post-mortem tissue weights were recorded from non-pregnant and 
pregnant (GD18) WKY and SHRSP and normalised to tibia length. Whilst there was 
no significant strain difference in heart weight between non-pregnant animals; 
there was a significant increase in heart weight in pregnant SHRSP relative to WKY 
(Fig. 3-3A). There was no pregnancy or strain-dependent difference in the weight 
of the lungs or spleen (Fig. 3-3B-C). There was a similar pregnancy-dependent 
increase in liver weight in both WKY and SHRSP (Fig. 3-3D). With respect to kidney 
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weight, this was increased in both non-pregnant and pregnant SHRSP relative to 
WKY (Fig. 3-3E). Additionally, there was no pregnancy dependent change in kidney 
weight in either strain (Fig. 3-3E).  
 
 
126 
 
 
Figure 3-2 Maternal weight gain over pregnancy is reduced in the SHRSP relative to the WKY. 
Bodyweight was recorded in untreated WKY and SHRSP (n=6). Maternal weight gain over the course 
of pregnancy (A) was significantly decreased in SHRSP relative to WKY (*** p<0.005 vs. WKY GD18 
analysed by comparing area under the curve values using Student’s t-test). Since this reduction in 
weight gain could be a result of a reduction in litter size in these animals, the animals were weighed 
at GD18 without the uteroplacental unit which we have referred to as “pregnancy independent” 
weight gain. Pregnancy independent weight gain (B) was significantly reduced in the SHRSP (** 
p<0.01 vs. WKY GD18 analysed by Student’s t-test).  
 
Table 3-1 Raw maternal weights recorded over gestation in the WKY and SHRSP 
Gestational Day WKY SHRSP P value 
0 172.43 ± 5.25 g 159.33 ± 2.76 g 0.06 
6 203.79 ± 3.04 g 178.19 ± 3.74 g <0.01 
12 228.74 ± 2.95 g 197.89 ± 3.80 g <0.01 
18 254.41 ± 5.20 g 212.61 ± 4.82 g <0.01 
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Figure 3-3 Heart and kidney weight are increased in SHRSP relative to the WKY. 
Post-mortem organ weight was measured in non-pregnant (n=5) and pregnant (GD18) (n=5) WKY 
and non-pregnant (n=5) and pregnant (n=5) SHRSP. Organ weights were normalised to tibia length 
as bodyweight changes over gestation. Heart weight (A) was not significantly different between non-
pregnant animals but was greater in pregnant SHRSP relative to pregnant WKY (* p<0.05 vs. WKY 
GD18 analysed by one-way ANOVA followed by a post-hoc Tukey’s test). There were no significant 
differences in the lungs or spleen between non-pregnant and pregnant animals or between WKY and 
SHRSP (B-C). Liver weight (D) was significantly increased in a pregnancy-dependent manner in both 
WKY and SHRSP (** p<0.01 vs. NP analysed by one-way ANOVA followed by a post-hoc Tukey’s 
test). Kidney weight (E) was greater in SHRSP at both non-pregnant and pregnant time-points 
relative to the WKY (* p<0.05 vs. WKY analysed by one-way ANOVA followed by a post-hoc Tukey’s 
test). 
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3.3.1.1 SHRSP Exhibit Features of Pregnancy-dependent Left Ventricular 
Hypertrophy 
Left ventricle weight was increased in a pregnancy and strain dependent 
manner similar to that of heart weight (Fig. 3-4A) in SHRSP relative to WKY (Fig. 
3-4B). Gene expression of natriuretic peptides, ANP and BNP, were  altered in the 
left ventricle of SHRSP relative to WKY. ANP (Nppa) expression was increased in 
left ventricle taken from both non-pregnant and pregnant SHRSP relative to the 
WKY (Fig. 3-4C). BNP (Nppb) expression in the left ventricle tissue was not 
significantly different between strains in non-pregnant animals but was 
significantly increased in left ventricle tissue from pregnant SHRSP relative to WKY 
(Fig. 3-4D).  
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Figure 3-4 SHRSP exhibit features of left ventricular hypertrophy during pregnancy. 
Heart (A) and left ventricle (B) weight was increased in pregnant (GD18) SHRSP (n=5) relative to 
WKY (n=5) (* p<0.05, **p<0.01 vs. GD18 WKY analysed by one-way ANOVA followed by a post-hoc 
Tukey’s test) but not between non-pregnant WKY  (n=5) and non-pregnant SHRSP (n=5).  Gene 
expression of ANP (Nppa) in left ventricle (n=5) tissue (C) was increased in both non-pregnant and 
pregnant (GD18) SHRSP relative to WKY (* p<0.05, **p<0.01 vs. GD18 WKY analysed by one-way 
ANOVA followed by a post-hoc Tukey’s test). Gene expression of BNP (Nppb) in left ventricle tissue 
(n=5) (D) was increased only in pregnant (GD18) SHRSP relative to WKY (* p<0.05, **p<0.01 vs. 
GD18 WKY analysed by one-way ANOVA followed by a post-hoc Tukey’s test). 
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3.3.1.2 Maternal biomarkers associated with hypertensive pregnancy are 
altered in pregnant SHRSP 
Biomarkers which have been previously shown to be associated with the 
incidence of hypertension during pregnancy were measured in maternal plasma 
from pregnant (GD18) WKY and SHRSP. The potent vasoconstrictor molecule 
endothelin-1 (ET-1) was significantly increased in plasma from pregnant SHRSP 
relative to WKY (Fig. 3-5A). Anti-angiogenic soluble receptor, soluble Flt-1 (sFLT-
1) was also significantly increased in plasma from pregnant SHRSP (Fig. 3-5B). 
There was a trend for a decrease in placental growth factor (PlGF) in plasma from 
SHRSP relative to WKY (Fig. 3-5C). Accordingly, the sFLT-1:PlGF ratio was 
significantly increased in SHRSP relative to WKY (Fig. 3-5D). As sFLT-1 can also act 
as a receptor for VEGF; VEGF was measured in the plasma. However, the levels 
were absent or below the limit of detection of the assay at GD18. Using plasma 
samples from earlier gestational time points showed that plasma VEGF decreased 
over the course of pregnancy in both WKY and SHRSP (Fig. 3-5E). 
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Figure 3-5 Maternal plasma biomarkers associated with hypertensive pregnancy are altered in the 
SHRSP. 
Biomarkers were measured using ELISA in maternal plasma taken from pregnant (GD18) WKY (n=8) 
and SHRSP (n=8). Endothelin-1 (ET-1) (A) and soluble FLT-1 (sFLT-1) (B) were increased in plasma 
from SHRSP relative to WKY (* p<0.05, ** p<0.01 vs. GD18 WKY analysed by Student’s t-test). 
Placental growth factor (PlGF) showed a trend for a decrease in SHRSP (p = 0.057 vs. GD18 WKY 
analysed by Student’s t-test) (C). The sFLT-1/PlGF ratio was increased in SHRSP relative to WKY 
(** p<0.01 vs. GD18 WKY analysed by Student’s t-test) (D). The detection of free vascular endothelial 
factor (VEGF) in the plasma (E) showed a trend to decrease over the course of gestation in both 
WKY (NP n=3, GD6 n=5, GD12 n=6, GD18 n=8) and SHRSP (F) (NP n=2, GD6 n=4, GD12 n=4, 
GD18 n=8) and as a result was undetectable in most samples at GD18. 
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  Placental Biology is Altered in Pregnant SHRSP 
The rat placenta is composed of distinct layers with characteristic cellular 
composition and function (discussed in section 1.6.1). A protocol was developed 
for dissecting the tissue into four constituent layers: the mesometrial triangle and 
decidua, junctional zone, labyrinth and chorionic plate. To verify accurate 
dissection, qPCR markers were used (Fig. 3-6). Desmin (Des) was highest in the 
uterine tissue (mesometrial triangle and decidua) (Fig. 3-6A), prolactin (Prl8a4) 
was highest in the junctional zone (Fig. 3-6B) and VEGF receptor 2 (Vegfr2) was 
highest in the vascularised mesometrial triangle and labyrinth zone (Fig. 3-6C). 
The chorionic plate had the lowest expression for all of these markers (Fig. 3-6A-
C). 
Gene expression markers associated with oxidative stress were tested in 
dissected placental tissue from pregnant (GD18) WKY and SHRSP. Expression of 
hypoxia inducible factor 1 α (Hif1α) (Fig. 3-7A) and superoxide dismutase 1 (Sod1) 
(Fig. 3-7B) were increased in SHRSP in the vascular compartments of the placenta; 
the uterine tissue and labyrinth. Vascular endothelial growth factor (Vegf) (Fig. 
3-7C) was increased in the main placental unit (junctional zone and labyrinth) of 
the SHRSP relative to the WKY. 
Upon visual inspection of the placental tissue on dissection, a darkened 
area of potential haemorrhage or necrosis was identified within the outer - region 
of the junctional zone in the majority (>50%) of SHRSP placenta which was not 
evident in the WKY (Fig 3-8A). Perl’s Prussian blue staining revealed a significant 
increase in free blood principally localised in the junctional zone of the placenta 
in the SHRSP compared to the WKY (Fig 3-8B-C). Cell death in the placental tissue 
was evaluated using western blot for caspase-3 cleavage. A greater amount of 
caspase-3 cleavage was observed in GD18 placental tissue from SHRSP relative to 
WKY (Fig 3-8D-E).  
Haematoxylin and eosin staining for cellular structure showed that there 
was no difference in the size of the layers of the uteroplacental unit at GD18 
between WKY and SHRSP (Fig 3-9A-B). However, periodic acid-Schiff (PAS) stain 
revealed that the SHRSP had a significantly reduced proportion of PAS positive 
glycogen cells in the junctional zone of the GD18 placenta compared to WKY (Fig 
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3-9C-D). There was no significance difference in PAS positive staining in the 
decidua and mesometrial triangle between strains (Fig. 3-9E). 
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Figure 3-6 qPCR markers for placental layers. 
The placenta was dissected into four layers: maternal tissue (the mesometrial triangle and decidua) 
(Dx), junctional zone (Jx), labyrinth (Lx) and chorionic plate (CP) in pregnant (GD18) WKY (n=6). 
Desmin (Des) (A) was most highly expressed in the maternal tissue (Dx) (** p<0.01 vs. Dx analysed 
by one-way ANOVA followed by post-hoc Tukey’s test). Prl8a4 (B) was most highly expressed in the 
junctional zone (Jx) (** p<0.01 vs. Jx analysed by one-way ANOVA followed by post-hoc Tukey’s 
test). Vegfr2 (C) had highest expression in the vascularised areas of the placenta; the Dx and the Lx 
(** p<0.01 vs. Lx analysed by one-way ANOVA followed by post-hoc Tukey’s test).  
A B
C
Dx Jx Lx CP
0.0
0.5
1.0
1.5
**
**
D
e
s
R
Q
 v
s
. 
D
x
/G
a
p
d
h
D
x Jx Lx C
P
0
1
2
** **
P
rl
8
a
4
 R
Q
 v
s
. 
J
x
/G
a
p
d
h
D
x Jx Lx C
P
0.00
0.25
0.50
0.75
1.00
1.25
**V
e
g
fr
2
R
Q
 v
s
. 
L
x
/G
a
p
d
h
 
 
135 
 
  
 
 
Figure 3-7 Placental markers of hypoxia are increased in placenta from pregnant SHRSP. 
Placentae from pregnant (GD18) SHRSP (n=8) and WKY (n=8) were dissected into the main layers 
of the placental unit: decidua (Dx), junctional zone (Jx), labyrinth zone (Lx) and chorionic plate (CP). 
Genes of interest were assessed in these zones separately; the SHRSP showed an increase in Hif1a 
(A) and Sod1 (B) expression in both the decidua and labyrinth whilst Vegf (C) expression was 
upregulated in the junctional zone and labyrinth (* p<0.05, ** p<0.01 vs. GD18 WKY analysed by 
Student’s t-test). 
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Figure 3-8 The SHRSP placenta at 
GD18 exhibits increased free blood 
and cell death. 
Visual inspection of the placental 
tissue from SHRSP exhibited 
blackened areas that were localised 
to the edges of the junctional zone 
(Jx) (A). Perl’s Prussian blue 
staining (B) in sections of placenta 
from WKY (n=8) and SHRSP (n=8) 
showed that SHRSP had an 
increase in free blood localised to 
the Jx of the SHRSP placenta 
relative to the WKY (C) (* p<0.05 vs. 
GD18 WKY analysed by Student’s 
t-test). Western blotting for 
caspase-3 showed that placenta 
from GD18 SHRSP showed an 
increased proportion of cleaved: full 
length caspase-3 relative to WKY (2 
technical replicates; n=3 SHRSP 
and WKY) (D-E) (* p<0.05 vs. GD18 
WKY analysed by Student’s t-test). 
Dx: decidua, Jx: junctional zone, Lx: 
labyrinth. 
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Figure 3-9 The SHRSP placenta exhibits premature glycogen cell loss from the junctional zone. 
Haematoxylin & eosin stain was used to assess cellular structure of the placenta in WKY (n=8) and 
SHRSP (n=8) (A). Analysis of haematoxylin & eosin stained sections of placenta showed that there 
was no significant difference in the size of the layers of the uteroplacental unit (B). Mes: mesometrial 
triangle, Dx: decidua, Jx: junctional zone, Lx: labyrinth, CP: chorionic plate. Periodic acid Schiff stain 
in sections of placenta from WKY (n=8) and SHRSP (n=8) showed that SHRSP had less glycogen 
cells present in the Jx relative to the WKY (C-D). This did not appear to be due to migration into the 
uterine tissue as there was no significant difference in PAS positive cells in this area (E). 
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  Blastocyst Implantation is Not Impaired in the SHRSP 
Using a dye injection technique at GD6 (Fig. 3-10A), the number of 
implantation sites was not found to be different between WKY and SHRSP (Fig. 3-
10B). 
 
Figure 3-10 Blastocyst implantation is not altered in the SHRSP relative to the WKY. 
Blastocyst implantation was determined at GD6 in untreated SHRSP (n=3) and WKY (n=4) using 
Evans’ blue dye infusion (A) under terminal anaesthesia. There were no significant difference 
between WKY and SHRSP in the number of implantation sites detected (B). 
 
  Resorption frequency is increased in SHRSP 
Sites of late spontaneous pregnancy loss, termed resorptions, were counted 
at GD18 in WKY and SHRSP (Fig. 3-11). The number of dams that presented with 1 
or more resorptions was greater in the SHRSP (66.7 %) relative to WKY (36%). Of 
those dams which had resorptions, the percentage of the litter that were lost was 
also increased in SHRSP relative to WKY at GD14 and GD18 (Table 3-2). 
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Figure 3-11 Example of a fetal resorption. 
 
 
Table 3-2 Resorption frequency is increased in SHRSP at GD14 and GD18. 
% Resorption Frequency WKY SHRSP 
GD14 11.67 ± 0.72 % 30.63 ± 0.79 % 
GD18 14.82 ± 0.58 % 28.45 ± 0.69 % 
GD14 WKY n=5; SHRSP n=5. GD18 WKY n=8; SHRSP n=8. Figures are presented as mean of 
each strain of the percentage of the litter affected by resorption ± SEM. 
  Fetal and Placental Growth is Not Restricted in the SHRSP 
Post-mortem placental and fetal weights were recorded from WKY and 
SHRSP at GD 14, 18 and 20. There was no significant difference in placental or 
fetal weight at any time point between strains (Fig 3-12A-B). More detailed fetal 
measurements were taken at GD20 from WKY and SHRSP. There was no difference 
in fetal head: weight ratio (Fig 3-12C) or fetal heart: liver ratio (Fig. 3-12D) 
between strains. 
 
Placenta Fetus
Resorption
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Figure 3-12 Fetal and placental weight is not altered in the SHRSP relative to the WKY. 
Post-mortem placental and fetal weight was measured in GD14 (n=5), (GD18) (n=8) and GD20 (n=5) 
WKY and GD14 (n=5), (GD18) (n=8) and GD20 (n=5) SHRSP (A-B) where there were no strain-
dependent differences. Detailed fetal measurements were taken at GD20 only (n=5 in both WKY and 
SHRSP) (C-D). There was no significant difference in fetal head: weight ratio (C) or heart: liver ratio 
(D). Data are expressed as an average weight from each litter. 
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3.4 Discussion 
The work presented in this Chapter shows that the SHRSP exhibits altered 
maternal adaptation to pregnancy relative to the WKY. Furthermore, the SHRSP 
exhibits placental pathology characterised by an increase in oxidative stress-
related genes, increased cell death and a loss of glycogen cells at GD18. There are 
no strain dependent differences in placental and fetal weight or blastocyst 
implantation. 
Normal pregnancy in humans and rodents is associated with physiological 
eccentric cardiac hypertrophy in response to a prolonged increase in cardiac load 
secondary to an increase in blood volume (discussed in section 1.5.1) (358). In this 
study, the WKY shows no significant pregnancy-dependent increase in heart or left 
ventricular weight however, there was a significant increase in both of these 
parameters in the SHRSP. The expression of ANP is increased from non-pregnant 
to pregnant animals from both strains; this may be in response to increased 
cardiac load due to volume expansion. In normal human pregnancy, serum ANP is 
increased early in pregnancy; however it is not known how directly related this is 
to cardiac ANP secretion (359). Increased ANP has been detected in cardiac tissue 
from rat models of hypertensive pregnancy but these were not compared to non-
pregnant controls (360). In contrast to ANP, BNP is only increased during 
pregnancy in SHRSP. Levels of serum BNP in healthy women has been reported to 
be not changed (361) or slightly increased (362) during pregnancy. Further 
echocardiogram and histology could be used to assess features of left ventricular 
hypertrophy that are not detectable in post-mortem analysis such as 
cardiomyocyte structure.  
The potent vasoconstrictor molecule, endothelin-1 (ET-1), was modestly but 
significantly increased in maternal plasma from SHRSP at GD18 relative to 
normotensive WKY. ET-1 has been shown to be instrumental in the vascular 
dysfunction that is seen in hypertension which occurs independently of pregnancy 
(363) and during pre-eclampsia (364). One limitation of the measurements in this 
study are the lack of a non-pregnant comparison as SHRSP are hypertensive before 
and during pregnancy. The ratio of maternal plasma biomarkers sFLT-1: PlGF has 
been shown to have predictive ability in women who went on to develop pre-
eclampsia in the recent PROSPECTIVE study (365). In addition, lower maternal 
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PlGF measured in the plasma has been shown to be predictive of the development 
of superimposed preeclampsia in women with chronic hypertension (366). An 
increase in sFLT-1: PlGF ratio is also seen in the SHRSP; but these changes are 
much smaller (approximate sFLT-1: PlGF increase of 1) than those seen in models 
of pre-eclampsia such as the RUPP (approximate sFLT-1: PlGF increase of 30) 
(329). Similarly to the RUPP rat, an sFLT-1: PlGF of above 38 has been shown to 
have some predictive value for women who may be at risk of developing pre-
eclampsia in the PROSPECTIVE cohort (365). Plasma (free) VEGF was not 
detectable at late pregnancy (GD18) in either strain in this study in contrast to 
other work in pregnant rats (367). Similarly to this study, free VEGF is not 
detectable in most women during late gestation (368). A recent study by 
Weissgerber et al. identified that utilising different commercially available ELISA 
kits for VEGF led to inconsistent results in rodent models (369). The Weissgerber 
study showed that plasma VEGF was below the limit of detection of the R&D 
Systems rat VEGF ELISA assay, such as the one used in this study, at GD18. 
Placental weight or the size of the uteroplacental layers are not altered 
between WKY and SHRSP. However, a darkened area was identified in the majority 
of the SHRSP placentas upon visual inspection which we hypothesised could be 
haemorrhage or necrosis. There was a small but significant increase in free blood 
in the SHRSP relative to the WKY evaluated by Perl’s Prussian blue staining but 
this was not marked enough to suggest haemorrhage. There was a significant 
increase in caspase-3 cleavage, which is indicative of an increase in cell death. 
These findings suggest that these black areas are most likely to be necrotic tissue. 
Placental tissue from women with pre-eclampsia also shows an increase in cell 
death and caspase-3 activation (370). Further investigations should employ other 
markers for upstream mediators of apoptosis such as Bcl-2 and Bax. Hypoxia-
reoxygenation has been shown to induce placental cell death (371). In-keeping 
with these findings, an increase in oxidative stress related genes was detected in 
placenta from the SHRSP. Further work should measure reactive oxygen species 
such as superoxide and hydrogen peroxide as well as assess oxidative stress 
induced DNA damage in the placenta of the SHRSP.  
The SHRSP placenta exhibited a premature loss of glycogen cells from the 
placenta relative to the WKY at GD18. This can be attributed to a loss rather than 
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a migration as there was no significant difference in the number of PAS positive 
cells in the mesometrial triangle or decidua. Firstly, this could be explained by 
increased cell death in the placenta as assessed by caspase-3 western blotting. 
Notably, caspase-3 protein was measured in whole placenta homogenate 
(junctional zone and labyrinth) so no localisation was possible. Alternatively, the 
glycogen cells have been proposed to be an energy store for the placenta (372). 
The reduction in uteroplacental perfusion in the SHRSP may cause the placenta to 
utilise glycogen stores prematurely relative to the WKY. Future studies should 
assess strain-dependent differences in glucose metabolism in the placenta which 
have thus far not been reported in whether this model or in women with chronic 
hypertension. In addition, placental samples from earlier time points should be 
tested for glycogen cell content to determine when in gestation these stores are 
lost. A technique such as TUNEL-labelling of the sections of placenta would be 
able to localise whether cell death is taking place in these glycogen cells. In 
addition to these hypotheses, the SHRSP has been shown to have abnormal glucose 
metabolism relative to WKY (373); therefore the SHRSP could also be metabolising 
placental glycogen stores in a strain-specific way. Glycogen cells are not present 
in the human placenta therefore the clinical translation of these findings is not 
clear. 
As a reduction in litter size had previously been identified at GD18 in the SHRSP 
relative to the WKY, the number of implantation sites was examined. There was 
no difference in the number of blastocyst implantation sites between strains there 
was, however, an increase in resorption frequency with respect to the number of 
dams presenting with resorptions and the percentage of the litter affected. This 
suggests that whilst the same number of implantations takes place in both WKY 
and SHRSP; more fetuses are lost sometime between GD6 and 14 in the SHRSP. An 
increase in resorption rate is a similar trait observed in other rodent models of 
hypertensive pregnancy (374, 375). In the absence of fetal growth restriction, an 
increase in resorption rate alone is not directly translatable to the human 
condition. SHRSP dams exhibit reduced weight gain during pregnancy relative to 
the WKY. This will be, in part, attributed to the smaller litter size in the SHRSP. 
In order to remove this variable, the SHRSP dam was weighed once the uterine 
horn had been removed at the point of sacrifice; this was also significantly reduced 
in the SHRSP. To explore these findings further, individual fat pads could be 
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excised and weighed. In disagreement with our hypothesis, there was no evidence 
of fetal growth restriction in the SHRSP. This is in contrast to work in the related 
SHR strain which showed evidence of fetal growth restriction at GD20 (376).  
 The findings presented in this chapter provided a better understanding of 
pregnancy in the SHRSP. Further work went on to identify a molecule that could 
be targeted for the therapeutic benefit of the deficient uterine artery remodelling 
and adverse pregnancy outcome in this model. 
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Chapter 4 Excess TNFα Signalling Plays a Central 
Role in Deficient Uterine Artery Function in the 
SHRSP 
4.1 Introduction 
Recent work has redefined the role of immunology in pregnancy, such that 
normal gestation is characterised by a dynamic regulation of the immune system. 
This is relative to the classical hypothesis that pregnancy was characterised by a 
universal shift to an anti-inflammatory state (377, 378). In this new model, the 
initial and final “immunological stages” of gestation refer to the first trimester 
and parturition respectively. During these stages, there is tightly regulated sterile 
inflammation (379, 380). In contrast, during the middle stage, characterised by 
rapid fetal development, there is an anti-inflammatory environment (378). The 
pro-inflammatory cytokine TNFα has vital roles in the physiology of normal 
pregnancy. In particular, it promotes blastocyst implantation and the remodelling 
of the maternal spiral arteries through stimulation of invasive extravillous 
trophoblasts (381). In humans, placental TNFα is increased in the second trimester 
in comparison to the first and third trimesters (382). The balance between normal 
and pathological levels of TNFα is fine and, paradoxically, excess amounts have 
prohibitive effects on the physiological role of TNFα (383, 384). 
Activation of the immune system is linked to adverse maternal and fetal 
outcome in humans (377).  This observation has been recapitulated in rat models 
using lipopolysaccharide injection to induce low-grade systemic inflammation 
which results in the manifestation of PE-like symptoms (385), preterm labour 
(386), fetal growth restriction and/or fetal loss (387, 388). In these studies, TNFα 
was shown to play a central role. TNFα infusion into pregnant rats results in a 
dose-dependent increase in blood pressure associated with an increase in 
vasoconstriction (389). This is similar to what is observed in non-pregnant human 
subjects (discussed in section 1.3.3.1) suggesting that the mechanisms by which 
TNF induces vascular dysfunction are broadly conserved. Increased circulating 
TNFα levels have been reported in women with severe hypertension during 
pregnancy (390-392), however, TNFα expression in the placenta is more 
controversial (393, 394). A single nucleotide polymorphism in the TNFα gene 
(G308A) in humans has also been associated with a significantly increased risk of 
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pre-eclampsia (395) but not in all studies (396). Furthermore, whether an increase 
in pro-inflammatory TNFα is a cause or effect of an abnormal vascular response to 
pregnancy is unknown. 
A chronic increase in TNFα is a common observation in hypertension and 
adverse pregnancy outcome (138, 139) (discussed in section 1.3.3.1). From our 
earlier characterisation study (Chapter 3), we identified TNFα as a candidate 
molecule for abnormal pregnancy response in the SHRSP. We hypothesised that 
pro-inflammatory TNFα provides a link between vascular dysfunction and adverse 
pregnancy outcome and plays a causative role in the abnormal uterine vascular 
remodelling observed in our model. To investigate this hypothesis we carried out 
an intervention study using etanercept, a monoclonal antibody which binds and 
sequesters TNFα, in SHRSP. 
4.2 Materials & Methods 
General materials & methods can be found in Chapter 2. 
  Etanercept Treatment 
 Etanercept (Wyeth Pharmaceuticals, Maidenhead, UK) was prepared fresh 
on the day of use using sterile phosphate buffered saline (PBS) (Thermo Fisher 
Scientific, Paisley, UK). SHRSP were treated with 0.8 mg/kg dose or vehicle (PBS) 
via subcutaneous injection at gestational day 0, 6, 12 and 18. This treatment 
regimen was chosen as etanercept is given weekly to treat inflammatory 
conditions such as rheumatoid arthritis in humans. Etanercept was always given 
by 10am with no more than 100 µl total injected using a disposable 1ml syringe 
and 26 G x ½” needle (BD Bioscience, Oxford, UK) given to the back of the neck. 
Animals were either subject to radiotelemetry implantation and allowed to 
progress to parturition or sacrificed at gestational day (GD) 18 for myography. 
  Radiotelemetry Probe Implantation 
 Systolic (SBP) and diastolic blood pressure (DBP), heart rate and activity 
were directly monitored using the Dataquest V telemetry system (Data Sciences 
International). Prior to implantation, the radiotelemetry transmitter was 
calibrated to be accurate within ± 6 mmHg. For reuse, radiotelemetry probes were 
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sterilised in Terg-A-Zyme (Alconox Inc) for 24 hours. Radiotelemetry implantation 
was performed at 10 weeks of age when the animals were of a sufficient 
bodyweight to undergo the surgery. Radiotelemetry implantation was carried out 
as described previously by our group (397) and detailed in section 2.3.3. The data 
represented has been analysed to show a daily average from the daytime and 
nighttime values. 
  Doppler Ultrasound 
 Doppler waveform recordings were used to assess uterine artery blood flow. 
Rats were lightly anaesthetized throughout the procedure at approximately 1.5 % 
isoflurane in oxygen. Hair on the abdomen was removed by shaving. Ultrasound 
gel was applied to exposed skin as an ultrasound coupling medium. Rats were 
imaged trans-abdominally using an Acuson Sequoia c256 imager fitted with a 15 
MHz linear array transducer (Siemens). An example of where measurements were 
taken from the uterine artery is shown in Figure 4-1. Peak systolic velocity (PSV) 
and end diastolic velocity (EDV) was measured from 6 consecutive cardiac cycles. 
Resistance index (RI) was calculated as (RI = [PSV- EDV]/PSV). 
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Figure 4-1: Representative ultrasound image of the uterine artery used for Doppler measurements. 
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  Placental Tissue Explants 
Placental tissue was harvested in ice cold PBS from WKY and SHRSP. Under 
sterile conditions, the tissue was dissected into pieces <5mm in ice cold DMEM F-
12 Media +0.5% FBS +1% penicillin/streptomycin (Thermo Fisher Scientific, Paisley, 
UK). The tissue pieces were split evenly between 2 wells of a 24 well plate 
(Thermo Fisher Scientific, Paisley, UK) in 1ml of media. After 1 hour, the explants 
were washed in PBS and replaced with 1ml of fresh media. Explants were 
incubated for 20 hours at 37 °C, after which the media was collected, aliquoted 
and stored at -80 °C until use. 
  TNFα Measurement in Plasma, Urine and Explant Media using 
Enzyme Linked Immunosorbent Assay (ELISA) 
TNFα in plasma, urine and explant was measured using a commercially 
available kit (RTA00) (R&D Systems, Abingdon, UK) according to manufacturer’s 
instructions. Kits were controlled using a positive control provided by the 
manufacturer and a negative control where dH2O was used instead of sample.  The 
method used a 7-point standard curve consisting of 1-in-2 serial dilution steps from 
the top standard where TNFα concentration was 800 pg/ml down to a bottom 
standard with concentration of 12.5 pg/ml. The limits of detection for this kit are 
< 5pg/ml and plasma samples are expected to fall below the lowest standard of 
12.5 pg/ml. All results shown in this Chapter were from one plate therefore there 
it was not necessary to calculate inter-assay variation. 
  Pressure Myography 
 Pressure myography was used to construct pressure-diameter relationships 
to assess uterine artery structure under isobaric conditions. Vessels for pressure 
myography were mounted in calcium free PSS (0.25 M NaCl, 0.001 M KCl, 2 mM 
MgSO4, 50 mM NaHCO3, 2 mM KH2PO4, 1 mM glucose). The pressure myograph 
system (Danish Myo Technology, Aarhus, Denmark) was set up and equilibrated 
according to manufacturer’s instructions. Arteries were tied to two glass cannulas 
using nylon thread. Any side branches of the artery were also tied closed with 
nylon thread. The myography had two in-line pressure transducers which 
continually measured inflow and outflow pressure which was altered by adjusting 
the height of reservoirs of calcium free PSS. Vessels were maintained at 37 ºC and 
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95 % O2 and 5 % CO2 throughout the experiment. After equilibration at 70 mmHg 
for one hour, the vessels were subject to increasing intraluminal pressure: 10, 20, 
40, 60, 80, 100 and 110 mmHg. Measurements of internal and external diameter 
were taken after five minutes at each pressure. Wall thickness was calculated as 
[(external diameter - internal diameter) / 2]. Cross sectional area was calculated 
as [(π/4) x (external diameter² - internal diameter²)]. 
  Wire Myography 
 Wire myography was used to assess mesenteric and uterine artery function 
under isometric conditions. Uterine artery rings were mounted in PSS (0.25 M 
NaCl, 0.001 M KCl, 2 mM MgSO4, 50 mM NaHCO3, 2 mM KH2PO4, 1 mM glucose, 2.5 
mM CaCl2). Uterine artery rings (4.8 – 5.2 µm in length) were mounted on two 
stainless steel wires on a four channel small vessel myograph (AD Instruments, 
Oxford, UK). Changes in contraction and relaxation were detected by a force-
sensitive transducer connected to a laptop running LabChart 8 (AD Instruments, 
Oxford, UK). Vessels were maintained at 37 ºC and 95 % O2 and 5 % CO2 throughout 
the experiment. Vessels were normalized and subject to a wake up procedure as 
previously described (398). To establish the vessel’s contractile response curve, 
noradrenaline (Sigma-Aldrich, Dorset, UK) was added at the following increasing 
concentrations: 1x10-9, 1x10-8, 1x10-7, 1x10-6, 1x10-5 and 3x10-5 M. To determine 
the vessel’s endothelium-dependent relaxation response, vessels were pre-
constricted with 1x10-5 M noradrenaline followed by the addition of carbachol 
(Sigma-Aldrich, Dorset, UK) at the following increasing concentrations: 1x10-8, 
1x10-7, 1x10-6, 1x10-5 and 1x10-5 M. Active effective pressure (P) in kPa was 
calculated by P = (active wall tension/[normalised lumen diameter/2]). 
Percentage relaxation was calculated [(active effective pressure at relevant 
carbachol dose / noradrenaline 1x10-5 response) x 100]. 
  Periodic acid-Schiff Stain 
 Periodic acid – Schiff stain was used to quantify glycogen cell content in the 
placenta. Slides were cleared and rehydrated as described in section 2.6.1. Slides 
were incubated in 1% periodic acid (Sigma-Aldrich, Dorset, UK) in dH2O for 10 
minutes to oxidise aldehyde groups followed by 1 minute wash under running tap 
water. Slides were then stained with Schiff’s reagent (Sigma-Aldrich, Dorset, UK) 
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for 10 minutes which reacts with the oxidised aldehyde groups to form a magenta 
dye. This was followed by a 1 minute wash under running tap water and 
dehydration through an ethanol gradient (70%, 90%, 100%; 5 minutes each). Slides 
were cleared in histoclear 2 x 5 minutes and mounted using DPX (Sigma-Aldrich, 
Dorset, UK). Slides were viewed using light microscopy and analysed using 
threshold quantification in ImageJ (National Institutes of Health, Bethesda, USA) 
as described in section 2.6.4. 
   Quantitative PCR (qPCR) for Tnfr1 Expression 
Gene expression for Tnfr1 was carried out using the following probes from 
Thermo Fisher, Paisley, UK: Tnfr1 (Rn01511602_m1) and Actb (4352340E). 
 Western Blot for Phosphorylated NFκB 
Western blot was carried out as described in section 2.5. Membranes were 
incubated in the following primary antibodies diluted in 5% bovine serum albumin 
(BSA) (Sigma-Aldrich, Dorset, UK) in TBS-T overnight at 4 ºC: phospho-NFκB 
(Ser536) #3033  1:1000 (Cell Signalling Technology, Leiden, Netherlands), total 
NFκB #8242 1:1000 (Cell Signalling Technology, Leiden, Netherlands) and GAPDH 
#ab8245 1:5000 (Abcam, Cambridge, UK). Phospho-NFκB and total NFκB were 
detected using horse radish peroxidase (HRP) conjugated swine-α-rabbit 
secondary antibody (Dako, Ely, UK) diluted 1:10000 in 5% BSA/TBS-T. GAPDH was 
detected using HRP conjugated rabbit-α-mouse secondary antibody (Dako, Ely, 
UK). 
4.3 Results 
 Tumor Necrosis Factor α (TNFα) is a Promising Target Molecule 
in Pregnant SHRSP 
TNFα was increased in pregnant (GD18) SHRSP plasma and urine relative to 
the pregnant WKY (Fig. 4-2A-B). In addition, increased secretion of TNFα was 
detected in media taken from placental tissue explants from GD18 SHRSP (Fig. 4-
2C). Gene expression of the main pro-inflammatory TNFα receptor-1 (Tnfr1), was 
also significantly increased in the GD18 uteroplacental unit from SHRSP relative 
to WKY (Fig. 4-2D). 
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Figure 4-2 TNFα is increased in the SHRSP relative to the WKY. 
TNFα was measured in plasma (A) and urine (B) using ELISA where pregnant (GD18) SHRSP (n=6) 
showed elevated levels relative to the GD18 WKY (n=6) (* p<0.05 vs. GD18 WKY analysed by 
Student’s t-test). Secretion of TNFα (C) was increased from placental explants taken from GD18 
SHRSP (n=5) relative to WKY (n=5) (* p<0.05 vs. GD18 WKY analysed by Student’s t-test). 
Placentae from pregnant (GD18) SHRSP and WKY (n=8) were dissected into the main layers of the 
placental unit: decidua (Dx), junctional zone (Jx), labyrinth zone (Lx) and chorionic plate (CP). Gene 
expression of TNFα receptor-1 (Tnfr1) (D) was significantly increased in the SHRSP (n=6) relative 
to the WKY (n=6) uteroplacental unit at GD18 (** p<0.01, *** p<0.005 vs. WKY GD18 WKY analysed 
by Student’s t-test).  
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  Etanercept Reduces Systolic Blood Pressure in the SHRSP 
Treatment with etanercept (0.8 mg/kg s.c.) was given at gestational day 
(GD) 0 of pregnancy and repeated at GD6, 12 and 18. The effect of etanercept 
treatment on blood pressure in the SHRSP relative to vehicle treated controls was 
monitored using radiotelemetry. SHRSP are hypertensive before and during 
pregnancy in contrast to the normotensive WKY strain (Fig. 4-3A-B). Etanercept 
treatment had no effect on SHRSP blood pressure in early pregnancy (GD0-12). 
After the dose administered at GD12, there was a significant (p<0.05) average 
decrease of 11.5 ± 2.1 mmHg in systolic blood pressure (SBP) from GD12-21 in 
SHRSP treated with etanercept relative to vehicle treated SHRSP (Fig. 4-3A). No 
significant difference in diastolic blood pressure (DBP) was observed between 
SHRSP and etanercept treated SHRSP (112.4 ± 1.2 mmHg vs. 108.5 ± 2.6 mmHg; 
p=0.13) (Fig. 4-3B). Relative to their pre-pregnancy blood pressure, etanercept 
treated SHRSP exhibited broadly the same pattern as vehicle treated SHRSP, 
notably there was no early decrease in systolic or diastolic blood pressure which 
is observed in the WKY (Fig. 4-3C-D). Activity was significantly decreased in both 
SHRSP and SHRSP treated with etanercept relative to the WKY over the course of 
pregnancy (Fig. 4-3E). Heart rate was not significantly different between groups 
(Fig. 4-3F).  
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Figure 4-3: Etanercept treatment significantly reduces systolic blood pressure from GD 12-21 of 
pregnancy in the SHRSP. 
Systolic blood pressure (SBP) (A) and diastolic blood pressure (DBP) (B) were monitored using 
radiotelemetry in untreated WKY (n=6), vehicle treated SHRSP (n=4) and etanercept treated SHRSP 
(n=6) from 7 days before pregnancy (GD-7 to -1) and during pregnancy (GD0 – 21). SHRSP were 
treated with etanercept (0.8 mg/kg s.c.) at GD 0, 6, 12 and 18. SHRSP and SHRSP treated with 
etanercept had significantly increased SBP and DBP relative to the WKY from GD-7 to GD21 (A-B) 
(* p<0.05 vs. WKY analysed by two-way ANOVA). Etanercept treated SHRSP had a significant 
decrease in SBP (A) from GD12-21 relative to vehicle treated SHRSP (# p<0.05 vs. SHRSP analysed 
by ΔSBP [SHRSP-ETN SHRSP] GD12-21 followed by a Student’s t-test). The difference in blood 
pressure relative to non-pregnant values shows that etanercept treatment does not restore the early 
decrease in SBP (C) and DBP (D) seen in WKY. Activity (E) was significantly decreased in both 
SHRSP and SHRSP treated with etanercept relative to the WKY (* p<0.05 vs. WKY analysed by two-
way ANOVA). Heart rate (F) was not significantly changed between the groups. Data points 
represent daily averages. Arrows in panels A and B represent days of treatment with etanercept. 
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  Etanercept Improves Placenta and Litter Size in the SHRSP 
Placental glycogen cell content was assessed using PAS stain at GD18. Glycogen 
storage in the placenta of SHRSP was reduced relative to the WKY (Fig. 4-4A-B). 
Etanercept treatment in the SHRSP restored PAS positive glycogen cells within the 
junctional zone of the placenta (Fig. 4-4A-B). Furthermore, litter size was 
significantly increased by etanercept treatment in SHRSP (Fig. 4-4C). There was 
no difference in fetal or placental weight between any of the groups (Fig 4-5). 
Concurrently, the number of dams which presented with 1 or more resorptions 
was decreased in SHRSP treated with etanercept (Table 4-1).  
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Figure 4-4: Etanercept treatment significantly improves glycogen cell loss from the placenta and 
litter size in the SHRSP. 
Glycogen cell content in the junctional zone (Jx) of the placenta was assessed by counting the 
number of PAS positive cells in untreated WKY (n=6), vehicle treated SHRSP (n=6) and etanercept 
treated SHRSP (n=6). A representative uteroplacental unit for each group is shown in (A) and 
quantified in (B) (## p<0.01 vs. SHRSP analysed by one-way ANOVA followed by a post-hoc Tukey’s 
test). Litter size was counted at GD18 in untreated WKY (n=12), vehicle treated SHRSP (n=6) and 
etanercept treated SHRSP (n=6) where etanercept treated SHRSP and WKY had a significantly 
increased litter size relative to the SHRSP (C) (## p<0.01vs.SHRSP analysed by one-way ANOVA 
followed by a post-hoc Tukey’s test).  
 
 
 
Table 4-1 Etanercept reduces the frequency of SHRSP with spontaneous pregnancy loss. 
 % Animals with 
Spontaneous 
Resorption 
WKY 30 
SHRSP 66.7 
SHRSP + Etanercept 25 
 
The percentage of animals with spontaneous pregnancy loss was calculated as (number of animals 
with 1 or more resorption/total number of animals) x 100 in untreated WKY (n=12), vehicle treated 
SHRSP (n=6) and etanercept treated SHRSP (n=6). 
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Figure 4-5: Maternal, fetal and placental weight are unaffected by etanercept treatment in the 
SHRSP. 
Fetal (A) and placental (B) weight did not show any significant differences between untreated WKY 
(n=12), vehicle treated SHRSP (n=6) and etanercept treated SHRSP at GD18 (n= 6). Maternal 
weight gain (B) during pregnancy was significantly decreased in both SHRSP and SHRSP treated 
with etanercept relative to WKY (** p<0.01 vs. WKY analysed by area under the curve followed by 
one-way ANOVA). 
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  Etanercept Improves Uterine Artery Function in Pregnant 
SHRSP 
Pressure myography was used to assess uterine artery (average diameter 
approximately 400 μm) properties from pregnant (GD18) WKY, SHRSP and SHRSP 
treated with etanercept. Etanercept treatment did not significantly alter the 
diameter or wall thickness of the uterine arteries from pregnant SHRSP (Fig. 4-6A-
D). Investigation of uterine artery vasomotor function using wire myography 
showed that uterine arteries from pregnant SHRSP had a significantly increased 
contractile response to noradrenaline (Fig. 4-6E) and a blunted endothelium-
dependent vasorelaxation (Fig. 4-6F) relative to the WKY (28). In contrast, uterine 
arteries from pregnant SHRSP treated with etanercept exhibited a marked 
reduction in contractile response which was not significantly different from the 
normotensive WKY (Fig. 4-6E) and a significant increase in the vasorelaxation 
response to carbachol (Fig. 4-6E). In contrast to the uterine arteries, etanercept 
did not improve the function of SHRSP third-order mesenteric arteries (average 
diameter approximately 270 μm) (Fig. 4-7A-B). 
These improvements in uterine artery vasomotor function translated into an 
increase in uterine artery blood flow assessed by Doppler ultrasound. Etanercept 
treatment partially restored the physiological increase in diastolic volume over 
the course of pregnancy which is present in the WKY but absent in the SHRSP (Fig. 
4-8A). This resulted in a significantly reduced uterine artery resistance index in 
etanercept treated SHRSP relative to control SHRSP (Fig. 4-8B). 
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Figure 4-6 Etanercept treatment improves uterine artery function in pregnant SHRSP but not 
structure. 
Isolated uterine artery structure was assessed using pressure myography to measure external (A) 
and internal (B) diameter, cross-sectional area (C) and wall thickness (D) in untreated WKY (n=6), 
vehicle treated SHRSP (n=6) and etanercept treated SHRSP (n=6) at GD18 of pregnancy. External 
and internal diameter as well as cross-sectional area was significantly decreased in both vehicle 
treated and etanercept treated SHRSP (* p<0.05 vs. WKY; ** p<0.01 vs. WKY analysed by area 
under the curve followed by one-way ANOVA and post-hoc Tukey’s test). Isolated uterine artery 
function was assessed using wire myography in untreated WKY (n=6), vehicle treated SHRSP (n=6) 
and etanercept treated SHRSP (n=6) at GD18 of pregnancy. Uterine arteries from vehicle treated 
SHRSP (GD18) had a significantly increased contractile response to noradrenaline (NA) (E) and 
significantly decreased relaxation response to carbachol (F) relative to uterine arteries from GD18 
WKY (## p<0.01 vs. SHRSP analysed by calculating area under the curve followed by one-way 
ANOVA). Uterine arteries from etanercept treated SHRSP had a significantly reduced contractile 
response to NA (E) relative to SHRSP (## p<0.01 vs. SHRSP analysed by calculating area under 
the curve followed by one-way ANOVA) and a significantly increased relaxation response to 
carbachol (F) at 1 x 10-5 M (# p<0.05 vs. SHRSP analysed by a Student’s t-test). 
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Figure 4-7 Etanercept treatment does not alter third-order mesenteric artery function in the SHRSP. 
Isolated third-order mesenteric artery function was assessed using wire myography in WKY (n=4), SHRSP (n=6) and SHRSP treated with etanercept (n=6) at GD18 of 
pregnancy. There was a trend for etanercept to shift the contractile response to noradrenaline (A). Etanercept treatment did not significantly improve endothelium 
dependent vasorelaxation to carbachol (* p<0.05 vs. GD18 WKY analysed by calculating area under the curve followed by one-way ANOVA and post-hoc Tukey test) 
(B). 
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Figure 4-8 Etanercept treatment improves uterine artery blood flow in pregnant SHRSP.  
Uterine artery blood flow was assessed using Doppler ultrasound in untreated WKY (n=6), vehicle 
treated SHRSP (n=6) and etanercept treated SHRSP (n=6) at GD6, 12 and 18. Representative 
Doppler traces are shown in (A). The pregnancy-induced increase in diastolic blood flow which is 
present in the WKY but not in SHRSP is partially restored in SHRSP treated with etanercept (A) 
resulting in a significant reduction in resistance index at GD18 (B) (## p<0.01 vs. SHRSP analysed 
by one-way ANOVA followed by a post-hoc Tukey’s test). 
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  Etanercept Affects the TNFα Pathway in the Placenta 
In order to determine whether etanercept treatment had an effect on the 
TNFα signalling pathway in the placenta, we studied a subset of TNFα signalling 
components (Fig. 4-9A). The transcription factor NFκB which is phosphorylated as 
a result of TNFR1 activation was down-regulated in the placenta of SHRSP treated 
with etanercept relative to both the WKY and SHRSP (Fig. 4-9B). The expression 
of the protease, ADAM17, which produces soluble TNFα from the transmembrane 
form was also significantly decreased in the uteroplacental unit from etanercept 
treated SHRSP relative to both the WKY and SHRSP (Fig. 4-9C). The release of 
soluble TNFα from placental explants cultured for 20 hours was significantly 
increased in both the SHRSP and SHRSP treated with etanercept relative to the 
WKY (Fig. 4-9D). 
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Figure 4-9 Etanercept Treatment Alters the TNFα signalling pathway in the Placenta. 
(A) Etanercept inhibits TNFα signalling by binding and sequestering the molecule. The activation of 
downstream NFκB shows a trend to be decreased in SHRSP treated with etanercept (n=3) relative 
to WKY (n=3) and vehicle-treated SHRSP (n=3)  (B). Gene expression of Adam17 was significantly 
decreased in SHRSP treated with etanercept relative to SHRSP and WKY (n=6) (C) (* p<0.05, ** 
p<0.01, *** p<0.005 vs. WKY GD18, ## p<0.01 vs. SHRSP GD18 analysed by one-way ANOVA 
followed by a post-hoc Tukey’s test) Dec = decidua, JX = junctional zone, Lab = labyrinth, CP = 
chorionic plate.  TNFα release from placental explants was measured using ELISA after 20 hours 
where it was significantly increased in both the SHRSP and SHRSP treated with etanercept relative 
to the WKY (n=4-6) (D) (* p<0.05 vs. WKY GD18 analysed by one-way ANOVA followed by a post-
hoc Tukey’s test). 
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4.4 Discussion 
The work presented in this Chapter demonstrates that etanercept treatment 
has beneficial effects on the placenta and litter size of the SHRSP, which was 
associated with an improvement in uterine artery function and uteroplacental 
blood flow.  
Etanercept has been shown to reduce blood pressure in a rat model of pre-
eclampsia (343, 399), insulin resistance (400) and lupus (401). In contrast, it had 
no effect on blood pressure in non-pregnant hypertensive rats (402). These 
differing results suggest that etanercept has context-dependent effects on blood 
pressure; this may be related to the extent or localisation of inflammation present 
in each condition. Etanercept treatment reduced SBP but not DBP; this suggests 
that there should be a decrease in peripheral resistance in etanercept treated 
SHRSP. However, the wire myography data from the third order mesenteric 
arteries shows that etanercept treatment does not improve the function of these 
vessels. Further functional investigations should be carried out in resistance 
vessels, as well as determination of the collagen content of these vessels. The 
average SBP reduction of 11.5 mmHg in the pregnant SHRSP in this study is 
comparable to the reduction seen in other work using pregnant hypertensive rats 
(343, 399). Notably, the decrease in SBP is not present in the SHRSP until after 
GD12. This coincides with the development of the rat placenta from GD10-12 
where the five distinctive layers which define the mature uteroplacental unit are 
present (246). This suggests that the placenta may be the source of excess TNF-α 
which contributes specifically to blood pressure regulation in late pregnancy. This 
significant reduction in SBP in late pregnancy has no negative impact on fetal 
growth as no significant difference in fetal weight was observed between vehicle 
and etanercept treated SHRSP. In fact, pregnancy outcome is improved in SHRSP 
treated with etanercept where there is a significant increase in litter size and a 
decrease in dams presenting with resorptions at GD18. Etanercept treatment has 
been previously shown to reduce spontaneous pregnancy loss in a model of 
abnormal maternal inflammation during pregnancy (388). 
Etanercept does not have an effect on the structure of the uterine arteries 
from pregnant SHRSP. Therefore, from these findings, we propose that TNFα does 
not play a central role in activating the mechanisms involved in the outward 
 
 
165 
 
hypertrophic remodelling of the uterine arteries that is associated with 
pregnancy. However, etanercept treatment does improve the endothelium-
dependent vasorelaxation in uterine arteries from pregnant SHRSP. TNFα has a 
well-defined role in endothelial dysfunction by diminishing the bioavailability of 
vasodilator nitric oxide through down-regulation of the expression of the eNOS 
pathway (35, 36) and through increased superoxide production (37). In this study, 
L-NAME was not used to investigate the specific contribution of nitric oxide to the 
carbachol-mediated relaxation in these vessels. Therefore, the impaired 
vasorelaxation could be due to a lack of bioavailable nitric oxide or differences in 
the muscarinic receptor itself. Etanercept also significantly reduces the uterine 
artery vasocontractile response to noradrenaline in our model. The role of TNFα 
as an active mediator of contractile ability of vascular smooth muscle cells is less 
well defined. TNFα can induce the production of vasoconstrictor endothelin-1 (38) 
and can alter calcium handling (39). In the context of the myography experiment 
presented here, etanercept may have a role in down-regulation or desensitisation 
of contractile adrenoreceptors in order to blunt response to noradrenaline. In 
another vascular function study using resistance vessels from ovarectomized 
female rats where systemic TNFα is elevated; etanercept treatment reduces 
contractility and improves endothelium dependent vasorelaxation (40). In keeping 
with the improvement in uterine artery function in the SHRSP, uteroplacental 
blood flow is partially restored with etanercept treatment. In this study, intra- 
and inter-observer variability for uterine artery doppler was not calculated; this 
should be taken into account in future studies to ensure that the changes observed 
in blood flow are solely attributed to treatment. Correction of deficient 
uteroplacental blood flow during pregnancy using a TNFα antagonist has not 
previously been shown in the literature. However, plasma TNFα has been shown 
to have a positive correlation with abnormal uterine artery resistance index and 
the presence of notching in humans (35). We have previously hypothesised that 
deficient uteroplacental perfusion in SHRSP leads to the premature utilization of 
glycogen stores in the placenta. In agreement, improvement of uteroplacental 
blood flow in etanercept treated SHRSP restores the presence of placental 
glycogen cells at GD18. 
Small amounts of etanercept have been shown to cross the placental barrier in 
humans; a ratio of between 14:1 and 30:1 (maternal serum: cord blood) has been 
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reported in the literature (403, 404). Therefore, etanercept may reach the rat 
placenta and have effects on the TNFα signalling pathway. In the placenta of 
SHRSP, etanercept treatment did have an effect on the TNFα pathway. Etanercept 
treatment inhibited phosphorylation of downstream NFκB in the placenta of 
SHRSP. ADAM17 has been shown to be the major producer of soluble TNFα in 
human placental trophoblasts (405). In placental tissue from etanercept treated 
SHRSP, Adam17 was significantly down-regulated relative to vehicle treated SHRSP 
and WKY. However, soluble TNFα released from the placenta was still increased 
in SHRSP treated with etanercept and vehicle treated SHRSP. It could be that the 
increase in soluble TNFα in etanercept treated SHRSP may act as a negative 
feedback mechanism which turns off ADAM17 expression. However, why this 
system is not present in the vehicle treated SHRSP where an increase in soluble 
TNFα from the placenta is similar to etanercept treated animals cannot be 
explained by this data. With respect to strain-specific differences between the 
SHRSP and WKY, there is a trend for an increase in the phosphorylation of NFκB 
which could be indicative of an increase in TNFR1 signalling in the placenta. Whilst 
there is an increase in soluble TNFα in the SHRSP relative to the WKY, there is no 
significant difference in ADAM17 expression. This suggests that it could be that 
ADAM17 is more active in SHRSP than WKY despite similar levels in the placenta. 
Currently, etanercept has not been utilised in a clinical study for the treatment 
of hypertensive pregnancy. Evidence of a therapeutic effect comes predominantly 
from studies in the RUPP rat model of pre-eclampsia where it has been shown to: 
reduce mean arterial blood pressure by approximately 16 mmHg (343), reduce 
cardiac hypertrophy and improve NO bioavailability (399), reduce cerebral 
oedema (406) and reduce the release of anti-angiogenic sFLT-1 from the placenta 
(407). Etanercept also improved abnormal placentation in a mouse model of 
hypertensive pregnancy (408). Etanercept has been used during pregnancy in 
women with inflammatory bowel disease and rheumatoid arthritis where small 
studies have reported no adverse pregnancy outcomes; reviewed in (409). It has 
also been used in pilot studies as a treatment for women with recurrent 
spontaneous miscarriage where it has been shown to have a promising therapeutic 
benefit and reduce the number of peripheral pro-inflammatory NK cells (410, 
411). Therefore, etanercept has been classified FDA class B for use in pregnancy. 
More convincing evidence of the safety of anti-TNFα therapy in pregnancy will 
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come from the ongoing OTIS (Organisation of Teratology Information Specialists) 
Autoimmune Diseases in Pregnancy Project (NCT01086059) expected to report in 
early 2017. This is a large prospective study enrolling women with autoimmune 
diseases who have been treated with anti-TNFα therapy, encompassing separate 
arms for a number of TNFα antagonists including etanercept, during the first 
trimester of pregnancy and followed up to 1 year postpartum. These women will 
be matched to a non-treated control population with a similar autoimmune 
disease (412). 
These findings shown in this Chapter indicated that excess TNFα from an 
unidentified source in the SHRSP plays a central role in abnormal uterine artery 
function and pregnancy outcome in this model. Following on from this, the next 
set of experiments set out to identify the source of excess TNFα in the SHRSP. 
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Chapter 5 The Role of Natural Killer Cells in 
SHRSP Pregnancy 
5.1 Introduction 
The immune system is dynamic over the course of gestation (413) and whilst 
the maternal-fetal interface is a major area of maternal immune cell regulation 
during pregnancy; changes also occur in the circulating leukocytes. Pregnancy is 
associated with a modest leukocytosis (414). This is likely to be influenced by 
placenta derived factors such as growth factors, cytokines or hormones or 
particles derived from placental shedding such as syncytiotrophoblast vesicles or 
fetal and placental cell-free DNA which are detecTable in the maternal circulation 
(415). Changes in the immune system during pregnancy principally occur in cells 
of the innate immune system whereas the adaptive immune system is relatively 
suppressed (416). The hypothesised up-regulation of cells with immunosuppressive 
function such as regulatory T cells (Tregs) during pregnancy has produced a 
number of conflicting results with some studies showing an increase (417), no 
change (418) or even a decrease (419). Pregnancy is associated with an increase 
in number and activation of circulating monocytes and granulocytes (420). 
However, not all cellular components of the innate immune system are activated. 
Notably, the activity of dendritic cells (421) and NK cells (422) are suppressed 
during pregnancy. 
The study of NK cells in pregnancy has principally focussed on the uterine 
specific population of these cells (uNK) which play an important role in 
remodelling the uterine spiral arteries (discussed in section 1.6.2.1) (423). 
Changes in peripheral NK cells do not directly mirror the status of uNK cells; 
therefore the two populations should be considered separately (424). For the 
purposes of this work, the focus will be on circulating (peripheral) NK cells in 
pregnancy. In humans, circulating NK cell numbers are increased relative to non-
pregnant women in the first trimester followed by a decline in late pregnancy. 
The cytotoxicity of NK cells follows this pattern (425). A similar temporal study of 
NK cell number over pregnancy has not yet been reported in rats. Alterations in 
peripheral NK cells have mostly been associated with recurrent pregnancy loss and 
infertility however these findings are based on relatively small, observational 
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studies (424). Other small studies have also explored a pro-inflammatory shift of 
NK cells in pre-eclampsia (PE) (426).  
It was identified that excess TNFα played a causative role in abnormal 
uterine artery function and adverse pregnancy outcome in the SHRSP from the 
intervention study using etanercept (Chapter 4). It was hypothesised that the 
excess TNFα was due to an activation of the maternal immune system in the 
pregnant (GD18) SHRSP relative to the WKY. To investigate this hypothesis, a flow 
cytometry based approach was employed to measure maternal immune cell 
subtypes in the circulation and placenta. 
5.2 Materials & Methods 
General materials & methods can be found in Chapter 2. 
  Etanercept Treatment 
 Etanercept (Wyeth Pharmaceuticals, Maidenhead, UK) was prepared fresh 
on the day of use using sterile phosphate buffered saline (PBS) (Thermo Fisher 
Scientific, Paisley, UK). SHRSP were treated with 0.8 mg/kg dose or vehicle (PBS) 
via subcutaneous injection at gestational days 0, 6, 12 and 18.  This treatment 
regimen was chosen as etanercept is given weekly to treat inflammatory 
conditions such as rheumatoid arthritis in humans. Etanercept was always given 
by 10am with no more than 100 µl total injected using a disposable 1ml syringe 
and 26 G x ½” needle (BD Bioscience, Oxford, UK) given to the back of the neck. 
  Flow Cytometry 
Leukocytes were isolated on the day of collection. Tissue from three 
uteroplacental units from pregnant (GD18) WKY, SHRSP and SHRSP treated with 
etanercept were dissected, perfused with PBS (Thermo Fisher Scientific, Paisley, 
UK) then harvested in ice-cold PBS (Thermo Fisher Scientific, Paisley, UK). The 
placental tissue was disrupted using scissors to produce a single cell suspension 
which was passed through a 70 μm cell strainer (BD Bioscience, Oxford, UK). 
Leukocytes were isolated from blood collected in heparinized tubes (BD 
Bioscience, Oxford, UK) from non-pregnant and pregnant (GD18) rats by density 
gradient centrifugation with Histopaque® (Sigma-Aldrich, Dorset, UK). Cells were 
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washed once (1300 rpm for 6 minutes) and resuspended in 3ml of 2% FBS/PBS 
(FACS buffer) and placed on ice. Cells were counted using a haemocytometer and 
1 x 106 leukocytes were subject to staining procedure. Cells were used for staining 
on the day of tissue collection. 
5.2.2.1 Extracellular Flow Cytometry Panel 
Isolated leukocytes from WKY (NP: n=4, GD18: n=5), SHRSP (NP: n=4, GD18: 
n=5) and SHRSP treated with etanercept were stained using Zombie® live/dead 
dye (Biolegend, London, UK) for 15 minutes at room temperature in the dark 
followed by staining for extracellular markers using fluorochrome conjugated 
primary antibodies for 20 minutes on ice in the dark. Two panels of antibodies 
were used. Panel 1: anti-CD45-PerCP/Cy5.5, anti-CD3-APC, anti-CD4-PE/Cy7, 
anti-CD8-FITC and anti-CD161-PE, (Biolegend, London, UK). Panel 2: anti-CD45-
PerCP/Cy5.5, anti-CD103-AlexaFluor®647, anti-CD4-PE/Cy7, anti-RT1B-FITC 
(Biolegend, London, UK) and anti-HIS36-PE (BD Bioscience, Oxford, UK). Cells were 
washed and resuspended in FACS buffer for immediate analysis using a BD 
FACSCanto II machine (BD Bioscience, Oxford, UK) with BD FACSDIVA™ software 
where 10,000 CD45+ events was used as a cut-off in each sample. Exported data 
was analysed using FlowJo (FlowJo, LLC) where leukocytes in blood were 
expressed as a percentage of total and in tissue were expressed as an absolute 
number. 
5.2.2.2 Intracellular Staining  
Cells from pregnant (GD18) WKY, SHRSP and SHRSP treated with etanercept 
were cultured in RPMI 1640 media +10% FBS +1% penicillin/streptomycin (Thermo 
Fisher Scientific, Paisley, UK) then stimulated using a cell stimulation cocktail at 
2 µl/ml media and incubated at 37 °C for 4 hours. The cell stimulation cocktail 
contained polycolonal activators: concanavalin A, lipopolysaccharide, phorbol 
esters plus ionomycin, phytohaemaglutinin and staphylococcus enterotoxin B (BD 
Bioscience, Oxford, UK). Cells were harvested after this time and stained using 
Zombie® live/dead dye (Biolegend, London, UK) for 15 minutes at room 
temperature in the dark followed by staining for extracellular markers using 
fluorochrome conjugated primary antibodies for 20 minutes on ice in the dark 
(anti-CD45-PerCP/Cy5.5, anti-CD3-APC and anti-CD161-PE; Biolegend, London, 
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UK). Cells were then fixed in intracellular fixation buffer (eBioscience, Hatfield, 
UK) for 45 minutes and washed in 1% permeabilisation buffer (eBioscience, 
Hatfield, UK) at 1100rpm for 6 minutes at 4 °C. Cells were then stained 
according to manufacturer’s instructions for intracellular TNFα (anti-TNFα-PE-
Cy7; eBioscience, Hatfield, UK) and Granzyme-B (anti-granzyme-B-FITC 
antibody, Biolegend, London, UK) at room temperature for 30 minutes in the 
dark. Cells were washed and resuspended in FACS buffer for immediate analysis 
using a BD FACSCanto II machine (BD Bioscience, Oxford, UK) with BD FACSDIVA™ 
software where 10,000 CD45+ events was used as a cut-off in each sample. 
Exported data was analysed FlowJo (FlowJo, LLC) where cells expressing positive 
intracellular staining were given as a percentage of the total cell of interest 
population. 
  Immunohistochemistry for Granzyme B 
Slides were cleared and rehydrated as described in section 2.6.1. To quench 
endogenous peroxidase, sections were incubated in 3% hydrogen 
peroxide/methanol for 30 minutes at room temperature followed by 2 x 10 minute 
washes in dH2O. Antigen retrieval was achieved using laboratory-prepared 0.01M 
sodium citrate buffer (pH 6) (Appendix I) heated to 95 °C in a water bath for 15 
minutes followed by 2 x 10 minute washes in dH2O. Sections were blocked in a 
humidified chamber at room temperature with approximately 100 µl of 15% swine 
serum/PBS (Vector Laboratories, Peterborough, UK)).Briefly, sections from GD18 
placenta from WKY, SHRSP and SHRSP treated with etanercept were blocked in 15 
% swine serum (Vector Laboratories, Peterborough, UK) in PBS then incubated in 
a primary antibody for granzyme B (#ab53097; Abcam, Cambridge, UK) diluted in 
5% swine serum (Sigma-Aldrich, Dorset, UK) in PBS overnight at 4 ºC. Granzyme B 
was detected using horse radish peroxidase (HRP) conjugated swine-α-rabbit 
secondary antibody (Dako, Ely, UK) diluted 1:100 in 2% BSA/TBS-T. Slides were 
cleared and visualised using light microscopy as described in section 2.6.4. 
  Cytokine Array 
Cytokine array (R&D Systems, Abingdon, UK) was performed according to 
manufacturer’s instructions with 250 μg protein input. Mean pixel density was 
analysed using ImageJ software. Mean pixel density was normalised to the mean 
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of the reference spots present on the array. Data are presented as both normalised 
mean pixel density and as a percentage of WKY. 
  Cell Free DNA (cfDNA) Isolation from Placental Explant Media 
Placental tissue was harvested in ice cold PBS from WKY and SHRSP. Under 
sterile conditions, the tissue was dissected into pieces <5mm in ice cold DMEM F-
12 Media +0.5% FBS +1% penicillin/streptomycin (Thermo Fisher Scientific, Paisley, 
UK). The tissue pieces were split evenly between 2 wells of a 24 well plate 
(Thermo Fisher Scientific, Paisley, UK) in 1ml of media. After 1 hour, the explants 
were washed in PBS and replaced with a fresh 1ml of media. Explants were 
incubated for 20 hours at 37 °C after which the media was collected, and stored 
at -80 °C. Explant media (approximately 1ml) was centrifuged for 10 minutes at 
12000 x g to remove debris. The supernatant (800 µl) was subject to DNA isolation 
using the QIAamp DNA blood & tissue kit (QIAgen, Manchester, UK) according 
manufacturer’s instructions. The amount of proteinase K, lysis buffer AL and 
ethanol was modified in proportion to the larger amount of starting material. 
Immediately following extraction, DNA was quantified using a NanoDrop 2000 
(section 2.4.1.1) (Thermo Fisher, Paisley, UK). 
5.3 Results 
  CD3- CD161+ NK Cells are increased in the Maternal 
Circulation and Placenta in Pregnant SHRSP 
From the beneficial effects we observed in pregnancy outcome and uterine 
artery function in SHRSP treated with etanercept; we deduced that excess TNFα 
signalling played a causal role in the pathology observed during pregnancy in this 
model. Whilst TNFα can be produced in some quantity from almost all cell types, 
we focussed on one of the major producers, the immune cells, in order to identify 
the source(s) of excess TNFα in the SHRSP.  A flow cytometry panel was designed 
to quantify immune cell populations in pregnant WKY and SHRSP in the maternal 
blood and placenta (gating strategy example Fig. 5-1A). Of the populations 
analysed, NK cells (CD3- CD161+) were the most markedly increased in the SHRSP 
relative to WKY in both the maternal circulation (Fig. 5-1B) and placenta (Fig. 5-
1C-D). Further, pregnancy specific changes were detected in peripheral CD3- 
CD161+ cells in maternal blood (Fig. 5-1E). In WKY, these cells were significantly 
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decreased from non-pregnant (NP) to pregnant (GD18) (Fig. 5-1E). In contrast, 
there was a significant increase in peripheral NK cells in SHRSP from NP to GD18 
(Fig. 5-1E). 
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Figure 5-1 CD3- CD161+ natural killer cells are significantly increased in pregnant SHRSP.  
Flow cytometry was used to measure immune cell populations (gating strategy example (A) in 
maternal blood (B) and placenta (C) from pregnant (GD18) WKY (n=5) and SHRSP (n=6). A bimodal 
population of CD3-CD161+ was observed in (A), this analysis incorporated all CD161+ cells as 
indicated by the grey box (A) and the black box in (D). CD3+ T cells and CD3- CD161+ NK cells 
were elevated in maternal blood from SHRSP relative to WKY (B) (* p<0.05 vs. WKY, ** P<0.01 vs. 
WKY analysed by Student’s t test). CD3- CD161+ NK cells were also significantly increased in 
placenta from SHRSP relative to WKY (C). A representative dot plot showing the increase in CD3- 
CD161+ cells in placenta from SHRSP relative to WKY is shown in (D). Natural killer (NK) cell 
numbers were assessed using flow cytometry in virgin (NP) (n=4) and GD18 (n=5-6) SHRSP and 
WKY (E). WKY exhibited a significant decrease in the percentage of NK cells in the maternal blood 
from NP to GD18 (†† p<0.01 vs. WKY NP analysed by one-way ANOVA followed by post-hoc Tukey 
test).  In contrast, SHRSP exhibited a significant increase in the percentage of NK cells in the 
maternal blood from NP to GD18 ($$ p<0.01 vs. SHRSP NP analysed by one-way ANOVA followed 
by post-hoc Tukey test). Th: T helper cell, Tc: cytotoxic T cell. 
 
  CD3- CD161+ NK Cells are a Source of Excess TNFα in 
the Maternal Circulation and Placenta in Pregnant SHRSP 
The significant increase in NK cell number in the maternal circulation and 
placenta of the SHRSP made this cell type a promising candidate for a source of 
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excess TNFα. Therefore, this population was investigated further using 
intracellular staining. Intracellular staining of CD161+ cells in both the maternal 
circulation (Fig. 5-2A-B) and placenta (Fig. 5-2C-D) showed that TNFα production 
is significantly increased in the SHRSP relative to the WKY at GD18. TNFα 
production from CD161+ cells is not different between strains pre-pregnancy (Fig. 
5-3). Furthermore, TNFα production from CD3+ T cells or other CD45+ cells was 
not significantly different between the strains (Fig. 5-4). 
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Figure 5-2 CD161+ cells are a source of excess TNFα in pregnant SHRSP maternal circulation and 
placenta. 
Intracellular flow cytometry was used to measure TNFα production in CD161+ natural killer cells in 
maternal blood (A-B) and placenta (C-D) from pregnant (GD18) WKY (n=4) and SHRSP (n=4). 
CD161+ cells from the maternal circulation (A-B) and placenta (C-D) showed an increased 
production of TNFα from pregnant SHRSP relative to WKY (* p<0.05, **p<0.01 vs. WKY GD18 
analysed by Student’s t test).  
 
 
  
S
S
C
CD161
S
S
C
TNFα
WKY WKY
SHRSP SHRSP
M
A
T
E
R
N
A
L
 B
L
O
O
D
P
L
A
C
E
N
T
A
S
S
C
CD161
S
S
C
TNFα
WKY WKY
SHRSP SHRSP
A B
C D
Placenta
W
K
Y
SH
R
SP
0
5
10
15
20
25
30
35
40
45 **
*
%
 C
D
1
6
1
+
 T
N
F

+
Maternal Blood
W
K
Y
SH
R
SP
0.0
2.5
5.0
7.5
10.0
12.5
##
*
%
 C
D
1
6
1
+
 T
N
F

+
 
 
177 
 
 
Figure 5-3 TNFα producing CD161+ cells are increased in a pregnancy dependent manner in 
SHRSP. 
Intracellular flow cytometry was used to measure TNFα production in CD161+ natural killer cells from 
non-pregnant (NP) WKY (n=4), NP SHRSP (n=4), pregnant (GD18) (n=4) WKY and GD18 SHRSP 
(n=4). TNFα staining in CD161+ cells exhibited a trend for a decrease from NP to pregnant WKY; 
however there was the opposite trend in the SHRSP. CD161+ cells positive for TNFα were 
significantly increased in pregnant SHRSP relative to WKY (* p< 0.05 vs. WKY GD18 analysed by 
one-way ANOVA followed by post-hoc Tukey test).  
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Figure 5-4  TNFα production from CD3+ cells and other CD45+ cells is not significantly different between WKY and SHRSP. 
Intracellular staining was used to quantify TNFα production from immune cells in the maternal blood and placenta from WKY (n=4) and SHRSP (n=4). In placenta (A-B) 
and maternal blood (C-D) there was no significant difference in TNFα production from CD3+ or other CD45+ cells, only in CD161+ cells (* p<0.05, ** p<0.01 vs. WKY 
GD18 analysed by one-way ANOVA followed by post-hoc Tukey test). CD45+: Leukocytes, CD3+ T Cells, CD161+ NK Cells. 
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  Etanercept Reduces the Population of CD3- CD161+ NK Cells 
in the Placenta of Pregnant SHRSP 
As etanercept had previously been shown to have beneficial effects on both 
pregnancy outcome and uterine artery function in the SHRSP (Chapter 4), the 
effect of etanercept treatment in SHRSP on maternal blood and placental immune 
cell populations was investigated. In maternal blood samples, the number of CD3+ 
T cells was increased in both SHRSP and SHRSP treated with etanercept relative 
to the WKY; however no difference was observed in the balance of CD4+ or CD8+ 
T cells (Fig. 5-5A-C). Etanercept treatment also did not affect the percentage of 
CD3- CD161+ NK cells or CD3+ CD161+ NK-T cells in the maternal circulation (Fig. 
5-5D-E). There were no differences in the percentage of dendritic cells in the 
maternal blood between strains or with etanercept treatment (Fig. 5-5F).  
Etanercept treatment had independent effects on the immune cell 
populations of the placenta that differed from its effects on the maternal 
circulation (Fig. 5-6). Placental tissue from etanercept treated SHRSP had a 
greater number of CD3+ T cells, specifically CD4+ T helper cells relative to SHRSP 
and WKY (Fig. 5-6A-C). Etanercept treatment reduced the number of CD3- CD161+ 
NK cells present in the SHRSP placenta (Fig. 5-6D) but not the CD3+ CD161+ NK-T 
cells (Fig. 5-6E). Dendritic cells were not robustly detected in placental samples 
from all strains (Fig. 5-6F). There was a trend for etanercept treatment to reduce 
the number of macrophages in placenta from SHRSP; however this was not 
significant (p=0.069) (Fig. 5-6G). 
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Figure 5-5 Flow cytometry panel in maternal blood from pregnant WKY, SHRSP and SHRSP treated with etanercept. 
A flow cytometry panel was used to quantify immune cell sub-types in the maternal blood from pregnant (GD18) WKY (n=5), SHRSP (n=6) and SHRSP treated with 
etanercept (n=6). The percentage of T cells (A) in the maternal blood significantly increased in SHRSP and SHRSP treated with etanercept relative to the WKY (* p< 
0.05 vs. WKY GD18 analysed by one-way ANOVA followed by post-hoc Tukey test), however there were no significant differences between the balance of helper (B) 
and cytotoxic T cells (C). Both NK cells (D) and NK-T cells (E) were significantly increased in SHRSP and SHRSP treated with etanercept relative to the WKY (* p< 0.05, 
** p< 0.01 vs. WKY GD18 analysed by one-way ANOVA followed by post-hoc Tukey test). There were no significant alterations in the presence of dendritic cells (G). 
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Figure 5-6 Flow cytometry panel in 
placenta from pregnant WKY, SHRSP 
and SHRSP treated with etanercept. 
A flow cytometry panel was used to 
quantify immune cell sub-types in 
placenta from pregnant (GD18) WKY 
(n=5), SHRSP (n=6) and SHRSP treated 
with etanercept (n=6). T cells (A) were 
significantly (** p< 0.01 vs. GD18 WKY 
analysed by one-way ANOVA followed 
by post-hoc Tukey test) and Th cells (B) 
were significantly increased in SHRSP 
treated with etanercept relative to WKY. 
NK cells (D) were significantly increased 
in the SHRSP relative to the WKY and 
SHRSP treated with etanercept (## p< 
0.01 vs. GD18 SHRSP analysed by one-
way ANOVA followed by post-hoc Tukey 
test). NK-T cells were significantly 
increased in SHRSP and SHRSP treated 
with etanercept (* p < 0.05, ** p< 0.01 vs. 
WKY analysed by one-way ANOVA 
followed by post-hoc Tukey test) (E). The 
detection of dendritic cells was variable 
and not measurable in all samples (F). 
There was a trend for macrophages to be 
increased in SHRSP relative to WKY and 
SHRSP treated with etanercept (G). 
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  Etanercept Treatment Reduces CD161 Expression and 
Granzyme B Production in NK cells from the Placenta of 
Pregnant SHRSP. 
Etanercept treatment in the SHRSP significantly reduced the number of CD161+ 
NK cells present in the SHRSP placenta (Fig. 5-7A) but not the maternal circulation 
(Fig. 5-7B). From the dot plot derived from flow cytometry analysis, the CD161+ 
population of cells from SHRSP but not WKY placental tissue could be divided into 
a CD161 low (CD161Low) population and a CD161 positive (CD161+) population (Fig. 
5-7C). Reduction of CD161+ cells in the placenta from SHRSP treated with 
etanercept was associated with a significant increase in the CD161Low population 
(Fig. 5-7D). These two sub-populations were investigated further using 
intracellular staining for granzyme B as a marker of cytotoxicity. The CD161+ 
population had a characteristically cytotoxic phenotype where the majority of 
these cells (~70%) stained positively for intracellular granzyme B from placenta in 
both SHRSP and SHRSP treated with etanercept (Fig. 5-7E-F). In contrast, the 
CD161Low population had a significantly decreased proportion of granzyme B 
expression (~12%) from placenta in both SHRSP and SHRSP treated with etanercept 
(Fig. 5-7E-F).  
In order to investigate whether the increase in NK cells was localised to a 
particular area in the placenta, immunohistochemistry for granzyme B was carried 
out in sections of placenta from WKY, SHRSP and SHRSP treated with etanercept 
at GD18. Concurrent with the flow cytometry data, granzyme B positive cells were 
increased in the SHRSP placenta relative to the WKY (Fig. 5-8). The granzyme B 
positive cells were low in number and appeared to be randomly distributed 
throughout the labyrinth zone (Fig. 5-8B-C). 
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Figure 5-7 Etanercept reduces granzyme B-producing CD161+ cells in the SHRSP placenta. 
Flow cytometry was used to quantify CD3- CD161+ NK cells in SHRSP (n=6) and SHRSP treated 
with etanercept (n=5). Etanercept treatment significantly decreased CD3- CD161+ cells in the 
SHRSP GD18 placenta (A) (## p<0.01 vs. SHRSP GD18 analysed by one-way ANOVA followed by 
post-hoc Tukey test) but not maternal blood (B) (graphs are repeated from Fig. 5-5 & 5-6). Etanercept 
treatment caused a shift in CD161+ expression from a high to low phenotype; arrows indicate 
CD161Low population and boxes indicate CD161+ population (# p<0.05, ## p<0.01 vs. SHRSP GD18 
analysed by one-way ANOVA followed by post-hoc Tukey test) (C-D). CD161+ cell populations were 
characterised using intracellular staining where CD161+ populations exhibited high expression of 
cytotoxic granzyme B and CD161Low population exhibited significantly lower expression of granzyme 
B (E-F) (** p<0.01 vs. CD161Low analysed by Student’s t test). 
W
K
Y
S
H
R
S
P
E
ta
ne
rc
ep
t
0
250
500
750
##
##
N
K
 C
e
ll
s
 (
C
D
3
- 
C
D
1
6
1
+
)
C
e
ll
s
/m
g
 P
la
c
e
n
ta
l 
T
is
s
u
e
W
K
Y
S
H
R
S
P
E
ta
ne
rc
ep
t
0
1
2
3
4
5
6
7
** **
%
 N
K
 C
e
ll
s
 (
C
D
3
- 
C
D
1
6
1
+
)
M
a
te
rn
a
l 
B
lo
o
d
C
D
3
CD161
WKY SHRSP Etanercept
A B
C D
E
S
S
C
CD161
SHRSP
Etanercept
S
S
C
Granzyme B
CD161+
CD161+
S
S
C
Granzyme B
CD161Low
CD161Low
P
L
A
C
E
N
T
A
P
L
A
C
E
N
T
A
SH
R
SP
Et
an
er
ce
pt
0
25
50
75
** **
%
 G
ra
n
zy
m
e
 B
+
F
S
H
R
S
P
E
ta
ne
rc
ep
t
0
250
500
750
1000
1250
CD161Low
CD161+
**
*
C
e
ll
s
/m
g
 p
la
c
e
n
ta
S
H
R
S
P
E
ta
ne
rc
ep
t
0
250
500
750
1000
1250
CD161Low
CD161+
#
##C
e
ll
s
/m
g
 p
la
c
e
n
ta
S
H
R
S
P
E
ta
ne
rc
ep
t
0
250
500
750
1000
1250
CD161Low
CD161+
**
*
C
e
ll
s
/m
g
 p
la
c
e
n
ta
 
 
184 
 
 
Figure 5-8 Granzyme B positive cells are increased in placenta from SHRSP.  
Immunohistochemistry for granzyme B was used to detect cytotoxic cells in the placenta of WKY 
(n=6), SHRSP (n=6) and SHRSP treated with etanercept (n=6). A 100x magnification image of 
a granzyme B positive immune cell is shown in (A). Granzyme B positive cells were detecTable 
in the labyrinth zone of SHRSP but not WKY or etanercept treated SHRSP (B-C). 
 
  Peptide Array Demonstrates that Placenta from SHRSP is a 
Site of Global Inflammation 
Differences in immune cells were detected in SHRSP relative to WKY, which 
were also altered by etanercept treatment. In order to explore other cytokines 
which could be playing a role in this process, a cytokine array was performed in 
placental tissue from GD18 WKY, SHRSP and SHRSP treated with etanercept (Fig. 
5-9 & 5-10). Of the 29 cytokines that were spotted on the array; 19 were 
detectable in of placenta from SHRSP and 10 were detectable in placenta from 
WKY and SHRSP. The 9 cytokines that were detected in all samples from SHRSP 
but not from all WKY or etanercept treated SHRSP were: interleukin (IL) -1a, IL-
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1b, IL-1ra, IL-2, IL-3, IL-13, IP-10, ciliary neurotrophic factor (CNTF), 
CXCL31/fractalkine and CXCL9/monocyte induced by gamma interferon (MIG). 
From visual inspection of the cytokine arrays from WKY, SHRSP and SHRSP 
treated with etanercept there is a striking increase in the number and intensity 
of positive spots in SHRSP relative to both the placenta samples from WKY and 
etanercept treated SHRSP (Fig. 5-10A). Analysis of the pixel density of the positive 
spots showed that IL-17, CXCL7, intracellular adhesion molecule 1 (ICAM-1), L-
selectin and VEGF were highest expressed cytokines across all groups (Fig. 5-10B). 
All of the cytokines measured demonstrated consistent significant up-regulation 
in placenta from SHRSP relative to lower levels in WKY and SHRSP treated with 
etanercept (Fig. 5-10C). With respect to fold change, the highest cytokine in the 
SHRSP relative to the WKY was CXCL31/fractalkine expressed approximately 10-
fold greater (Fig. 5-10C). 
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Figure 5-9 Representative array for WKY, SHRSP and SHRSP treated with etanercept. 
Representative cytokine array for WKY (n=4), SHRSP (n=4) and SHRSP treated with etanercept (n=4) is shown in (A) with an accompanying map in (B). Red text 
indicates cytokines that were not detected in this experiment; bold black text indicates cytokines that were detected. IL: interleukin, IP-10: interferon gamma induced 
protein 10, CINC-1: cytokine induced neutrophil chemoattractant 1, CNTF: ciliary neurotrophic factor, CXCL: chemokine ligand, ICAM-1: intracellular adhesion molecule-
1, RANTES: regulated on activation, normal T cell expressed and secreted, TIMP-1: tissue inhibitor of metalloproteinases 1, VEGF: vascular endothelial growth factor. 
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Figure 5-10 The array profile is altered 
in GD18 placenta from SHRSP relative 
to WKY and SHRSP treated with 
etanercept. 
An array was used to profile cytokine 
expression in placenta taken at GD18 in 
WKY (n=4), SHRSP (n=4) and SHRSP 
treated with etanercept (n=4). A 
representative result for each group is 
shown in (A); more positive spots were 
present in the SHRSP (19/29 cytokines 
detected) than the WKY and etanercept 
treated SHRSP (10/29 cytokines 
detected). Mean pixel density was 
normalised to the mean of the reference 
spots on the array and across all 
samples IL-17, CXCL7, intracellular 
adhesion molecule 1 (ICAM-1), L-
selectin and VEGF were the most highly 
expressed (B). Normalised pixel density 
was compared to WKY (C) where all 
cytokines showed a similar pattern of up-
regulation in the SHRSP relative to the 
WKY and etanercept treated SHRSP (* 
p<0.05, **p<0.01 *** p<0.005 vs. GD18 
WKY analysed by one-way ANOVA 
followed by post-hoc Tukey test) (C). 
Graphs in (B) and (C) are split due to the 
large number of hits.  IL: interleukin, IP-
10: interferon gamma induced protein 
10, CINC-1: cytokine induced neutrophil chemoattractant 1, CNTF: ciliary neurotrophic factor, CXCL: chemokine ligand, ICAM-1: intracellular adhesion molecule-1, 
RANTES: regulated on activation, normal T cell expressed and secreted, TIMP-1: tissue inhibitor of metalloproteinases 1, VEGF: vascular endothelial growth factor.  
WKY SHRSP Etanercept
A
C
IN
C
1
C
N
TF
C
XC
L5
 (L
IX
)
C
XC
L7
C
XC
L9
 (M
IG
)
C
XC
3L
1 
(F
ra
ct
al
ki
ne
)
IC
A
M
-1
L-
Se
le
ct
in
R
A
N
TE
S
TI
M
P
-1
V
EG
F
0
250
500
750
1000
1250
*
*
**
**
**
**
***
***
***
**
N
o
rm
a
li
s
e
d
 P
ix
e
l 
D
e
n
s
it
y
(%
 W
K
Y
)
C
IN
C
1
C
N
TF
C
X
C
L5
 (L
IX
)
C
X
C
L7
C
X
C
L9
 (M
IG
)
C
X
C
3L
1 
(F
ra
ct
al
ki
ne
)
IC
A
M
-1
L-
Se
le
ct
in
R
A
N
TE
S
TI
M
P
-1
V
EG
F
0
250
500
750
1000
1250
WKY
SHRSP
Etanercept
*
*
**
**
**
**
***
***
***
**
N
o
rm
a
li
s
e
d
 P
ix
e
l 
D
e
n
s
it
y
(%
 W
K
Y
)
IL
-1
a
IL
-1
b
IL
-1
ra
IL
-2
IL
-3
IL
-1
3
IL
-1
7
IP
-1
0
0
100
200
300
400
500
600
700
800
*
**
**
** **
**
**
***
N
o
rm
a
li
s
e
d
 P
ix
e
l 
D
e
n
s
it
y
(%
 W
K
Y
)
C
IN
C
1
C
N
TF
C
X
C
L5
 (L
IX
)
C
X
C
L7
C
X
C
L9
 (M
IG
)
C
X
C
3L
1 
(F
ra
ct
al
ki
ne
)
IC
A
M
-1
L-
Se
le
ct
in
R
A
N
TE
S
TI
M
P
-1
V
EG
F
0
250
500
750
1000
1250
WKY
SHRSP
Etanercept
*
*
**
**
**
**
***
***
***
**
N
o
rm
a
li
s
e
d
 P
ix
e
l 
D
e
n
s
it
y
(%
 W
K
Y
)
IL
-1
a
IL
-1
b
IL
-1
ra
IL
-2
IL
-3
IL
-1
3
IL
-1
7
IP
-1
0
0
5
10
75
100
125
150
*
**
**** **
** **
***
**
N
o
rm
a
li
s
e
d
 P
ix
e
l 
D
e
n
s
it
y
C
IN
C
1
C
N
TF
C
X
C
L5
 (L
IX
)
C
X
C
L7
C
X
C
L9
 (M
IG
)
C
X
C
3L
1 
(F
ra
ct
al
ki
ne
)
IC
A
M
-1
L-
Se
le
ct
in
R
A
N
TE
S
TI
M
P
-1
V
EG
F
0
250
500
750
1000
1250
WKY
SHRSP
Etanercept
*
*
**
**
**
**
***
***
***
**
N
o
rm
a
li
s
e
d
 P
ix
e
l 
D
e
n
s
it
y
(%
 W
K
Y
)
C
IN
C
1
C
N
TF
C
XC
L5
 (L
IX
)
C
XC
L7
C
XC
L9
 (M
IG
)
C
XC
3L
1 
(F
ra
ct
al
ki
ne
)
IC
A
M
-1
L-
Se
le
ct
in
R
A
N
TE
S
TI
M
P
-1
V
EG
F
0
10
20
30
40
50
75
100
125
**
**
**
**
**
*
**
***
***
**
N
o
rm
a
li
s
e
d
 P
ix
e
l 
D
e
n
s
it
y
C
IN
C
1
C
N
TF
C
X
C
L5
 (L
IX
)
C
X
C
L7
C
X
C
L9
 (M
IG
)
C
X
C
3L
1 
(F
ra
ct
al
ki
ne
)
IC
A
M
-1
L-
Se
le
ct
in
R
A
N
TE
S
TI
M
P
-1
V
EG
F
0
250
500
750
1000
1250
WKY
SHRSP
Etanercept
*
*
**
**
**
**
***
***
***
**
N
o
rm
a
li
s
e
d
 P
ix
e
l 
D
e
n
s
it
y
(%
 W
K
Y
)
B
C
 
 
188 
 
  The Placenta from SHRSP Reveals Increased Shedding of DNA 
In addition to the measurement of cytokine profiles from the placenta, DNA 
detected in placental explant media from GD18 WKT and SHRSP was quantified 
using a NanoDrop spectrophotometer. Explant media from placenta of SHRSP 
displayed a trend for increased total DNA relative to the WKY (Fig. 5-11). As a 
negative control, fresh media only was subject to the same DNA extraction and 
quantification procedure. DNA was not detected by NanoDrop in this negative 
control sample. 
 
Figure 5-11 Cell free DNA is increased in media of placental explants from SHRSP relative to 
WKY. 
Placental tissue explants from WKY (n=5) and SHRSP (n=5) were cultured from 20 hours then the 
media was collected. Quantification of DNA using the nanodrop spectrophotometer showed that total 
DNA was increased relative to the WKY (p=0.06 vs. GD18 SHRSP analysed by Student’s t test). 
 
5.4 Discussion 
The work presented in this Chapter reveals that there are alterations in both 
immune cells and cytokines between pregnant (GD18) WKY and SHRSP. 
Specifically, a population of CD3- CD161+ NK cells have been identified to be 
increased in a pregnancy-dependent manner in the SHRSP maternal circulation 
and placenta. These NK cells were a source of excess TNFα at GD18 in SHRSP 
pregnancy. Etanercept treatment reduced the number of NK cells in the placenta, 
but not the maternal circulation, by down-regulating the expression of CD161 
which was associated with a decrease in cytotoxic granzyme B production. 
Additionally, the placenta from SHRSP expressed an altered cytokine profile 
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indicating a pro-inflammatory environment which is not present in WKY and was 
reduced by treatment with etanercept. 
In order to identify the source of excess TNFα in pregnant SHRSP, a flow 
cytometry panel was designed for TNFα-producing immune cells. The number of 
CD3- CD161+ NK cells was increased in a pregnancy-dependent manner in the 
SHRSP but not in the control WKY. Investigations of circulating NK cells in other 
rodent models of hypertensive pregnancy are limited. A study in NOD.SCID mice 
(90% depletion in peripheral NK cells but a 57% increase in uNK proliferation) has 
reported that there is a significant increase in blood pressure during pregnancy 
relative to the background NOD strain (427). These results indicate that NK cells 
appear to play a role in blood pressure regulation during pregnancy. Notably, these 
results may be affected by the fact that NK cell biology differs between mouse 
strains as discussed in section 1.3.2.  Some small clinical studies which have 
focussed on pre-eclampsia have reported an increase in circulating NK cells which 
express a greater amount of IFNγ relative to samples from normotensive women 
(428). However, this paper did not define which cell-surface markers were used 
for NK cell detection nor did it investigate the expression of TNFα. Another study 
showed that CD56+ NK cells derived from maternal blood express VEGF and that 
this population was reduced by 45% in women with preeclampsia (429). Whilst it 
is well established that the uNK cell population express VEGF which is thought to 
be important for their role in spiral artery remodelling (430); these findings 
indicate that perhaps circulating NK cells are not all potentially damaging. 
CD161+ cells from SHRSP produced excess TNFα relative to control WKY. 
Whilst the data presented cannot conclusively prove that excess TNFα is not being 
produced by other cell types; intracellular staining for TNFα was not significantly 
different in CD3+ or other CD45+ cells. TNFα is also produced by invasive 
extravillous trophoblasts, however, at GD18 of pregnancy trophoblasts do not 
exhibit potent invasive behaviour in rats (431). Recent work has proposed an 
interaction between TNFα and the activation of peripheral NK cells in women with 
preeclampsia. In this study by Fukui et al., NKp46+ (an activating NK receptor) NK 
cells show a sustained reduction from 3 months prior to delivery in women with 
preeclampsia (422). The number of NKp46+ cells was found to be negatively 
correlated with numbers of TNFα producing NK cells and the authors hypothesised 
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that excess TNFα production was driving the NK cells to a pro-inflammatory 
phenotype which lacked NKp46 expression.  
The numbers of total CD161+ cells were increased in placenta from SHRSP 
and SHRSP treated with etanercept whereas numbers were small in the WKY 
placenta. Therefore, a currently unknown TNFα-independent mechanism exists 
which recruits NK cells to the placenta of SHRSP. Within this placental CD161+ cell 
population, etanercept induces a significant reduction in CD161 expression which 
is associated with a reduction in granzyme B production. Conversely, this infers 
that TNFα signalling is a critical step involved in CD161 up-regulation and 
granzyme B production in NK cells. Previously, TNFα has been shown to work in 
concert with IFN-γ to promote the cytotoxic activity of NK cells (122). The CD161 
antibody used in this study detects the NKRP1A and NKRP1B cell surface receptors 
selective for NK cells. As discussed in section 1.3.2.1, the killer ability of NK cells 
is protected by a sophisticated mechanism of activating and inhibitory receptors 
whereby the resulting action is determined by the balance of these signals. 
NKRP1A (112) is an activating receptor and NKPR1B an inhibitory receptor in the 
rat (115). CD161 is conserved in mice where it is also selective for NK cells (106) 
and in humans where it is only expressed on a subset of NK cells (108). Whilst this 
study has shown that CD161+ NK cells are associated with a cytotoxic phenotype, 
future work should examine the balance of activating and inhibiting receptors on 
the NK cell surface in hypertensive pregnancy in order to further define their role 
in pathology. Definitive causality could be investigated by using NK cell depleting 
antibodies during pregnancy in SHRSP or using adoptive transfer of NK cells from 
pregnant SHRSP into pregnant WKY. 
From the findings regarding the effect of etanercept treatment on the 
CD161+ NK cells in the placenta of the SHRSP; it was hypothesised that there were 
two independent, sequential mechanisms. The first was a TNFα independent 
recruitment of NK cells to the placenta which only occurred in the SHRSP but not 
WKY. The second was a TNFα dependent expression of CD161 and granzyme B 
which led to a classically cytotoxic NK cell which was down-regulated by 
etanercept treatment in the SHRSP. In order to test this hypothesis, a cytokine 
array was performed in GD18 placental tissue from WKY, SHRSP and SHRSP treated 
with etanercept. The aim was to identify an SHRSP-specific cytokine that was not 
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affected by etanercept treatment which would be a candidate for promoting NK 
cell recruitment to the placenta. The results of the array revealed that the 
placenta at GD18 in the SHRSP was a site of active inflammation with an increase 
in number of cytokines detected by the array. Analysis of the array did not show 
the hypothesised SHRSP-specific cytokine; in fact every cytokine displayed a 
similar pattern of down-regulation in placenta from both the WKY and etanercept 
treated SHRSP relative to untreated SHRSP. Therefore, etanercept normalised the 
global inflammatory response seen in the SHRSP. Whether this has to do with 
changes in cytokine profile resulting from the etanercept induced shift from 
CD161+ to CD161Low cell remains to be investigated. One limitation of this assay is 
that the main cytokines produced from NK cells; TNFα and IFNγ, were not 
detectable in any samples. This could be due to technical issues, such as, these 
are soluble factors or were below the limit of detection of the assay. However, 
the assay did detect an increase in molecules which play a critical role in the 
activation and proliferation of NK cells such as IL-2 (432), upstream molecules 
which stimulate TNFα and IFNγ production and signalling such as IL-1 (433, 434) 
and downstream messengers whose transcription is turned on specifically in 
response to an increase in IFNγ such as IP-10/CXCL10 (435) and MIG/CXCL9 (436). 
The promising findings from this work should be confirmed in blood and 
tissue samples from women with chronic hypertension in pregnancy to define their 
clinical relevance. One advantage of studying the peripheral population of NK cells 
rather than the uNK cells is that they can be collected by standard phlebotomy. 
Furthermore, changes in peripheral immune cells can be detected from 12 weeks 
of gestation (437) giving rise to their potential as early biomarkers of future 
pregnancy complications. The increase in NK cells could be a maternal immune 
response against debris shed from the placenta. As there was no “SHRSP-specific 
cytokine” found in the previously discussed array; this could be an alternative 
mechanism for NK cell recruitment to the placenta in the SHRSP. This debris which 
encompasses apoptotic bodies, deported syncytiotrophoblast and extracellular 
vesicles as well as sub-cellular fragments including DNA has been shown to be 
increased in women with preeclampsia (415, 438). This debris could act as a 
danger-associated molecular pattern (DAMP) which triggers pattern recognition 
receptors on cells of the innate immune system; including NK cells (discussed in 
section 1.3.2.3). Total DNA quantified from placental tissue explants shows that 
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SHRSP have a greater total concentration relative to the WKY. This 
spectrophotometer data should be confirmed using quantitative PCR for a 
placental specific genre. Placental debris may also communicate messages from 
the placenta to the mother in a more specific way as exosomes derived from 
syncytiotrophoblast have been shown to express an array of receptors and 
molecules involved in mechanisms of angiogenesis (439), thrombin generation 
(440), gene expression by miRNAs (441) and immunomodulation (442) including of 
circulating  NK cells (443). 
The findings presented in this Chapter provide an explanation for the source 
of excess TNFα observed in the SHRSP and defines a novel action of etanercept on 
NK cells in the placenta. The pathway, which leads to an increase in NK cell 
number and/or activation in this model, may have clinical relevance for women 
with hypertension. 
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Chapter 6 Kidney Dysfunction and Urinary 
Peptidomics in Pregnant SHRSP 
6.1 Introduction 
The kidney plays a central role in healthy pregnancy. This is highlighted by 
the fact that women with chronic kidney disease have an increased risk of 
developing pregnancy complications; where up to 70% experience preterm 
delivery and up to 40% will develop preeclampsia (444, 445). Significant structural 
and functional changes occur in the kidney during pregnancy including a 1 - 1.5cm 
increase in size, a 50% increase in glomerular filtration rate (GFR), and up to an 
80% increase in renal plasma flow (RPF) (446, 447) (Fig. 6-1). These alterations 
are broadly conserved in rats (discussed in section 1.5.1) (448). In addition, the 
kidney is the site of water and electrolyte balance which ultimately contributes 
to the regulation of maternal blood pressure (449). Kidney pathology is commonly 
observed in hypertensive individuals and women with preeclampsia. Chronic 
hypertension can result in arteriosclerosis, altered filtration of electrolytes and 
perturbed renin production (450). With respect to preeclampsia, the presence of 
proteinuria is a key diagnostic criteria which differentiates the condition from 
pregnancy-induced hypertension (451). Preeclampsia is associated with an 
impaired glomerular filtration (452) which is thought to be due to a characteristic 
swelling of the endothelial cells in the glomeruli, known as glomerular 
endotheliosis, detecTable in histological examination of kidneys from women with 
pre-eclampsia (452) and in rodent models (341, 453). 
 
Figure 6-1 Normal renal structural and functional changes in response to pregnancy. 
RPF: renal plasma flow, GFR: glomerular filtration rate. Image from Odutayo et al. (2012). 
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Urine is produced as the filtrate passes through the nephron in three stages: 
filtration, absorption and secretion. Blood cells and large proteins cannot pass as 
plasma is filtered through the glomeruli. This filtrate passes through the tubules 
where ions, water and other small molecules are absorbed back into the body and 
waste products are secreted into the filtrate from the capillaries. The remaining 
fluid forms the urine which is passed through the collecting duct into the bladder 
then excreted. Due to this process, the urinary peptidome can give information 
about proteins that may be currently involved in local processes in the kidneys 
and some that are reflective of more distant organs obtained through filtration of 
the dynamic plasma peptidome giving a “snapshot” of what is currently happening 
in the body (454) (Fig. 6-2). Peptides derived from processes in the kidney and 
urogenital tract form the majority of those detected in the urinary peptidome 
(70%) whilst peptides from the circulation constitute the remainder (455). In 
humans, urine is a useful biological fluid for analysis as it is an easily accessible 
and plentiful resource, it is relatively stable at room temperature for a short 
period of time and at -20oC for several years (456). The small peptides present are 
generally soluble and due to their size do not require protein digestion before 
analysis (455). Urinary peptidomics has been investigated in the field of 
cardiovascular research two-fold: to develop biomarker panels for prediction and 
risk stratification and as a screening tool for novel peptides involved in disease 
pathology (457). In particular, a number of studies have shown that there are 
alterations in the urinary peptidome in people with hypertension (458) and in 
healthy pregnant women compared to those who develop pre-eclampsia (459). 
Despite this, research characterising the urinary peptidome in women with chronic 
hypertension are limited. 
The kidney is centrally involved in both blood pressure regulation and 
undergoes extensive changes in response to pregnancy. Whilst chronic 
hypertension and preeclampsia have been associated with an altered urinary 
peptidome; a similar study has not been conducted in chronic hypertension during 
pregnancy. We hypothesised that the urinary peptidome would be altered in both 
a pregnancy-dependent and strain-dependent manner in the WKY and SHRSP. We 
aimed to investigate this hypothesis by conducting a non-biased peptidome screen 
of urine collected pre-pregnancy, at gestational day (GD) 12 and 18. 
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Figure 6-2 The urinary peptidome. 
The kidney filters plasma from the circulation which then passes through the tubules where water 
and small molecules are reabsorbed and waste products are passed from the capillaries into the 
filtrate. The resulting urine is then representative of both the circulation and of local action at the 
kidney. Image from Decramer et al. (2008). 
 
6.2 Materials & Methods 
General materials & methods can be found in Chapter 2. 
  Animals 
The work presented in this Chapter has used pregnant WKY and SHRSP that 
were untreated. Females were time mated at 12 weeks of age (± 4 days). Non-
pregnant animals were age-matched at 15 weeks ± 4 days (i.e. 12 weeks of age + 
21 days of pregnancy). The number of animals and particular gestational day (GD) 
is given in the associated Figure legend. 
 Histology 
Preparation of paraffin blocks and sections were carried out as described 
in section 2.6.1. 
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6.2.2.1 Periodic acid-Schiff Stain 
Sections of 2 μm where used for periodic acid – Schiff stain to stain the 
basement membrane of the kidney for morphological scoring. Slides were cleared 
and rehydrated as described in section 2.6.1. Slides were incubated in 0.5 % 
periodic acid (Sigma-Aldrich, Dorset, UK) in dH2O for 15 minutes to oxidise 
aldehyde groups followed by 3 changes of dH2O. Slides were then stained with 
Schiff’s reagent (Sigma-Aldrich, Dorset, UK) for 15 minutes which reacts with the 
oxidised aldehyde groups to form a magenta dye followed by a wash in warm 
running tap water for 1 minute and two changes of dH2O. Sections were counter-
stained using Gill’s haematoxylin (Sigma-Aldrich, Dorset, UK). This was followed 
by a 1 minute wash under running tap water and dehydration through an ethanol 
gradient (95%, 2 x 100%; 5 minutes each). Slides were cleared in histoclear 2 x 5 
minutes and mounted using DPX (Sigma-Aldrich, Dorset, UK).  
6.2.2.2 Histological analysis of the kidneys 
Slides were visualised using an Aperio Slide Scanner (Leica Biosystems, 
Milton Keynes, UK) at 20x magnification by Clare Orange at the Queen Elizabeth 
University Hospital pathology unit. Images were downloaded from Leica Digital 
Image Hub then analysed using Image J by two independent operators who were 
blinded to the identity of the sections. Measurement of the cortex and medulla 
area was carried out by drawing around the relevant area and calculating the 
number of pixels. Glomerular density was counted as the number of glomeruli/ 
10x field of view in 25 fields of view/section. Glomerular diameter was measured 
using 4 lines/glomerulus in 25 glomeruli/section. Glomerular lobule count was 
conducted manually in 25 glomeruli/section. 
  Urinary Peptidomics 
6.2.3.1 Urinary Peptidome Extraction 
700 µl aliquot of urine was diluted with 700 µl of 2 M urea and 0.1 M NH4OH 
containing 0.02% SDS. A size cut-off for peptides <20 kDa was carried out using 
Centrisart ultracentrifugation filter devices (Sartorius, Gottingen, Germany) at 
3000 x g for 1 hour at 4 oC. To remove urea, electrolytes, and salts the filtrate 
was then ran through a PD-10 desalting column (Amersham Bioscience, 
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Buckinghamshire, UK) and peptide elution was done using 0.01 % aqueous  NH4OH. 
Finally, all samples were lyophilized, stored at 4 °C, and resuspended in high-
performance liquid chromatography grade H2O to a final concentration of 2 µg/µl 
before analysis. 
6.2.3.2 Capillary Electrophoresis-Mass Spectrometry (CE-MS) for Peptide 
Detection 
CE-TOF-MS analysis was performed using a P/ACE MDQ CE sytem (Beckman 
Coulter, Fullerton, USA) online coupled to a microTOF MS (Bruker Daltonic, 
Bremen, Germany) as described in (460). Samples were injected with 2 psi for 99 
seconds (250 nl) and separation of peptides in the cartridge maintained at 25 oC 
was attained at 25 kV for 30 minutes and increasing pressure (0.5 psi) for another 
35 minutes. The sheath liquid consisted of 30% isopropanol, 0.4% formic acid in 
HPLC grade water, and running buffer consisted of 79:20:1 (v/v) water, 
acetonitrile and formic acid. The ESI sprayer (Agilent Technologies, California, 
USA) was grounded and the ion spray inference potential was set at -4,5 kV.  
Spectra were accumulated over a mass-to-charge ratio of 350-3000 for every 3 
seconds. 
Peak picking, deconvolution, deisotoping of mass spectral ion peaks were 
processed using MosaiquesVisu software (461). The CE-migration time and ion 
signal intensity were normalized based on reference signal from internal peptide 
standards/calibrants (peptides from housekeeping proteins) in rats (462). For 
calibration, a local regression algorithm was applied with calibrants. The peak list 
generated for each peptide consisted of molecular weight (kDa) and normalized 
CE migration time (minutes) and normalized signal intensity. The  peptide list from 
all the samples that passed the quality control criteria were compared and 
annotated in a Microsoft SQL database. The criteria for clustering peptides in 
different samples were: (i) mass deviation less than ± 50 ppm for small peptide 
(<800 Da) and gradually increasing to ±75 ppm for larger peptides (20 kDa) (ii) CE-
migration time deviation with linear increase from ±0.4 to ±2.5 min in the range 
from 19-50 minutes. Each peptide was given a unique identification number 
(Peptide ID). Peptides detected with the frequency of ≥70 % in at least one group 
were considered for further analysis. Peptides were considered significant 
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according to Wilcoxon rank-sum test (p < 0.05) followed by adjustment for 
multiple testing (Benjamini and Hochberg). 
6.2.3.3 Liquid Chromatography- Tandem Mass Spectrometry (LC-MS/MS) for 
Peptide Sequencing 
The peptide mixture extracted for CE-MS were also used for sequencing of 
the peptides in LC-MS/MS. Sequencing was performed on an Ulitmate 3000 nano-
flow system (Dionex/LC Packings, USA) connected to an LTQ Orbitrap hybrid mass 
spectrometer (Thermo Fisher Scientific, Germany) equipped with a nano-
electrospray ion source. After loading (5 µl) onto a Dionex 0.1 × 20 mm 5 µm C18 
nano trap column at a flowrate of 5 µl/min in 98 % 0.1 % formic acid and 2 % 
acetonitrile, sample was eluted onto an Acclaim PepMap C18 nano column 75 µm 
× 15 cm, 2 µm 100 Å at a flow rate of 0.3 µl/min. The trap and nano flow column 
were maintained at 35 °C. The samples were eluted with a gradient of solvent A: 
98 % 0.1 % formic acid, 2 % acetonitrile verses solvent B: 80 % acetonitrile, 20% 
0.1 % formic acid starting at 1 % B for 5 minutes rising to 20 % B after 90 minutes 
and finally to 40 %B after 120 minutes. The column was then washed and re-
equilibrated prior to the next injection. 
The eluant was ionized using a Proxeon nano spray ESI source operating in 
positive ion mode into an Orbitrap Velos FTMS (Thermo Finnigan, Bremen, 
Germany). Ionization voltage was 2.6 kV and the capillary temperature was 200°C. 
The mass spectrometer was operated in MS/MS mode scanning from 380 to 2000 
amu. The top 20 multiply charged ions were selected from each scan for MS/MS 
analysis using CID at 35% collision energy. The resolution of ions in MS1 was 60,000 
and 7,500 for CID MS2. 
MS and MS/MS data files were searched, in this case, against the Uniprot 
mouse non-redundant database using SEQUEST (Thermo Proteome Discoverer) 
with non-specific enzyme as enzyme specificity. Peptide data were extracted 
using high peptide confidence and top one peptide rank filters. A peptide mass 
tolerance of ± 10 ppm and a fragment mass tolerance of ± 0.8 Da. Determine the 
false discovery rates by reverse database searches and empirical analyses of the 
distributions of mass deviation, whereby Ion Scores can be used to establish score 
and mass accuracy filters. 
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  Quantitative PCR (qPCR) for Umod Expression 
Gene expression for Umod was carried out using the following probes from 
Thermo Fisher, Paisley, UK: Umod (Rn01507237_m1) and Actb (4352340E). 
6.3 Results 
  The SHRSP Kidney is increased in Size Relative to the WKY 
but does not Exhibit Histological Abnormalities 
Post-mortem kidney weight was increased in both NP and GD18 SHRSP 
relative to WKY (Fig. 6-6A). PAS staining was then used to examine the kidneys 
histologically (Fig. 6-6B). There was a trend towards an increase in the size of the 
medulla region in NP SHRSP relative to NP WKY (p = 0.059); however there was no 
significant strain difference between pregnant animals (Fig. 6-6C). In contrast, 
cortex size was significantly increased in pregnant SHRSP relative to pregnant WKY 
but with no difference in NP animals (Fig. 6-6D). 
Further histological analysis was implemented to examine the glomeruli 
and for evidence of hypertension-associated pathology. Firstly, the anatomical 
distribution and structure of the glomeruli was analysed (Fig. 6-7A). Glomerular 
density in the cortex was increased in the SHRSP relative to WKY at both NP and 
GD18 time points (Fig. 6-7B). The number of glomerular lobules was decreased 
from NP to GD18 WKY but was not significantly different between NP and GD18 
SHRSP or between strains (Fig. 6-7C). There were no significant strain-dependent 
or pregnancy-dependent differences in glomerular diameter (Fig. 6-7D). 
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Figure 6-3 Kidney size is increased in non-pregnant and pregnant (GD18) SHRSP relative to WKY. 
Post-mortem kidney weight was found to be increased in both non-pregnant (NP) and pregnant 
(GD18) SHRSP relative to WKY (* p<0.05 vs. WKY analysed by Student’s t test) (A). Kidneys were 
then analysed histologically using periodic acid-Schiff stain (representative image B) in NP and GD18 
WKY and SHRSP (n=4-6). Medulla area showed a trend to be increased in NP SHRSP (p=0.059 
analysed by Student’s t test) but not in pregnant animals (C). Cortex area did not show strain-
dependent differences in NP animals but was increased in GD18 SHRSP relative to WKY (* p<0.05 
vs. GD18 WKY analysed by Student’s t-test). P: papilla. 
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Figure 6-4 Glomeruli distribution is altered in non-pregnant and pregnant (GD18) SHRSP relative to WKY. 
The distribution and anatomical structure of the glomeruli (A) was quantified in kidney sections from non-pregnant (NP) and GD18 WKY and SHRSP (n=4-6). Glomerular 
density was increased in a strain dependent manner in the SHRSP and was not affected by pregnancy (* p<0.05 vs. WKY analysed by Student’s t-test) (B). Glomerular 
lobules were decreased from NP to GD18 WKY (** p<0.01 vs. GD18 WKY analysed by Student’s t-test) but this change was not significant in the SHRSP (C). There 
were no strain-dependent or pregnancy-dependent changes in glomerular diameter (D). 
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  Detailed inspection of the slides was performed to examine pathologies 
associated with systemic hypertension and hypertensive pregnancy: namely 
capillary occlusion, protein resorption droplets and vasculopathy. There were no 
major pathologies detecTable in the kidney sections in a strain-dependent or 
pregnancy-dependent manner (Fig. 6-8A-B). There was a trend for the diameter 
of the vessels supplying the kidney to be increased between NP and pregnant 
animals in both strains but this could not be formally quantified as these samples 
were not collected by perfusion-fixation (Fig. 6-8B). 
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Figure 6-5 The SHRSP does not show histological abnormalities in the glomeruli or vessels of the kidney 
Kidney sections from non-pregnant (NP) and GD18 WKY and SHRSP were stained with periodic acid-Schiff stain and inspected for pathology (n=4-6). No noTable 
changes in glomerular structure were detected in a strain or pregnancy dependent manner (A). There was no evidence of vasculopathy; however there was a trend for 
vessel size to increase during pregnancy in both strains (C). 
50 μm 50 μm 50 μm 50 μm
20 μm 20 μm 20 μm 20 μm
WKY NP WKY GD18 SHRSP NP SHRSP GD18
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  The Urinary Peptidome is altered during Pregnancy and 
between WKY and SHRSP 
 A peptidome screen was performed in WKY and SHRSP urine at pre-
pregnancy, GD12 and GD18 to identify strain, pregnancy and disease-dependent 
alterations (Fig. 6-9). The various comparisons were: (i) WKY against various 
gestational days, (ii) SHRSP against various gestational days and (iii) comparison 
between WKY and SHRSP at a given gestational day (Fig. 6-10). The longitudinal 
comparison (i and ii) within the WKY and SHRSP) resulted in identification of 630 
and 739 peptides respectively, which were considered to be strain- and pregnancy-
dependent alterations (Fig. 6-10). While the comparison between WKY and SHSRP 
resulted in 788 peptides which were differentially expressed in a disease-specific 
manner and were taken forward for further study (Fig. 6-10). 
The 788 disease-specific peptide markers (Appendix III) were further 
evaluated using repeated measure ANOVA. Peptides were grouped by their pattern 
of gestation-dependent regulation where some were significantly altered at all 
time points, a single time point or at two different time points (Table 6-1).  
The peptides which showed significantly different expression at all gestational 
days or at GD12 and GD18 only (marked in bold on Table 1-1) were considered for 
further analysis. These 123 peptides were investigated for their gestation-
dependent regulation pattern between strains with cut-off criteria of ≥1.5 fold 
change and p ≤ 0.05 (Appendix IV). Principal component analysis (PCA) on the 
peptide intensities for the 123 differential peptides was performed (Fig. 6-11) 
which was able to differentiate between samples. The heat map was also plotted 
for these 123 differentially expressed peptides to observe peptide clusters with 
common patterns of regulation (Fig. 6-12). Compared to WKY, SHRSP consisted of 
7 and 39 peptides up- and down-regulated, respectively, at pre-pregnancy, GD12 
and 18. Also, 36 peptides were up-regulated and 41 peptides were down-regulated 
in SHRSP at GD12 and GD18.  Of the 123 peptides, 35 were able to be sequenced 
using LC-MS/MS (Appendix V). 
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Figure 6-6 Contour plots for peptide mass fingerprint in WKY and SHRSP at pre-pregnancy (NP), gestational day (GD) 12 and 18. 
The x-, y- and z-axis represents CE-migration time, mass-to-charge ratio and peptide peak intensities, respectively. 
WKY NP WKY GD12 WKY GD18
SHRSP NP SHRSP GD12 SHRSP GD18
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Figure 6-7 Venn diagram for various comparisons. 
Figures show Venn diagram comparison for (A) comparison within WKY strain against various gestational days, (B) comparison within SHRSP strain against various 
gestational days and (C) comparison between WKY and SHRSP at a given gestational day. The numbers represent the number of significant differential peptides. 
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Table 6-1 Number of differentially expressed peptides between WKY and SHRSP at different 
gestational time point comparisons 
 
Regulation Pattern Number of peptides 
NP, GD12 and GD18 46 
NP and GD12 63 
GD12 and GD18 77 
NP and GD18 23 
NP 104 
GD12 285 
GD18 99 
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Figure 6-8 Principal component analysis of 123 differentially expressed peptides in WKY and SHRSP at pre-pregnancy (NP), gestational day (GD) 12 and 18. 
The first principal component (PC1: strain) accounted for 28.6 % of total variance. The second principal component (PC2: gestation) accounted for 8.4 % of total variance. 
The cumulative variance of components was 43 %. Samples included in analysis were n=7 for each group represented by the labelled, coloured circles. Loading variables 
were the 123 differentially expressed peptides. 
 
 
209 
 
 
Figure 6-9 Heat map analysis of 123 differentially expressed peptides in WKY and SHRSP at pre-pregnancy (NP), gestational day (GD) 12 and 18. 
Peptides were clustered in the heat map according to their gestation-dependent pattern of regulation. Intensities were converted to a logarithmic scale (Log2) and the 
colour code represents the peptide intensity green (3) through black to red (14). 
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  Uromodulin is increased in the Urine and Kidney of Pregnant 
SHRSP relative to WKY  
Sequencing by LC-MS/MS was carried out on the 123 differentially expressed 
peptides where 35 were successfully sequenced and aligned to the rat protein 
database using UniProt (Appendix V). From these sequenced peptides, those 
derived from the protein uromdulin were found to be significantly increased in 
the SHRSP relative to the WKY in a pregnancy-dependent manner (Fig. 6-13). As 
uromodulin has previously been identified as a candidate molecule involved in 
renal dysfunction and hypertension, this was chosen to be investigated further. 
 Gene expression of Umod was measured in the kidney to investigate 
whether the increase in urinary uromodulin in the SHRSP could be derived from 
this tissue. Umod gene expression was increased in kidney tissue from SHRSP at 
pre-pregnancy (NP) and GD18 (Fig. 6-14). 
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Figure 6-10 Urinary uromodulin peptides are increased in the SHRSP relative to WKY in a 
pregnancy-dependent manner. 
Seven peptides (3188, 9646, 11288, 12110, 12757, 14390 and 16914) detected in the urinary 
peptidome were derived from uromodulin protein (A-G). Of these peptides, they were all increased 
in a pregnancy-specific manner in SHRSP (n=7) relative to WKY (n=7) at GD12, GD18 or GD12 and 
18.Taking into account the sum of all of the seven peptides (H) showed that uromodulin peptides 
were increased in a pregnancy-specific manner at GD12 and GD18 in SHRSP relative to WKY (* 
p<0.05, ** p<0.01 vs. WKY analysed by Student’s t test). 
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Figure 6-11 Gene expression of Umod in kidney tissue from WKY and SHRSP pre-pregnancy (NP) 
and gestational day (GD) 18. 
Gene expression of Umod was measured in kidney tissue from non-pregnant and pregnant (GD18) 
WKY and SHRSP (n=5). Umod expression was increased in kidney tissue from SHRSP at both NP 
and GD18 time points (** p<0.01, *** p<0.005 vs. WKY analysed by one-way ANOVA). 
  
6.4 Discussion 
 The work presented in this chapter shows that SHRSP exhibit strain-dependent 
and pregnancy-dependent alterations in the urinary pepidome. Uromodulin was 
identified to be increased in SHRSP in a pregnancy specific manner from this 
screen which was then validated at mRNA level in the kidney. 
 histological analysis was carried out to interrogate kidney structure. The 
SHRSP kidney weight was increased relative to the WKY in both non-pregnant and 
pregnant animals suggesting this was a strain-dependent difference; this has also 
been documented in this model previously (463). In-keeping with the increased 
post-mortem tissue weight; the cortex and medulla size was increased in SHRSP 
relative to WKY. However, cortex size was only increased in GD18 SHRSP compared 
to WKY and not in non-pregnant animals. Glomerular density was also significantly 
increased in both NP and pregnant SHRSP relative to WKY but there was no change 
in glomerular diameter between strains or during pregnancy. These measurements 
could have been improved by carrying out stereology on serial sections to 
determine glomerular volume. Close inspection of the kidney sections did not 
reveal any major pathology of the kidney vasculature or glomeruli in the SHRSP 
relative to the WKY. There was a trend for an increase in vessel size from NP to 
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pregnant animals in both strains however this could to be formally quantified as 
these tissues were not collected under perfusion fixation. This could be a 
worthwhile future study to investigate vascular remodelling in the kidney given 
the abnormal vascular function that has already been characterised in this model 
(349). It was perhaps not unexpected that there was no detectable glomerular 
damage by histological evaluation as it has been shown previously that male SHRSP 
do not develop kidney pathology until 1 year of age or this can be accelerated 
with salt treatment (464). Chronic hypertension during pregnancy in humans is not 
normally associated with renal damage unless these women go on to develop 
super-imposed preeclampsia. Therefore, the functional changes that have been 
detected in the SHRSP urine may be suggestive of a mild, pre-structural 
dysfunction of the kidney. Whether this itself is pathological and contributes to 
the reduction in plasma volume expansion in SHRSP or has a lasting effect on 
kidney function remains to be seen. A similar study looking at changes in urinary 
metabolites has not been conducted in women with chronic hypertension. 
This study then went on to characterise the urinary peptidome in SHRSP and 
WKY at three time points: pre-pregnancy, mid-pregnancy (GD12) and late 
pregnancy (GD18). To identify relevant peptides, there was a focus on 123 
peptides which were found to be differentially expressed between WKY and SHRSP 
at all time points (NP, GD12 and GD18) or at GD12 and 18 only. The 123 peptides 
were principally composed of collagen alpha chains, serum albumin, pro-
thrombin, actin, serpin A3K, pro-epidermal growth factor and uromodulin. In 
comparison, in urinary peptidomic screens of women with preeclampsia the most 
common constituents are: albumin and tubular proteins which is thought to reflect 
renal tubule damage. However, a characteristic signature is yet to be determined 
despite a number of studies (451). As uromodulin has been previously highlighted 
to play a role in renal dysfunction and systemic arterial hypertension (465) this 
led us to investigate this molecule in the WKY and SHRSP.  
Uromodulin was first isolated from the urine of pregnant women (466) and it’s 
excretion is increased in a time-dependent manner over gestation in humans 
(467). All of the urinary uromodulin peptides detected in the screen were 
increased in a pregnancy-dependent manner in the SHRSP relative to the WKY. In 
a recent study which took an untargeted approach to study the urinary peptidome 
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in women with and without preeclampsia; the authors identified the exact same 
seven peptides as we have identified in our study to be increased in the 
preeclampsia group (468). The SHRSP pregnancy-dependent increase in 
uromodulin was validated by increased Umod gene expression in kidney tissue. 
However in contrast to the urinary peptide levels, there was also a significant 
increase in Umod gene expression from kidney tissue between WKY and SHRSP at 
a non-pregnant time point. Total levels of uromodulin peptides were significantly 
correlated with both urinary sodium and urinary albumin levels. Uromodulin acts 
at the thick ascending limb of the kidney to promote sodium retention through 
NKCC2 (465, 469). Therefore, the results in our study of a negative correlation 
between uromodulin peptides and urinary sodium are in-keeping with these 
findings. Future work should measure NKCC2 expression in non-pregnant and 
pregnant WKY and SHRSP. 
In conclusion, SHRSP exhibit strain-dependent and pregnancy-dependent 
functional and structural alterations in the kidney relative to the WKY. This was 
associated with an altered urinary peptidome. The protein uromodulin, which has 
already been shown to have a role in systemic hypertension, has been highlighted 
in this pilot study as a potential protein of interest. These findings represent pre-
clinical work which can be used as a starting point for similar studies specifically 
in pregnant women with chronic hypertension which remains an under-researched 
area. 
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Chapter 7 General Discussion 
It is well established that chronic hypertension during pregnancy confers an 
increased risk for maternal and fetal morbidity and mortality (301, 305, 306). 
However, studies which solely focus on this growing clinical problem (303) are 
wanting. This work sought to establish a rat model of chronic hypertension in 
pregnancy utilising the SHRSP in order to investigate the pathological mechanisms 
involved in the vascular response to pregnancy. Previous work showed that the 
SHRSP exhibited deficient uterine artery remodelling in response to pregnancy 
which was associated with adverse pregnancy outcome at GD18 (349). The 
significant reduction of blood pressure using nifedipine from 6 weeks of age in the 
SHRSP did not improve these factors (349). Therefore, we hypothesised that the 
abnormal adaption to pregnancy in the SHRSP was due to other maternal 
cardiovascular risk factors.  
 
Figure 7-1 Excess TNFα in pregnant SHRSP is central to the pathology in this model. 
The flow chart summarises the TNFα – dependent mechanism proposed in this thesis. Black arrows 
indicate conclusions that have been made from evidence presented in this thesis whereas red 
dashed arrows indicate that further work is required. 
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Inflammation is a central component of the phenotype in pregnant SHRSP; 
however the underlying cause remains to be elucidated (Fig. 8-1) Genetic 
mutations can lead to activation of the immune system in the context of human 
autoimmune diseases (470). Linkage analysis has also uncovered quantitative trait 
loci which contribute to circulating inflammatory biomarkers in clinical studies 
(471). Whilst linkage analysis has been carried out in the SHRSP and WKY to 
explore a genetic component for heart rate (472), left ventricular mass (473), 
hypertension (474) and renal injury (475) among other traits; components of 
inflammation have not been explored. Linkage analysis studies such as those 
discussed have generated a number of congenic strains. To date, pregnancy has 
not been studied in existing strains of congenic SHRSP or WKY. Linkage analysis 
for inflammation-associated phenotype may yield new loci involved in the 
regulation of the immune system in the SHRSP. The genome sequence is also 
available for the WKY and SHRSP which could be utilised to identify variants in, 
for example, the gene for TNFα which exist between the two strains. Such 
investigations may highlight a genetic contribution to adverse pregnancy outcome 
or inflammatory response in the SHRSP.  Secondly, there could also be a 
physiological stimulus which leads to inflammation in the pregnant SHRSP. An 
increase in sub-cellular fragments or debris shed from the placenta can activate 
the maternal immune system (415). A preliminary investigation into shed placental 
cfDNA suggested that this could be a promising area of further study in this model. 
Placental DNA is hypomethylated at CpG islands (476) which differentiates it from 
maternal circulating DNA fragments. Hypomethylated DNA is recognised by TLR9 
in humans (477) and this mechanism is conserved in rats (478). TLR9 is expressed 
on NK cells, among other immune cells, and could be measured in a future 
extracellular flow cytometry experiment in circulating maternal leukocytes from 
WKY and SHRSP.  
Increased maternal inflammation in the SHRSP manifests itself as an 
increase in CD3- CD161+ NK cells. Etanercept treatment decreased the expression 
of CD161 and granzyme B in placental CD3- CD161+ NK cells thus limiting their 
cytotoxic ability. It has also been shown in this thesis that placenta from GD18 
SHRSP have an increase in caspase 3 cleavage which indicates the induction of 
programmed cell death. NK cell mediated apoptosis results in up-regulation of 
caspase 3 cleavage (479) therefore it is reasonable to propose that the effectors 
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of increased cell death in the placenta are the CD3- CD161+ Granzyme B + NK cells 
which are increased in number in the SHRSP relative to WKY. Despite the 
appearance of significant necrosis by gross examination; there was no difference 
in placental weight between WKY and SHRSP at GD18. On histological analysis the 
glycogen cells in particular were depleted in the SHRSP. Why these cells in 
particular would be targeted for apoptosis or if they indeed were lost to increased 
cell death in the placenta of the SHRSP is unknown. There exists a technical 
difficulty in staining the glycogen cells with immunohistochemistry in that the 
thick matrix of glycogen stored within the cytoplasm of these cells traps the 
antibody and leads to false positive staining. With further optimisation, it would 
be beneficial to be able to stain the placenta for activated caspases using 
immunohistochemistry to localise this increase in cell death in the SHRSP 
placenta. Another mechanism for glycogen cell loss could be premature utilisation 
of the energy stores in SHRSP placenta to compensate for the reduced nourishment 
from deficient uteroplacental blood flow. Indeed, it could be a combination of 
both of these mechanisms whereby the glycogen cells are utilised and then the 
cells are targeted for apoptosis. 
Excess TNFα is central to the pathology in pregnant SHRSP; etanercept 
treatment improved uterine artery function and blood flow as well as pregnancy 
outcome. UMOD was identified from the peptidomics screen to be increased in a 
pregnancy-specific manner in SHRSP. In clinical studies, urinary UMOD is increased 
in people with essential hypertension and correlated significantly with increased 
plasma biomarkers of inflammation including TNFα (480). Additionally, UMOD has 
the ability to bind cytokines, including TNFα (481). The expression of TNFα was 
not measured in kidneys from pregnant WKY and SHRSP nor was sodium assessed 
in etanercept treated animals. In answering these two questions, it may be 
possible that there is an interaction between UMOD, TNFα and sodium balance in 
the kidney during pregnancy in the SHRSP. An alternative mechanism of interest 
which links inflammation and UMOD is the sub-cellular localisation of the protein. 
UMOD plays a key role in the activation of the innate immune system at the kidney 
and has been shown to induce both monocytes and granulocytes to produce pro-
inflammatory cytokines (482). UMOD, which is normally localised to the thick 
ascending limb of the kidney, can be found within immune complexes in the renal 
interstitial space in humans (483) and a rat model (484) of nephritis. When in the 
 
 
218 
 
interstitium, UMOD can interact with dendritic cells via TLR4 to mount a humoral 
immune response (485). Immunohistochemistry for UMOD in the kidney of WKY 
and SHRSP would be necessary to determine whether UMOD itself is involved in 
inflammation at the kidney. 
The vascular work in this thesis has focussed predominantly on the uterine 
artery. As the SHRSP exhibits spontaneously deficient uterine artery remodelling 
it would be interesting to study the smaller, downstream vessels such as the radial 
and spiral arteries. Deficient remodelling of the radial arteries is a characteristic 
of human preeclampsia but not fetal growth restriction (486). Notably, the 
decrease in lumen size has been shown to be due to inward eutrophic remodelling 
(486). There was no change in wall thickness between uterine arteries from WKY 
and SHRSP; however this may not be the case for the smaller radial arteries as 
seen in this human study. Radial artery remodelling occurs in healthy pregnant 
rats with a 4.8 fold change in length and 60% change in lumen diameter reported 
(487). Radial arteries from pregnant rats either supply the myometrium or 
placenta; these two lineages have different vascular reactivity and relaxation 
response to NO (488) thus care must be taken with which vessel is isolated. Studies 
of the radial arteries in rat models of hypertensive pregnancy are limited. Using 
anti – peroxisome proliferator-activated receptor γ (PPARγ) treatment it is 
possible to induce a preeclampsia like syndrome in rats (489). Utilising anti- PPARγ 
from GD15 - 21 has been shown to significantly reduce endothelium dependent 
vasorelaxation of rat radial arteries (490). In addition, a recent study showed that 
testosterone treatment between GD15 - 19 in rats impairs radial artery 
remodelling (63).  
  Failure of the spiral arteries to remodel is a pathological hallmark of 
preeclampsia. Whilst women with chronic hypertension have an increased risk of 
developing preeclampsia; trophoblast invasion has never been explored in women 
with chronic hypertension. At the maternal-fetal interface, TNFα is expressed by 
decidual uNK cells, decidual macrophages, invading extravillous trophoblast (491) 
and intervillous cytotrophoblast (492). TNFα production from decidual leukocytes 
plays a key role in the regulation of trophoblast migration and programmed cell 
death as they invade into the uterine wall (491). However, increased levels of 
TNFα have been shown to reduce the migration of first trimester villous explant 
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cultures through up-regulation of plasminogen activator inhibitor 1 (PAI-1) (492-
494). PAI-1 acts to inhibit the activation of plasminogen into plasmin which in turn 
prevents pro-MMPs being turned into MMPs; MMPs play a critical role in trophoblast 
invasion (495). In combination with IFNγ, the effects of TNFα were augmented 
such that trophoblast apoptosis was increased and proliferation and MMP secretion 
were also inhibited (492). This suggests that the balance of cytokines is important 
and that TNFα and IFNγ, both produced from NK cells, have synergistic effects. In 
addition, TNFα treatment also inhibited the integration of a trophoblast cell line 
(JEG-3) into an in vitro model of endothelial cell tube formation. In this case the 
mechanism was proposed to be through a failure of correct integrin expression 
(496). TNFα  treatment has also been shown to promote trophoblast shedding from 
first trimester villous explants which induce endothelial cell activation in an in 
vitro model potentially linking placental inflammation and vascular dysfunction 
(497). As there is evidence of global inflammation in the SHRSP placenta a next 
step would be to treat VSMCs and endothelial cells with explant culture medium 
to assess molecular changes in these cell types.  
Uterine uNK cells play a key role in remodelling the spiral arteries in humans 
and rodents. However, the CD3- CD161+ cells in this thesis are more 
representative of peripheral NK cells and not the uterine specific population of 
uNK cells. As there have been changes identified in the peripheral NK cell 
population it would be logical to explore uNK cells in the WKY and SHRSP. At 
present, there is no specific marker for rat uNK cells however these do exist in 
humans and mice. Immunohistochemistry for perforin has been used to identify 
uNK cells in rats (498). It has also been shown that the migration of uNK cells into 
the uterus precedes trophoblast invasion in the rat; indicating they may have a 
priming role to play for trophoblast invasion (499). Whilst the vascular remodelling 
capacity of uNK cells is subject of intense study; the role of peripheral NK cells in 
systemic vascular remodelling has not yet been reported in the literature. 
Leukocytes found in the perivascular adipose tissue have been shown to alter 
vascular function in obesity and cardiovascular disease (500). Recent work has also 
shown that perivascular adipose tissue surrounding mesenteric arteries from late 
pregnant (GD20) rats had a blunted (44%) contractile effect to phenylephrine. 
Leukocyte populations in perivascular adipose tissue during pregnancy have 
currently not been reported in the literature. Given the perturbation of peripheral 
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NK cells in the SHRSP and the role of TNFα in uterine artery dysfunction; 
investigation of NK cells in the perivascular adipose tissue of the uterine arteries 
may provide a closer link to inflammation and vascular dysfunction observed in 
this model.   
NK cells were once thought to be a unique example of an innate lymphoid 
cell (ILC) however recent work has identified that, in fact, the NK cell belongs to 
a much larger family of ILCs which encompasses a number of smaller sub-sets. The 
ILC family are defined by their ability to produce Th like cytokines but lack lineage-
specific markers of other immune cell subtypes and a T cell receptor therefore do 
not respond in an antigen-dependent manner (501). Whilst work on ILC families in 
rats is currently non-existent within the literature; a number of studies have 
defined extracellular markers which differentiate between ILC subtypes in humans 
and mice (501). In particular, group 3 innate lymphoid cells (ILC3s) express the NK 
cell activating receptor NKp46 but do not express cytotoxic molecules such as 
perforin or granzymes or IFNγ and TNFα; instead they predominantly produce IL-
22 (502). In the placenta of the SHRSP, a CD3- CD161Low Granzyme B- population 
was identified that was increased when SHRSP were treated with etanercept. This 
population of cells share a similarity with the ILC3 discussed. NKp46 expression is 
conserved on rat NK cells and serves as an activating receptor (503) however it 
could not be measured in this study as it is not a commercially available antibody. 
Further classification of this CD3- CD161Low Granzyme B- population of cells may 
show that these are not NK cells where CD161 expression has been reduced but 
the related ILC3. 
The SHRSP is not a model of superimposed preeclampsia as it does not exhibit 
a pregnancy-specific rise in blood pressure or proteinuria. In another hypertensive 
rat strain, the Dahl S, the introduction of salt treatment (1.9 % NaCl in drinking 
water) from GD 15 onwards induced characteristics of preeclampsia (504). In 
addition, follow-up studies from this model have shown abnormal uterine artery 
function (505) and an increase in placental cell death (506). The SHRSP blood 
pressure is salt sensitive whereby treatment with 1 % NaCl in drinking water results 
in approximately a 30 mmHg increase (187). Female and male SHRSP respond to 
salt loading (1 % NaCl) differently. Male SHRSP show a significant increase in blood 
pressure after 2 months of salt treatment but no change after a further 5 months 
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of treatment. In female SHRSP, there was a rise in SBP after 1 month of treatment 
and a further gradual increase over the next 6 months of treatment (507).  4 % 
NaCl in drinking water of female SHRSP resulted in a 60 mmHg increase in SBP 
relative to the control group; however these rats started to exhibit stroke from 12 
weeks and mortality rate was 100 % at 20 weeks of age (508). However, the salt 
sensitivity of blood pressure is subject to sub-strain dependent differences. The 
Glasgow sub-strain of SHRSP males exhibit almost 100% lethality after three weeks 
of treatment with 1% NaCl. Glasgow female SHRSP are less salt sensitive and tend 
to survive longer than 3 weeks on 1% NaCl (Dr. Delyth Graham, Personal 
Communication). Therefore, for future studies using salt loading in pregnant 
SHRSP both the sub-strain used and the dose of NaCl should be carefully 
considered. From the findings of this thesis, inflammation has been shown to be a 
causative factor for pathology in the pregnant SHRSP. A recent editorial 
highlighted a potential role of salt and activation of the immune system in 
hypertensive pregnancy (509). A mechanism involving macrophages has recently 
been shown to be able to regulate intradermal storage of sodium (510). Increased 
salt has also been shown to activate Th17 cells, a pro-inflammatory cell type, in a 
rat model of autoimmune disease (511). Th17 cells in the placenta have been 
shown to play a role in preeclampsia and adverse pregnancy outcome as well as 
interacting with NK cells at the maternal-fetal interface (512). Therefore, a 
reasonable hypothesis is that salt treatment may worsen the inflammatory 
phenotype seen in pregnant SHRSP. IL-17 production in the SHRSP placenta was 
not measured and this should be taken into account in a future salt study in light 
of this this evidence. 
Chronic hypertension during pregnancy has been a relatively neglected area 
of research. In Figure, 7-2, PubMed was used to search for the terms “chronic 
hypertension pregnancy” and “pre-eclampsia/preeclampsia” from 2004 to 2014 as 
a crude marker to quantify research output in each area. PubMed hits for 
preeclampsia were of a 7-10 magnitude higher than those hits for chronic 
hypertension (Fig. 7-2). In addition, whilst research output in pre-eclampsia 
underwent a steep increase between 2010 and 2014; chronic hypertension 
research has stayed relatively sTable (Fig. 7-2). There are a few reasons to explain 
this trend. From the available literature, poorer outcomes for maternal and fetal 
morbidity and mortality occur in mothers with pre-eclampsia than in mothers with 
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chronic hypertension alone (306) which has driven the need to prioritise 
preeclampsia research. However, women with maternal chronic hypertension are 
a growing population (302) whereas total cases of preeclampsia have been shown 
to have a relatively sTable incidence over the last 30 years in the developed world 
(513). Women with chronic hypertension are also more commonly included as a 
sub-group in part of a bigger preeclampsia study. Indeed, women with chronic 
hypertension also have a higher risk of developing superimposed preeclampsia 
where the risk is that they are inappropriately included in a preeclampsia cohort. 
As recent meta-analysis and editorials indicate there is an acute need to develop 
clinical and pre-clinical work which focusses on pre-existing maternal 
cardiovascular disease and how this affects pregnancy outcome (305, 306, 310). 
Additionally, no large patient cohort currently exists which specifically examines 
women with maternal chronic hypertension. 
 
Figure 7-2 PubMed hits comparing search terms for “pre-eclampsia/preeclampsia” and “chronic 
hypertension pregnancy”.  
Data accessed and compiled by the author using PubMed (http://www.ncbi.nlm.nih.gov/pubmed) 
on the 2/12/15. 
 
Whilst there is no immediate novel clinical treatment which can be derived 
directly from the findings presented in this thesis; the translational value lies in 
elucidating a novel TNFα-dependent mechanism in the first pre-clinical rat model 
of maternal chronic hypertension which can act as a stimulus for future clinical 
studies. In addition, observations from such human studies can now be tested in a 
well-characterised model yielding the elucidation of novel clinically-relevant 
mechanisms in this previously under-researched area.  
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Appendix I: Laboratory-Prepared Solutions 
Acidified Ferrocyanide Reagent 
Prepare reagent A and B separately. 
To make 200 ml: 
 Reagent A 4 % potassium ferrocyanide in dH2O (w/v): 4g potassium ferrocyanide 
(K4Fe(CN)6 · 3H2O; Sigma-Aldrich, Dorset, UK) dissolved in 100 ml dH2O. 
 Reagent B 4 % hydrochloric acid in dH2O (v/v): 4 ml concentrated HCl (36.5 – 38.0 %; 
Sigma-Aldrich, Dorset, UK) diluted in 100 ml dH2O. 
Mix reagents A and B immediately before adding to slides. 
Must be made fresh each experiment. 
 
Flow Cytometry Wash Buffer 
To make 500 ml: 
Dilute 10 ml fetal bovine serum (FBS) in 490 ml dH2O. 
Must be made fresh each experiment. 
 
Phosphate Buffered Saline 10x 
To make 1 l: 
Dissolve 
NaCl (Sigma-Aldrich, Dorset, UK) 80 g  
KCl (Sigma-Aldrich, Dorset, UK) 2.0 g 
Na2HPO4 (Sigma-Aldrich, Dorset, UK) 14.4 g 
KH2PO4 (Sigma-Aldrich, Dorset, UK) 2.4 g 
in 800 ml dH2O. 
Adjust pH to 7.4. 
Top up to 1 l with dH2O. 
Can be kept at room temperature up to 24 months. 
 
Phosphate Buffered Saline 1x 
To make 1 l: 
Dilute 100 ml of Phosphate buffered saline 10 x in 900 ml of dH2O. 
Can be kept at room temperature up to 24 months. 
 
Physiological Salt Solution 
Prepare stock solution A and B which can be kept at 4oC for up to 3 months. 
 To make 1 l PSS Stock Solution A: Dissolve 139.1 g NaCl, 7.0 g KCl and 5.92 g MgSO4 (all 
Sigma-Aldrich, Dorset, UK) in 1 l dH2O. 
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 To make 1 l PSS Stock Solution B: Dissolve 42 g NaHCO3 and 3.2 g KH2PO4 (all Sigma-
Aldrich, Dorset, UK) in 1 l dH2O. 
To make 2 l physiological salt solution: 
Dilute 100 ml Stock Solution A 
100 ml Stock Solution B 
in 500 ml dH2O. 
Dissolve 4 g glucose (Fisher Scientific, Loughborough, UK). 
Bubble in 95 % O2 5% CO2 for 5 minutes. 
Add 5 ml CaCl2 (Fisher Scientific, Loughborough, UK). 
Can be kept 4oC for up to 3 days. 
 
Physiological Salt Solution: Calcium Free 
To make 1 l physiological salt solution calcium free: 
Dilute 50 ml PSS Stock Solution A 
50 ml PSS Stock Solution B 
in 500 ml dH2O. 
Dissolve 2 g glucose (Fisher Scientific, Loughborough, UK). 
Bubble in 95 % O2 5% CO2 for 5 minutes. 
Add 0.5 ml 23 mM EDTA (Sigma-Aldrich, Dorset, UK). 
Can be kept 4oC for up to 3 days. 
 
Physiological Salt Solution: High Potassium 
 Prepare 500 ml Special PSS Stock Solution A: Dissolve 92.23 g KCl and 100 ml MgSO4 (all 
Sigma-Aldrich, Dorset, UK) in 500 ml dH2O. 
To make 500 ml physiological salt solution high potassium: 
Dilute 25 ml Special PSS Stock Solution A 
25 ml PSS Stock Solution B 
in 300 ml dH2O. 
Dissolve 1 g glucose (Fisher Scientific, Loughborough, UK). 
Bubble in 95 % O2 5% CO2 for 5 minutes. 
Add 1.25 ml CaCl2 (Fisher Scientific, Loughborough, UK). 
Can be kept 4oC for up to 2 months. 
 
RIPA Buffer 
Prepare 10ml stock solutions of: 
 1 M Tris-HCl: Dissolve 1.21 g Tris-HCl (Fisher Scientific, Loughborough, UK) in 10 ml 
dH2O. 
 5 M NaCl: Dissolve 2.9 g NaCl (Sigma-Aldrich, Dorset, UK) in 10ml dH2O. 
 0.5 M EDTA: Dissolve 1.86 g EDTA (Sigma-Aldrich, Dorset, UK) in 10 ml dH2O. 
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To make 100 ml of RIPA buffer, add: 
Sodium deoxycholate (Fisher Scientific, Loughborough, UK) 0.5g 
1 M Tris-HCl 5 ml 
5 M NaCl 3 ml 
0.5 M EDTA 0.2 ml 
to 75 ml of dH2O. 
Adjust pH to 8.8. 
Add: SDS 0.1 g 
NP-40 1ml 
Top up to 100ml. 
 
Sodium Citrate Buffer 
Prepare two stock solutions which can be kept at 4oC for up to 6 months. 
 To make 500 ml 0.1 M citric acid: Dissolve 10.5 g citric acid (Sigma-Aldrich, Dorset, UK) 
in 500 ml dH2O. 
 To make 500 ml 0.1 M trisodium citrate: Dissolve 14.7 g trisodium citrate (Sigma-Aldrich, 
Dorset, UK) in 500 ml dH2O. 
Make 0.01 M citrate buffer fresh on the day of experiment. To make 500ml: 
Dilute 9 ml 0.1 M citric acid 
41 ml of 0.1M trisodium citrate 
in 400 ml dH2O. 
Adjust pH to 6.0. 
Top up to 500 ml dH2O. 
Must be made fresh each experiment. 
 
Tris Buffered Saline 10x 
To make 1 l: 
Dissolve 
24.23 g Tris-HCl (Fisher Scientific, Loughborough, UK) 
80.06 g NaCl (Sigma-Aldrich, Dorset, UK) 
in 800 ml dH2O. 
Adjust pH to 7.6. 
Top up to 1 l dH2O 
Can be kept at room temperature up to 12 months. 
 
Tris Buffered Saline 1x 
To make 1 l: 
Dilute 100 ml of Tris buffered saline 10 x into 900 ml of dH2O. 
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Appendix II: Sacrifice Protocol Sheet 
Date: 
Strain: 
Maternal ID: 
Maternal weight: 
  
GD ............ 
 
     
Heart W                                         LV 
Lungs  
Liver  
Spleen  
Kidney L                                             R 
Tibia  
 
Fetal 
ID 
Fetal  
whole 
weight 
Placental 
weight 
Fetal weights 
Notes Head Heart Liver Kidney Spleen 
   
     
 
         
         
         
         
         
         
         
         
         
   
     
 
   
     
 
   
     
 
         
         
         
         
 
Fetal 
Location 
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Appendix III: 788 urinary peptides altered between 
WKY and SHRSP  
Pre-pregnancy                  
WKY Vs SHRSP 
Gestational day 12                                                         
WKY Vs SHRSP 
Gestational day 18                  
WKY Vs SHRSP 
PeptideID p value PeptideID p value PeptideID p value PeptideID p value 
2545 0.001 421 0.001 11725 0.010 519 0.001 
10647 0.001 1304 0.001 18543 0.010 880 0.001 
11171 0.001 1338 0.001 24940 0.010 4119 0.001 
13543 0.001 1699 0.001 101782 0.010 22329 0.001 
100383 0.001 2090 0.001 3791 0.011 4586 0.001 
8591 0.001 2684 0.001 5823 0.011 8591 0.001 
15819 0.001 2803 0.001 929 0.011 8661 0.001 
100359 0.001 3734 0.001 1054 0.011 13580 0.001 
101391 0.001 3930 0.001 3258 0.011 14788 0.001 
101695 0.001 4042 0.001 4379 0.011 14896 0.001 
106356 0.001 4170 0.001 6395 0.011 15819 0.001 
4119 0.001 4218 0.001 6531 0.011 100964 0.001 
6352 0.001 4586 0.001 8230 0.011 101154 0.001 
8230 0.001 5098 0.001 9006 0.011 101201 0.001 
12237 0.001 5147 0.001 9871 0.011 101695 0.001 
15972 0.001 5254 0.001 10732 0.011 102001 0.001 
14896 0.002 5661 0.001 10825 0.011 10647 0.001 
10625 0.002 6044 0.001 11875 0.011 11171 0.001 
22329 0.002 6304 0.001 12049 0.011 24031 0.001 
4197 0.002 6596 0.001 14090 0.011 36219 0.001 
9589 0.002 6975 0.001 14472 0.011 101391 0.001 
35922 0.002 7006 0.001 16054 0.011 101392 0.001 
100033 0.002 7441 0.001 100322 0.011 12407 0.002 
103080 0.002 8592 0.001 102908 0.011 35684 0.002 
5748 0.002 10615 0.001 3672 0.011 5661 0.002 
13928 0.002 10647 0.001 4446 0.011 13543 0.002 
11655 0.002 10835 0.001 4451 0.011 17594 0.002 
4864 0.002 11171 0.001 4836 0.011 5497 0.002 
6975 0.002 12407 0.001 6546 0.011 105750 0.002 
10311 0.002 12426 0.001 6565 0.011 100383 0.002 
12417 0.002 12582 0.001 7590 0.011 7574 0.002 
6333 0.003 12628 0.001 7979 0.011 10165 0.002 
5661 0.003 13543 0.001 8560 0.011 100572 0.002 
11852 0.003 13670 0.001 9286 0.011 5474 0.002 
7502 0.004 17939 0.001 9447 0.011 8590 0.003 
11488 0.004 18503 0.001 9571 0.011 9325 0.003 
13270 0.004 35922 0.001 13236 0.011 20566 0.003 
13578 0.004 100383 0.001 13570 0.011 11430 0.003 
19853 0.004 100773 0.001 15252 0.011 13851 0.003 
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100217 0.004 101176 0.001 15577 0.011 100773 0.003 
100433 0.004 101193 0.001 15972 0.011 6395 0.003 
100954 0.004 101420 0.001 18196 0.011 10197 0.003 
100964 0.004 2985 0.001 20303 0.011 9833 0.003 
101001 0.004 9647 0.001 25101 0.011 8128 0.004 
102001 0.004 11488 0.001 33216 0.011 8894 0.004 
102056 0.004 11744 0.001 100761 0.011 9820 0.004 
18164 0.004 14788 0.001 101145 0.011 10192 0.004 
19881 0.004 15819 0.001 101274 0.011 11488 0.004 
35466 0.004 31459 0.001 101730 0.011 17410 0.004 
35994 0.004 100359 0.001 102322 0.011 17742 0.004 
100495 0.004 100433 0.001 107303 0.011 100744 0.004 
100864 0.004 100806 0.001 107543 0.011 100806 0.004 
103088 0.004 100954 0.001 193 0.011 100954 0.004 
103092 0.004 100964 0.001 6367 0.011 101001 0.004 
109190 0.004 101001 0.001 8019 0.011 101219 0.004 
100218 0.004 101154 0.001 8661 0.011 101224 0.004 
5254 0.004 101201 0.001 9301 0.011 101403 0.004 
11841 0.004 101219 0.001 10081 0.011 101782 0.004 
20119 0.004 101403 0.001 11467 0.011 102908 0.004 
9729 0.005 101695 0.001 11550 0.011 106650 0.004 
15071 0.005 101850 0.001 13079 0.011 12729 0.004 
16262 0.005 102000 0.001 13819 0.011 13985 0.004 
13742 0.005 102001 0.001 13977 0.011 1512 0.004 
3813 0.005 102056 0.001 14697 0.011 4362 0.004 
13901 0.006 108357 0.001 15787 0.011 5254 0.004 
4933 0.006 109289 0.001 17163 0.011 4864 0.004 
8156 0.006 880 0.001 19102 0.011 34236 0.004 
11737 0.006 1512 0.001 100217 0.011 27020 0.005 
103116 0.006 1615 0.001 100537 0.011 14020 0.006 
193 0.006 1891 0.001 100545 0.011 21602 0.006 
101201 0.006 4119 0.001 101174 0.011 4692 0.006 
13580 0.007 4320 0.001 101275 0.011 5244 0.006 
24519 0.007 5952 0.001 101946 0.011 6367 0.006 
4218 0.007 6084 0.001 102804 0.011 10772 0.006 
7588 0.007 7578 0.001 102868 0.011 11573 0.006 
10884 0.007 8056 0.001 108122 0.011 16631 0.006 
17798 0.007 10311 0.001 109525 0.011 27487 0.006 
15724 0.008 10377 0.001 109530 0.011 36280 0.006 
1949 0.009 11841 0.001 12259 0.012 3784 0.007 
18591 0.009 13290 0.001 100343 0.012 10695 0.007 
7982 0.010 16047 0.001 7035 0.013 3135 0.007 
10197 0.010 16746 0.001 13742 0.013 13591 0.007 
35447 0.010 17843 0.001 100374 0.013 16914 0.007 
101392 0.010 100000 0.001 100572 0.013 10270 0.007 
107880 0.010 100173 0.001 3472 0.013 5596 0.007 
8709 0.010 2712 0.001 6647 0.013 20556 0.009 
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14788 0.010 4468 0.001 35161 0.013 5114 0.010 
4680 0.010 12124 0.001 9432 0.014 15395 0.010 
9113 0.010 13580 0.001 100226 0.014 15428 0.010 
17522 0.010 16333 0.001 9113 0.014 1756 0.010 
12583 0.010 19131 0.001 12110 0.014 3258 0.010 
1054 0.011 100139 0.002 100864 0.014 12958 0.010 
2186 0.011 101208 0.002 100977 0.014 20731 0.010 
5098 0.011 106579 0.002 105334 0.014 100063 0.010 
7006 0.011 108649 0.002 9131 0.014 102567 0.010 
11216 0.011 29610 0.002 21178 0.014 102712 0.010 
11667 0.011 13928 0.002 102119 0.015 102902 0.010 
12049 0.011 2637 0.002 7442 0.015 15228 0.010 
21160 0.011 7161 0.002 13152 0.015 3188 0.010 
35127 0.011 7982 0.002 35713 0.017 16054 0.010 
35169 0.011 102902 0.002 856 0.017 1406 0.011 
35490 0.011 106602 0.002 100360 0.017 9705 0.011 
101635 0.011 1107 0.002 1755 0.017 12605 0.011 
11837 0.011 3493 0.002 2619 0.017 2910 0.011 
17480 0.011 4706 0.002 2981 0.017 3668 0.011 
20506 0.011 8344 0.002 3668 0.017 7534 0.011 
21295 0.011 8184 0.002 4864 0.017 9863 0.011 
21651 0.011 13458 0.002 5198 0.017 10013 0.011 
100471 0.011 14896 0.002 5215 0.017 12628 0.011 
100585 0.011 106074 0.002 7083 0.017 13740 0.011 
108057 0.011 4828 0.002 8295 0.017 3943 0.011 
2102 0.011 13476 0.002 9144 0.017 6546 0.011 
2433 0.011 102911 0.002 10707 0.017 7560 0.011 
3265 0.011 109223 0.002 11099 0.017 8681 0.011 
4717 0.011 1140 0.002 11866 0.017 9199 0.011 
6367 0.011 1146 0.002 13159 0.017 11101 0.011 
6857 0.011 3114 0.002 13923 0.017 11141 0.011 
8600 0.011 5460 0.002 17077 0.017 13079 0.011 
11261 0.011 5635 0.002 31029 0.017 14066 0.011 
100333 0.011 6397 0.002 100658 0.017 14162 0.011 
100627 0.011 6441 0.002 100916 0.017 33248 0.011 
100744 0.011 9863 0.002 11250 0.019 34855 0.011 
101219 0.011 12289 0.002 107005 0.019 34882 0.011 
9178 0.013 13456 0.002 18031 0.020 100018 0.011 
2844 0.013 14426 0.002 5789 0.020 100095 0.011 
9571 0.013 15933 0.002 27418 0.020 100730 0.011 
14221 0.013 20939 0.002 29455 0.020 101024 0.011 
15118 0.013 100026 0.002 35234 0.020 101148 0.011 
35384 0.013 101092 0.002 101520 0.020 101216 0.011 
9042 0.014 7866 0.003 9251 0.020 101292 0.011 
102610 0.014 10322 0.003 11644 0.020 102056 0.011 
102676 0.014 11179 0.003 17878 0.020 102918 0.011 
109175 0.014 18217 0.003 2102 0.020 3628 0.012 
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6115 0.014 12742 0.003 102700 0.020 101186 0.012 
35539 0.014 102559 0.003 23262 0.020 16685 0.013 
6436 0.017 19332 0.003 7289 0.021 7588 0.013 
14030 0.017 101392 0.003 16914 0.021 14404 0.014 
100110 0.017 100887 0.003 106551 0.021 6545 0.014 
101985 0.017 100989 0.003 4457 0.021 3930 0.014 
100773 0.017 4692 0.003 13336 0.021 16262 0.014 
106579 0.017 4986 0.004 13711 0.021 101550 0.014 
2182 0.017 5014 0.004 14340 0.021 2981 0.015 
4362 0.017 8404 0.004 7181 0.021 11253 0.015 
9033 0.017 13615 0.004 6693 0.024 12439 0.015 
11492 0.017 25688 0.004 29323 0.024 3355 0.015 
35325 0.017 34349 0.004 31267 0.024 12582 0.015 
35348 0.017 100394 0.004 101528 0.024 5098 0.017 
35412 0.017 100885 0.004 5114 0.024 12185 0.017 
6084 0.019 101391 0.004 8688 0.024 16851 0.017 
13498 0.019 102091 0.004 14253 0.024 12757 0.019 
7119 0.020 106650 0.004 15563 0.024 5033 0.020 
8899 0.020 107308 0.004 100114 0.024 5119 0.020 
22263 0.020 286 0.004 101918 0.024 9006 0.020 
35678 0.020 431 0.004 103105 0.024 100468 0.020 
101733 0.020 1063 0.004 7741 0.024 16489 0.020 
8410 0.020 5083 0.004 8561 0.024 274 0.021 
103107 0.020 5870 0.004 100150 0.024 9226 0.021 
5546 0.020 6058 0.004 9325 0.025 20153 0.021 
7095 0.020 6624 0.004 32956 0.025 5065 0.021 
11671 0.021 7570 0.004 1251 0.026 7740 0.021 
10778 0.021 8621 0.004 1850 0.026 12561 0.021 
13970 0.021 12786 0.004 2749 0.026 7866 0.021 
12818 0.021 13794 0.004 3135 0.026 5215 0.024 
25712 0.021 15154 0.004 3392 0.026 1615 0.024 
3672 0.024 17570 0.004 4454 0.026 4673 0.024 
8464 0.024 34358 0.004 4922 0.026 6232 0.024 
10718 0.024 101325 0.004 5425 0.026 8862 0.024 
12786 0.024 101713 0.004 5497 0.026 12256 0.024 
100096 0.024 103116 0.004 7471 0.026 13270 0.024 
101332 0.024 103178 0.004 7653 0.026 13742 0.024 
102131 0.024 106000 0.004 9090 0.026 15071 0.024 
103131 0.024 106903 0.004 10030 0.026 15355 0.024 
2488 0.024 16870 0.004 10106 0.026 17998 0.024 
4364 0.024 12278 0.004 10197 0.026 29610 0.024 
4492 0.024 35907 0.004 11671 0.026 100111 0.024 
5067 0.024 3620 0.004 12640 0.026 100646 0.024 
7035 0.024 4824 0.004 12826 0.026 102160 0.024 
13060 0.024 6189 0.004 13740 0.026 106356 0.024 
13154 0.024 7302 0.004 14273 0.026 12579 0.024 
35714 0.024 8834 0.004 16851 0.026 6676 0.024 
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102918 0.024 11216 0.004 17688 0.026 929 0.025 
6380 0.025 12574 0.004 21602 0.026 10098 0.025 
12582 0.025 14404 0.004 24236 0.026 1850 0.026 
5699 0.026 15228 0.004 33722 0.026 4230 0.026 
6441 0.026 33289 0.004 35169 0.026 4824 0.026 
7051 0.026 33712 0.004 35204 0.026 7716 0.026 
7471 0.026 16000 0.004 101204 0.026 8418 0.026 
7740 0.026 19659 0.004 4134 0.026 11622 0.026 
9219 0.026 100218 0.004 5900 0.026 6647 0.026 
12574 0.026 100599 0.004 8316 0.026 12711 0.026 
13451 0.026 12958 0.004 19881 0.026 14169 0.026 
20566 0.026 6511 0.005 100050 0.026 18543 0.026 
35515 0.026 103080 0.005 102595 0.028 5402 0.028 
31459 0.026 9742 0.005 12969 0.028 100026 0.028 
13960 0.026 9744 0.005 29574 0.028 2269 0.028 
101166 0.026 8006 0.005 100973 0.029 6510 0.029 
8170 0.028 9589 0.005 102151 0.029 9720 0.029 
6323 0.028 35377 0.005 108590 0.029 13670 0.029 
11430 0.028 101230 0.005 17428 0.030 16079 0.029 
12969 0.028 10778 0.005 25557 0.030 100343 0.029 
13870 0.028 17863 0.005 102712 0.030 4042 0.029 
100231 0.028 15942 0.006 5623 0.033 4080 0.029 
1380 0.029 6252 0.006 100400 0.033 4710 0.029 
1304 0.029 7154 0.006 6755 0.034 9540 0.029 
101187 0.029 10983 0.006 100103 0.034 11686 0.029 
20438 0.029 15829 0.006 102021 0.034 23327 0.029 
3114 0.029 15872 0.006 10014 0.034 100000 0.029 
23845 0.029 20506 0.006 100863 0.034 8410 0.030 
100050 0.029 101324 0.006 108801 0.034 9090 0.033 
100916 0.029 3784 0.007 522 0.037 5128 0.034 
16657 0.030 4666 0.007 5306 0.037 12124 0.034 
9506 0.033 5474 0.007 646 0.038 13458 0.034 
1232 0.033 7534 0.007 4877 0.038 13819 0.034 
2637 0.033 7891 0.007 5030 0.038 15755 0.034 
9111 0.034 10013 0.007 5682 0.038 17548 0.034 
9186 0.034 10472 0.007 7299 0.038 101272 0.034 
7154 0.037 10683 0.007 7819 0.038 102640 0.034 
100240 0.037 13960 0.007 7910 0.038 1304 0.037 
4379 0.038 15042 0.007 8332 0.038 5460 0.037 
4586 0.038 17594 0.007 8420 0.038 5699 0.037 
4828 0.038 21320 0.007 9658 0.038 2684 0.038 
5030 0.038 33803 0.007 12020 0.038 12426 0.038 
6395 0.038 100913 0.007 13213 0.038 13878 0.038 
8343 0.038 35447 0.007 14405 0.038 11810 0.039 
8643 0.038 102776 0.008 14830 0.038 35697 0.039 
11115 0.038 2116 0.008 20549 0.038 17522 0.039 
16685 0.038 13822 0.009 20566 0.038 33097 0.039 
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100015 0.038 107577 0.009 21160 0.038 100542 0.039 
3599 0.039 109230 0.009 21880 0.038 11288 0.040 
8752 0.040 8591 0.010 34909 0.038 5396 0.041 
2061 0.041 13270 0.010 34927 0.038 9131 0.041 
16320 0.041 100744 0.010 105750 0.038 20589 0.041 
7451 0.041 101148 0.010 100141 0.039 100240 0.041 
15198 0.041 101261 0.010 107909 0.039 6739 0.041 
3628 0.041 101798 0.010 102309 0.039 34216 0.041 
9647 0.041 105083 0.010 108359 0.039 3791 0.041 
15755 0.041 101166 0.010 108412 0.039 4524 0.045 
3255 0.048 4895 0.010 35575 0.040 12969 0.045 
4768 0.048 13347 0.010 9601 0.040 14390 0.045 
5744 0.048 101733 0.010 4438 0.041 13154 0.048 
5623 0.048 4389 0.010 6545 0.041 27499 0.048 
20062 0.048 4843 0.010 6611 0.041 100263 0.048 
100045 0.048 7320 0.010 10393 0.041 100725 0.048 
107165 0.048 14661 0.010 100112 0.041 1054 0.050 
36481 0.050 17142 0.010 10563 0.041 6312 0.050 
100118 0.050 105953 0.010 11487 0.041 7982 0.050 
    15786 0.010 16121 0.041 8170 0.050 
    101667 0.010 22216 0.041 10958 0.050 
    5396 0.010 100100 0.041 16385 0.050 
    10077 0.010 13442 0.041 17878 0.050 
    9546 0.010 16657 0.041 109230 0.050 
    8178 0.047 13994 0.045     
    100353 0.048 4455 0.045     
    4549 0.050 10625 0.045     
    9646 0.050 101017 0.050     
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Appendix IV: 123 urinary peptides altered between WKY and SHRSP at all time points 
(NP, GD12 and GD18) or GD12 & GD18 only 
PeptideID Mass 
Migration 
time 
Log2 peptide intensity Fold change (WKY/ SHRSP) 
WKY 
NP 
SHRSP 
NP 
WKY 
GD12 
SHRSP 
GD12 
WKY 
GD18 
SHRSP 
GD18 
NP GD12 GD18 
929 857.4815 28.15 5.93 6.28 6.35 7.03 5.97 7.12 0.94 0.90 0.84 
1054 862.4315 22.67 6.57 8.10 8.11 6.86 6.86 6.36 0.81 1.18 1.08 
1304 874.4576 34.49 7.49 6.14 7.73 5.75 6.64 3.95 1.22 1.34 1.68 
4119 1009.498 37.80 12.33 13.33 12.23 12.91 11.82 13.09 0.92 0.95 0.90 
4706 1046.479 47.56 5.75 6.67 5.57 7.32 6.13 4.75 0.86 0.76 1.29 
5098 1073.363 46.52 13.04 13.67 13.11 13.83 13.28 14.25 0.95 0.95 0.93 
5254 1083.533 36.50 11.96 11.35 12.24 11.21 12.08 11.42 1.05 1.09 1.06 
5474 1099.53 36.52 8.98 7.83 9.31 7.72 9.86 8.23 1.15 1.21 1.20 
5497 1100.587 28.83 7.31 5.11 8.58 7.67 8.52 6.09 1.43 1.12 1.40 
5661 1111.608 30.47 7.52 4.06 8.29 5.98 7.90 5.15 1.85 1.39 1.53 
6367 1155.575 29.05 6.57 4.10 7.14 3.41 8.39 4.48 1.60 2.09 1.87 
6546 1167.54 47.90 4.49 5.59 4.63 3.92 5.08 4.30 0.80 1.18 1.18 
7006 1196.367 47.02 12.07 12.79 12.42 13.09 12.91 13.48 0.94 0.95 0.96 
7982 1255.65 26.25 6.73 4.55 7.88 3.90 6.75 5.44 1.48 2.02 1.24 
8591 1295.622 29.62 8.05 3.67 8.18 3.00 9.73 4.23 2.19 2.73 2.30 
9325 1341.649 38.48 6.65 5.63 6.62 5.30 7.52 5.21 1.18 1.25 1.44 
10270 1407.682 48.28 7.91 9.23 8.50 9.14 8.91 6.45 0.86 0.93 1.38 
10772 1444.684 40.04 4.60 5.84 4.28 3.39 7.37 4.59 0.79 1.26 1.61 
11141 1471.739 39.49 4.27 4.30 4.99 4.22 5.34 4.74 0.99 1.18 1.13 
12407 1564.769 39.41 7.19 5.89 8.34 6.64 8.90 5.66 1.22 1.26 1.57 
12582 1579.76 26.34 8.60 7.18 10.10 8.95 9.86 6.87 1.20 1.13 1.44 
12628 1584.553 47.97 10.32 12.13 11.42 12.12 11.48 12.24 0.85 0.94 0.94 
12969 1611.795 40.17 5.59 7.54 5.92 6.83 5.78 7.19 0.74 0.87 0.80 
13270 1635.838 33.09 6.11 4.45 6.30 3.66 7.01 4.56 1.37 1.72 1.53 
13543 1659.818 39.66 8.96 6.90 9.43 6.79 9.41 5.46 1.30 1.39 1.72 
13580 1663.806 40.59 8.70 5.54 9.39 4.19 8.92 4.80 1.57 2.24 1.86 
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13742 1679.814 40.76 7.82 6.23 8.45 5.75 7.40 5.22 1.25 1.47 1.42 
14788 1780.881 28.09 6.98 4.44 9.02 2.89 9.26 4.33 1.57 3.12 2.14 
14896 1790.854 33.26 6.62 4.42 8.29 5.42 8.28 4.66 1.50 1.53 1.78 
15819 1885.854 28.11 9.79 4.57 10.90 3.50 11.42 4.68 2.14 3.12 2.44 
100383 1139.544 28.69 9.92 6.65 10.46 7.06 10.89 6.37 1.49 1.48 1.71 
100433 1173.604 26.22 6.30 4.47 7.69 3.67 6.06 4.87 1.41 2.10 1.24 
100744 1417.721 26.35 5.87 4.27 7.21 4.15 6.42 4.65 1.37 1.74 1.38 
100773 1433.684 32.66 7.07 5.52 7.79 6.11 7.93 6.28 1.28 1.28 1.26 
100916 1532.692 39.51 6.33 8.34 8.62 9.19 7.00 9.06 0.76 0.94 0.77 
100954 1554.759 26.62 6.33 4.60 7.18 3.57 6.80 4.57 1.38 2.01 1.49 
100964 1561.754 28.12 7.59 4.19 8.80 3.89 8.20 4.91 1.81 2.26 1.67 
101001 1584.787 27.29 7.10 4.52 8.12 3.52 8.32 4.83 1.57 2.31 1.72 
101201 1713.872 28.25 7.19 4.43 8.82 3.54 9.03 4.84 1.62 2.49 1.87 
101224 1726.832 28.14 5.34 4.55 5.81 3.76 6.37 4.69 1.17 1.54 1.36 
101391 1832.94 33.34 6.33 4.54 6.28 3.54 7.78 4.94 1.39 1.77 1.57 
101392 1833.646 48.36 5.17 6.55 4.94 6.58 6.78 4.81 0.79 0.75 1.41 
101695 2013.958 25.17 8.05 4.63 8.93 3.74 9.39 5.05 1.74 2.39 1.86 
102001 2196.056 25.43 7.54 4.18 9.66 3.76 9.26 4.61 1.80 2.57 2.01 
102056 2239.077 26.87 8.01 4.65 9.33 3.52 8.34 5.06 1.72 2.65 1.65 
106356 1418.602 48.47 7.81 4.70 7.40 3.86 8.73 5.14 1.66 1.92 1.70 
880 855.4258 35.91 9.61 10.94 9.42 10.64 8.86 11.32 0.88 0.88 0.78 
1512 883.4193 35.35 7.59 8.27 7.77 6.69 8.43 6.66 0.92 1.16 1.27 
1615 888.4502 34.67 7.05 6.27 8.22 5.97 7.04 4.86 1.13 1.38 1.45 
2684 931.5043 27.26 7.97 7.67 7.49 9.31 7.82 8.83 1.04 0.80 0.89 
2981 947.4504 34.20 7.66 7.31 7.23 5.09 7.51 5.79 1.05 1.42 1.30 
3258 960.5006 29.69 5.54 6.03 7.14 5.88 5.93 4.99 0.92 1.21 1.19 
3668 982.5227 36.14 10.42 10.22 10.41 9.58 10.30 8.68 1.02 1.09 1.19 
3784 989.4635 47.52 6.51 6.42 6.74 7.99 7.02 5.54 1.01 0.84 1.27 
3791 989.5253 28.87 8.40 9.05 7.80 9.24 6.99 8.98 0.93 0.84 0.78 
3930 998.4752 34.70 10.08 9.68 9.56 8.17 9.43 6.41 1.04 1.17 1.47 
4042 1004.478 47.47 7.44 8.21 7.72 8.92 8.85 6.97 0.91 0.87 1.27 
4680 1044.505 36.33 6.11 7.63 6.18 5.59 6.53 5.53 0.80 1.11 1.18 
4824 1055.523 36.37 9.66 9.55 9.44 8.94 9.49 8.91 1.01 1.06 1.06 
5014 1068.567 29.18 5.30 4.67 5.62 3.91 5.66 4.84 1.14 1.44 1.17 
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5114 1073.515 36.41 6.52 5.76 5.98 3.96 6.25 5.09 1.13 1.51 1.23 
5789 1119.531 48.01 4.82 5.38 4.67 5.91 6.64 5.91 0.90 0.79 1.12 
6058 1134.515 47.95 6.16 4.69 4.99 5.56 7.18 5.16 1.31 0.90 1.39 
6252 1148.544 48.13 4.93 4.99 4.94 5.90 6.36 5.00 0.99 0.84 1.27 
6545 1167.564 29.66 8.30 5.88 5.88 7.50 5.67 9.18 1.41 0.78 0.62 
7181 1206.626 25.61 6.64 5.38 6.25 7.93 7.04 5.14 1.23 0.79 1.37 
7302 1214.566 37.03 11.12 11.34 11.69 11.14 11.60 12.04 0.98 1.05 0.96 
7534 1227.606 37.47 10.57 10.37 10.26 9.45 10.65 9.95 1.02 1.09 1.07 
8404 1283.405 47.36 6.44 6.77 7.21 3.99 8.16 6.39 0.95 1.81 1.28 
8590 1295.61 37.80 5.85 5.95 6.53 4.29 7.54 5.62 0.98 1.52 1.34 
8661 1300.715 39.78 5.99 4.46 7.22 3.86 8.35 4.88 1.34 1.87 1.71 
9006 1321.704 32.99 6.65 6.20 6.63 5.18 7.11 5.92 1.07 1.28 1.20 
9090 1324.681 29.94 7.57 7.03 9.26 7.61 9.05 6.34 1.08 1.22 1.43 
9131 1326.631 39.17 8.23 9.06 8.20 5.14 7.11 5.30 0.91 1.60 1.34 
9601 1358.66 32.35 7.02 7.36 5.34 6.53 6.96 5.43 0.95 0.82 1.28 
9863 1378.668 39.11 10.44 10.55 10.86 10.08 10.22 9.15 0.99 1.08 1.12 
9871 1378.731 31.31 6.94 6.50 8.40 7.60 8.35 6.65 1.07 1.11 1.26 
10013 1388.717 39.15 9.66 9.21 10.47 9.54 9.82 8.04 1.05 1.10 1.22 
10393 1415.706 39.41 5.71 5.70 5.80 6.85 6.18 5.72 1.00 0.85 1.08 
10625 1434.691 48.95 4.71 7.65 6.15 8.04 7.28 7.07 0.62 0.76 1.03 
11179 1474.77 26.54 4.98 4.51 5.79 4.18 5.51 4.64 1.10 1.38 1.19 
11487 1497.745 31.62 4.91 4.49 5.23 3.61 5.03 4.42 1.09 1.45 1.14 
11667 1511.678 39.29 5.95 6.83 6.13 5.35 6.38 5.45 0.87 1.14 1.17 
11737 1515.825 32.86 4.71 6.21 6.72 5.36 4.86 5.78 0.76 1.25 0.84 
12757 1594.92 33.72 6.04 5.80 4.70 6.45 5.86 8.83 1.04 0.73 0.66 
12958 1610.734 38.89 6.83 6.16 8.06 4.90 7.45 4.53 1.11 1.65 1.65 
13079 1620.735 32.13 5.06 4.48 5.99 3.96 6.87 4.57 1.13 1.51 1.50 
13290 1636.792 40.73 10.05 10.03 10.51 9.77 9.67 8.59 1.00 1.08 1.13 
13458 1650.839 33.29 5.19 4.89 6.68 4.79 5.98 4.59 1.06 1.39 1.30 
13670 1671.9 28.18 7.11 6.31 8.28 6.70 6.81 4.66 1.13 1.24 1.46 
13740 1679.77 32.30 9.18 9.20 9.07 8.01 9.78 8.75 1.00 1.13 1.12 
13819 1687.84 41.42 5.26 4.85 5.32 4.24 5.58 4.59 1.08 1.25 1.22 
14020 1706.866 41.37 7.12 8.04 8.11 7.12 7.37 5.42 0.89 1.14 1.36 
14404 1743.872 33.58 6.88 6.17 7.60 6.29 6.51 5.11 1.11 1.21 1.27 
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15228 1825.811 40.93 6.65 7.42 7.23 6.53 6.96 5.55 0.90 1.11 1.25 
16047 1905.941 34.11 8.35 7.80 9.16 7.25 6.44 5.27 1.07 1.26 1.22 
16054 1906.927 42.64 8.95 9.25 8.80 7.90 8.12 5.89 0.97 1.11 1.38 
16851 1992.943 42.36 8.77 9.29 9.21 8.36 8.20 7.30 0.94 1.10 1.12 
16914 2000.106 35.84 8.97 9.41 7.33 9.83 7.61 11.52 0.95 0.75 0.66 
17594 2072.013 40.74 6.32 6.90 7.02 5.83 6.98 5.04 0.92 1.20 1.38 
17878 2099.082 42.32 6.14 7.02 6.11 4.23 5.76 5.15 0.88 1.45 1.12 
20566 2420.078 44.61 7.04 7.68 7.16 5.77 6.39 4.77 0.92 1.24 1.34 
21602 2566.11 44.92 5.86 6.61 6.42 5.13 5.45 4.77 0.89 1.25 1.14 
29610 3981.973 38.00 5.17 4.45 7.19 4.64 6.16 4.40 1.16 1.55 1.40 
33289 5452.868 24.75 11.77 11.77 10.45 12.70 12.27 8.41 1.00 0.82 1.46 
100000 800.3959 33.34 8.16 7.23 7.97 6.08 8.15 6.32 1.13 1.31 1.29 
100026 828.4175 33.50 6.76 7.59 7.67 6.31 7.10 5.33 0.89 1.22 1.33 
100111 902.4517 29.35 6.53 5.56 5.89 4.96 5.69 4.71 1.18 1.19 1.21 
100343 1095.353 47.05 7.70 5.81 5.62 8.58 7.54 5.58 1.32 0.66 1.35 
100542 1253.576 37.28 6.04 5.74 6.71 3.38 7.61 5.45 1.05 1.98 1.40 
100572 1274.494 47.99 5.81 5.64 7.80 5.10 7.87 5.09 1.03 1.53 1.55 
100806 1456.767 27.87 4.88 4.34 6.49 3.77 6.23 4.55 1.12 1.72 1.37 
100913 1529.64 29.08 5.58 5.96 7.43 9.05 7.38 8.35 0.94 0.82 0.88 
101148 1675.841 41.45 5.90 5.66 6.60 3.80 6.44 4.69 1.04 1.74 1.37 
101272 1753.899 50.19 5.49 5.94 5.60 3.57 7.09 4.92 0.92 1.57 1.44 
101403 1837.903 28.25 5.91 4.33 8.18 3.73 8.58 4.47 1.37 2.19 1.92 
101420 1849.971 29.18 5.92 4.96 7.31 5.51 5.86 4.90 1.19 1.33 1.20 
101782 2060.054 42.88 5.29 6.96 6.97 4.05 6.43 4.22 0.76 1.72 1.52 
101946 2165.127 30.74 5.07 4.46 5.74 3.55 5.90 5.22 1.14 1.62 1.13 
102676 3411.458 28.83 5.13 5.84 5.77 5.83 5.64 4.81 0.88 0.99 1.17 
102804 4113.821 47.13 4.65 4.25 6.77 3.70 4.98 4.50 1.09 1.83 1.11 
102868 4816.223 32.08 5.01 4.66 5.19 3.56 5.06 4.41 1.08 1.46 1.15 
107005 1694.835 33.02 5.52 4.25 6.85 4.44 6.47 4.44 1.30 1.54 1.46 
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Appendix V: Sequenced peptides list 
PeptideID Mass Sequence Protein name 
Theoretical 
Mass 
Start Stop 
Rat Protein 
Accessions 
12757 1594.92 IDQTRVLNLGPITR Uromodulin 1594.91549 596 609 P27590 
16914 2000.106 SGNFIDQTRVLNLGPITR Uromodulin 2000.080323 592 609 P27590 
9131 1326.631 TVDETYVPKEF 
Serum albumin 
precursor 
1326.634348 516 526 P02770 
11179 1474.77 SVIHEDVYEEKK 
RCG32337, isoform 
CRA_a 
1474.730374 47 58 D3ZJA4 
14788 1780.881 DKTEKELLDSYIDGR 
Prothrombin 
precursor (Fragment) 
1780.884309 345 359 IPI:IPI00189981.1 
3668 982.5227 VPSYPGPpGP Protein Col19a1 982.569898 76 84 D3ZCQ0 
8590 1295.61 DPVESKIYFAQ 
Pro-epidermal growth 
factor precursor 
1295.639768 522 532 P07522 
11667 1511.678 AGPpGPpGpPGSIGHpG 
procollagen, type IX, 
alpha 3 (predicted), 
isoform CRA_a 
1511.700471 555 571 D3ZX71 
12958 1610.734 LAQLmANEWPHSQA 
NACHT, leucine rich 
repeat and PYD 
containing 5 
1610.751105 69.00 82.00 D3ZDM5 
9006 1321.704 DGILGRDTLPHE 
Contrapsin-like 
protease inhibitor 1 
precursor 
1321.662629 21 32 P05545 
11141 1471.739 ALYQAEAFVADFK 
Contrapsin-like 
protease inhibitor 1 
precursor 
1471.734731 155 167 P05545 
11487 1497.745 GPPGpPGDPGKPGAPGK 
Collagen alpha-1(IX) 
chain 
1497.757592 68 84 IPI:IPI00192793.6 
13742 1679.814 GMpGSpGGPGNDGKPGPpG 
Collagen alpha-1(III) 
chain 
1679.720948 536 554 IPI:IPI00366944.2 
14896 1790.854 GESGRpGPpGPSGPRGQpG 
Collagen alpha-1(III) 
chain 
1790.829588 557 575 P13941 
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16851 1992.943 QGIpGTSGPpGENGKpGEpGP 
Collagen alpha-1(III) 
chain 
1992.902478 640 660 P13941 
4706 1046.479 GppGPpGPpGPG 
Collagen alpha-1(II) 
chain 
1046.466889 1139 1150 P05539 
9863 1378.668 ApGEDGRpGPpGPQ 
Collagen alpha-1(II) 
chain 
1378.611322 512 525 P05539 
10625 1434.691 GPpGPpGPpGPPSGGY 
Collagen alpha-1(I) 
chain precursor 
1434.641559 1170 1185 P02454 
3784 989.4635 GppGPpGPpGP 
Collagen alpha-1(I) 
chain  
989.445425 131 141 P02454 
4042 1004.478 GPpGPpGPPSGG 
Collagen alpha-1(I) 
chain  
1004.456324 1173 1184 P02454 
4119 1009.498 GRVGPpGPSGN 
Collagen alpha-1(I) 
chain  
1009.494075 870.00 880.00 P02454 
6546 1167.54 GPpGPpGPPSGGY 
Collagen alpha-1(I) 
chain  
1167.519653 1173 1185 P02454 
4680 1044.505 ApGFpGARGPS 
Collagen alpha-1(I) 
chain 
1044.498815 397.00 407.00 P02454 
5254 1083.533 GVVGLpGQRGE 
Collagen alpha-1(I) 
chain 
1083.483267 828.00 839 P02454 
5789 1119.531 GPpGPTGPTGPpG 
Collagen alpha-1(I) 
chain 
1119.519653 - - P02454 
6252 1148.544 GLpGPpGApGPQG 
Collagen alpha-1(I) 
chain 
1148.546202 - - P02454 
9090 1324.681 GLpGpKGDRGDAGP 
Collagen alpha-1(I) 
chain 
1324.637142 - - P02454 
10013 1388.717 RpGEVGPpGPpGPAG 
Collagen alpha-1(I) 
chain 
1388.668442 907 921 P02454 
11737 1515.825 GPpGPpGPVGKEGGKGP 
Collagen alpha-1(I) 
chain 
1515.768157 882 898 P02454 
13079 1620.735 DGVAGPKGPAGERGSpGP 
Collagen alpha-1(I) 
chain 
1620.785598 488 505 IPI:IPI00188909.3 
13290 1636.792 GSpGSpGPDGKTGPpGPAG 
Collagen alpha-1(I) 
chain 
1636.732893 531 549 P02454 
13670 1671.9 PpGPpGPVGKEGGKGPRG 
Collagen alpha-1(I) 
chain 
1671.869268 882 899 P02454 
 
 
239 
 
14020 1706.866 TGPIGPpGPAGApGDKGET 
Collagen alpha-1(I) 
chain 
1706.811144 755 773 P02455 
13543 1659.818 GAPGAKGNVGppGEPGPpG 
Alpha 4 type V 
collagen 
1659.785263 620 638 P68136 
4824 1055.523 NELRVAPEE 
Actin, alpha skeletal 
muscle 
1055.524738 94 102 IPI:IPI00960053.1 
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